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D O N T  ouïr*
**When things go wrongs as they sometimes willy 
When the road you are trudging seems all uphill, 
When the funds are low, and the debts are high.
And you want to smile, but you have to sigh.
When care is pressing you down a bit.
Rest, if  you must -  but don't quit.
Life is queer with its twists and turns.
As every one of us sometimes learns.
And many a failure turns about
When he might have won had he stuck it out;
Don't give up, though the pace seems slow -  
You might succeed with another blow.
Often the goal is nearer than 
It seems to a faint and faltering man.
Often the straggler has given up
When he might have captured the victor's cup.
And he learned too late, when the night slipped down 
How close he was to the golden crown.
Success is failure turned inside out- 
The silver tint o f the clouds o f doubt- 
And you never can tell how close you are.
It may be near when it seems afar;
So stick to the fight when you're hardest hit- 
It's when things seem worst that you mustn't quit."
Those who lived through this thesis with me will understand the 
moral o f this poem, which was sent to me by my sister at a 
particularly difficult time.
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11 The centrai system.
The central nervous system (CNS) consists of two parts, the brain and spinal 
cord. In man, the CNS consist of perhaps one hundred billion interconnecung 
neurones; these are formed prenatally, and, if damaged, cannot be replaced. 
During the life span of the average adult approximately 3% of neurones are lost
as a result of wear and tcar.^
1i2i ThP neurone.
The neurone (fig 1.1) is the basic functional unit of the brain. It consists of a cell 
body (which contains the nucleus and deoxyribonucleic acid (DNA)), dendrites, 
axon and synapse. There are two main types of neurone; sensory, which convey 
information from the body to the CNS, and motor, which convey information
The synapse is the point of functional contact between the axon tenninal and 
other cells. It is also responsible for the biosynthesis, delivery, reception and 
removal of synaptic neurotransmitters, and thus provides a flow of chemical 
information from presynaptic to postsynaptic loci. (Rg 1.2).
Axonal transport
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'OCSr>^
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Release
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/metpbi 
holism
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Response
Presynaptlc receptors 
Postsynaptlc receptors
Effector cell
Metabolism
NeurotrnnsmissiQIl.
Transmission of a nerve impulse along the axon of a neurone in the form of 
depolarization causes a change in the ion permeabUity of the axonal 
membrane. This results in the transfer of sodium ions into the axon from the 
exterior and of potassium ions out of the axon. The arrival of the impulse at 
the ptesynaptic terminal triggers the release of calcium ions into the cell 
through the voltage-regulated calcium ion channels. This in turn triggers the 
release of neurotransmitters into the synaptic cleft, and their diffusion across
the synaptic space, to the postsynaptic receptor membranes. L-glutamic acid 
(1), the archetypal excitatory amino acid, binds to receptors that are linked to 
sodium ion channels. The influx of sodium ions causes the neurone to become 
depolarized; this process initiates the events of neuronal transmission. The sum 
of these depolarizations is known as the excitatory post synaptic potential 
(EPSP). The release of an inhibitory neurotransmitter such as GABA (2) 
results in the influx of chloride into the cell membranes. This causes 
hyperpolarization of the cell membranes, known as the inhibitory post synaptic
potential (IPSP).
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14. rriteria fnr neiirolransmitlers.
The criteria that should be satisfied for positive identification of a substance as 
a neurotransmitter in the CNS are:
1. Release The substance must be released from storage by stimulation of the
nerve.
2. Tripntifiration ûf action. Postsynaptic application of the putative 
neurotransmitter should mimic the effect of presynaptic stimulation.
3. Effect. Specific antagonists which block or potentiate transmission should 
have corresponding effects on the response to the applied substance.
4. Storage The substance and its associated enzymes must be present in
presynaptic nerve endings.
5. Tnartivation. One or more mechanisms for inactivation of the transmitter 
should be present.
These are the criteria on which characterization of various reported 
neurotransmitters has been based. The real situation is usually a distortion of 
the ideal, and it is rarely possible to meet all the theoretical criteria. Often the 
first criterion is the most difficult to fulfil.
1.5. Neurotransmitters.
The primary observation that synaptic communication might utilize chemical 
agents was made by by Elliot.2 This was extended by Loewi^ who 
demonstrated that an agent liberated on stimulation of the vagus nerve of the 
frog heart could, when administered to the heart of a second frog, mimic the 
effect of a parasympathetic stimulation. This substance, which Loewi called 
"vagusstoff, was later isolated from the spleen by Dale et alA  and identified 
as the neurotransmitter acetylcholine (ACh) (3). These pioneering studies 
increased our understanding of the nature of chemical transmitters, and led to 
the accepted view that neurotransmitters are chemical components which are 
synthesized, stored and released from presynaptic vesicles.
There is considerable diversity in the structure of molecules which have been 
identified as putative neurotransmitters,^ these include the phenylethylamines, 
such as adrenaline (4), noradrenaline (5) and dopamine (6); the indole, 5- 
hydroxytryptamine (7); the imidazole, histamine (8); acetylcholine (3), the 
excitatory amino acids, L-glutamic acid (1) and L-aspartic acid (9); the 
inhibitory amino acids, glycine (10), taurine (11) and y-aminobutyric acid (2).
as well as peptides, such as substance P (12).
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1.6. Excitatory neiirntransmitters.
Historically, identification of acidic amino acids as neuronal excitants was first 
reported by Hayashi,^ who, in 1952, discovered that L-glutamic acid (1), and 
L-aspartic acid (9) caused convulsions when introduced into the central 
nervous systems (CNS) of monkeys and dogs. Eight years later, Curtis et a l l  
demonstrated the excitation of single neurones in the CNS by L-glutamate (1), 
L-aspartate (9), and structurally related acidic amino acids.^ For the next ten 
years, iontophoretic studies provided evidence in support of transmitter roles 
for L-glutamic (1) and L-aspartic (9) acids.^
Since its isolation, L-glutamic acid has been the subject of numerous areas of 
research. Its involvement in biological processes is now well accepted. For 
example in mammals, it is involved in metabolic pathways, such as fatty acid 
synthesis, regulation of ammonia; (in the absence of a fully functional urea 
cycle, ammonia detoxification involves glutamic acid formation through 
amination of a-ketoglutaric acid (13) catalyzed by the enzyme glutamate 
dehydrogenase 10); it is incorporated into proteins and peptides, and is involved 
in the control of osmotic and amniotic balance; it is also a precursor for certain 
co-factors such as folic acid and glutathione. Its action as a major excitatory 
neurotransmitter in the CNS is well documented.! 1
CO 2 H
O COgH
(13)
Additionally, it is the major precursor of y-aminobutyric acid (GABA) (2), an 
inhibitory neurotransmitter in the CNS; the formation of GABA from L- 
glutamic acid is catalyzed by the enzyme glutamate decarboxylase. The 
efficiency of the blood-brain barrier in the isolation of sensitive neurones from 
circulating glutamate is responsible for the low concentration of the amino acid 
in the central nervous system (CNS). Extraneuronal concentrations are 
maintained at low levels by avid uptake systems. Defects in these mechanisms 
may be involved in certain neuropathological states, whereby sustained 
elevations of extracellular glutamate may ultimately result in cell death. 
Research into the role of L-glutamic acid as a neurotransmitter, particularly 
neurochemical aspects has, however, been fraught with difficulties because of 
its involvement in numerous biological processes. It is only recently that 
convincing evidence”^ has emerged about the specific role of the amino acid in 
behavioural and neuropathological manifestations. Encouraged by 
developments in the demonstration of GABA as a depressant of spinal 
neurones, Curtis et al. used the then newly developed technique of 
microiontophoresis to apply the amino acids L-glutamic acid (1), L-aspartic 
acid (9) and L-cysteic acid (14), to single spinal neurones of the cat. These 
researchers observed that the amino acids had the ability to produce membrane 
depolarization.^ 1,15,16 xhese early observations, and o thers ,suggested  that 
L-glutamic acid and L-aspartic acid represented a new class of neuronal 
excitants, distinguishable from calcium chelating agents and cholinomimetics. 
These findings were substantiated by Takeuchi,^^ who, in 1964, discovered 
that responses to L-glutamic acid, iontophoretically applied to crayfish muscle, 
were the same as those observed by Curtis. Similar observations were made 
by Usherwood^^ when L-glutamic acid was applied to locust neuromuscular
8
junction.
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1.7 Concept of the receptor.
The concept of the receptor site, with which drugs, hormones and 
neurotransmitters act to produce their biological effect, originated at the end of 
the nineteenth century through the studies of Langley and Ehrlich.^^
Langley, working on atropine and pilocarpine, and Ehrlich, on antibodies, 
demonstrated that in order for drugs and antibodies to act specifically, they 
must first interact with specific "receptive substances or receptors. The 
receptor concept has been substantiated in the last decade by the isolation and 
purification of macromolecular substances that fulfil all the criteria of being a 
receptor. It is now generally accepted that authentic receptors should have the 
following properties.21
1. .Specificity. Receptors are specific cellular components with which specific 
ligands interact to induce a physiological response.
2. Satnrahilitv. The concept of saturability of receptors follows from ligand 
binding studies and is depicted as a dose-response curve, is usually plotted as 
log (dose) vs. response.
3. .Sftlectivitv. The selectivity of receptors towards agonists and antagonists 
allows deductions to be made about the complementary functional groups 
which are involved in interactions with ligands. Selectivity is thought to be 
greater with agonists than with antagonists.
4. Rpyp-rsihilitv. Since transmitters, hormones, and most drugs act in a 
reversible manner, it follows that the binding of these agents to receptors 
should be reversible.
Electrophysiological and binding studies have provided the now generally 
accepted view that a receptor is a form of transducer that, when activated by 
interaction with an agonist, effects the characteristic response.22
I.K. Excitatory nmino acids.
Following the discovery of the likely neurotransmitter role of L-glutamic acid, 
a large number of acidic amino acids and related compounds were tested 
and their pharmacological effects evaluated. Among these were N-methyl-D- 
aspartate (15), D-homocysteic acid (16), and ibotenic acid (17),^^ which were 
found to be more potent as agonists than glutamate in the mammalian CNS .
In 1970, Shinozaki^^ investigated certain anthelmintics for their excitant 
properties on rat neurones, in a programme of research that was to prove 
extremely fruitful. One of these compounds was kainic acid (18). This ammo 
acid, which was first isolated in 1953 by Takemoto24 from the seaweed 
Digenea simplex, was found to be a potent excitant in the mammalian CNS.
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This finding led Watkins and co-workers to test the anthelmintic domoic acid, 
(19) a structural analogue of kainic acid isolated from the marine algae 
Chondi'iu armatu. When tested on frog and rat spinal neurones, it was found 
that the amino acid was a more potent agonist than L-glutamic acid, and was 
equipotent to kainic acid.^^ Continuing with his investigations into 
anthelmintics, Shinozaki^^ observed that the amino acid quisqualic acid (20) 
(isolated by Takemoto in the early seventies)^^ had potent excitant properties 
on the crayfish neuromuscular junction. This prompted Watkins and co­
workers to investigate quisqualic acid for its excitant properties on the frog and 
rat spinal neurones. They observed that on both kinds of neurones quisqualic 
acid was at least two orders of magnitude more potent than L-glutamic acid, 
and equal to or stronger than kainic acid.^^
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These observations extended the range of structures known at the time which 
could replace the terminal carboxymethyl group of glutamate with 
enhancement of activity. Among these compounds were bromowillardine (21), 
a potent agonist at the kainate receptor; and a-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid (AMPA) (22), a structural analogue of quisqualic acid
and a known neuroexcitant.26
Other exogenous agonists identified include |3-N-oxalylamino-L-alanine 
(BOAA) (23), a quisqualate agonist, and trans-2,3-piperidine dicarboxylic acid 
(24), an NMDA agonist.
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Endogenous agonists include L-glutamic acid, L-aspartic acid, quinolinic acid 
(25), and sulphur-containing excitatory amino acids such as cysteic acid (14), 
homocysteic acid (the L-epimer of (16)), cysteine sulphinic acid (26), 
homocysteine sulphinic acid (27), and S-sulphocysteine (28). These are all 
neuronal excitants, the effects of which are thought to be mediated primarily 
via the NMDA receptor.
SO,
(26)
HaN^ COg- 
(27)
H3N CO,
(28)
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The side-chains of these compounds contain ionizable acidic groups which 
presumably interact with a basic region on the receptor.
A greater understanding of the physiological and pathological roles of 
excitatory amino acid receptors was provided by the identification of useful 
antagonists. Among the acidic amino acids identified were the non-selective 
antagonists; y-D-glutamyl-glycine (29), cis-2,3-piperidine dicarboxylic acid
(30), and kynurenic acid (31).^^
COg- H2+
(29) (30)
(racemic)
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CO,
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CO.
(31)
1.0. F.xcilatorv nminnacid receptors.
Excitatory amino acid receptors are now accepted as the major 
neurotransmitter receptors mediating synaptic excitation in many sites in the 
mammalian,32 locust,33’34 and cockroaches central nervous systems (CNS). 
As structure-activity relationships of agonists and antagonists at these 
excitatory amino acid receptors began to emerge, the possibility that perhaps 
these responses were mediated by more than one receptor subtype became a 
focal point of research. Early speculation focused on the possibility of there 
being only one type of excitatory amino acid receptor, and that this receptor
14
contained at least two or possibly three charged sites which interacted with 
oppositely charged groups in the amino acid molecule.
-O
- o
NH« + 3
Two nnint receptor. Three point receptor.
Fio 1.3. Early receptor model/.
It was further hypothesized^^ that perhaps the glutamate receptor (in 
vertebrates) was part of a lipoprotein complex, or possibly was coupled to a 
divalent metal ion. While the principles on which such speculations were 
based remained tenable, the likelihood became increasingly doubtful as 
evidence began to emerge that the observed responses may have been mediated 
via two or more distinct receptor subtypes.^^^ xhis hypothesis was 
substantiated by Piggott,^^’^ ^ who investigated the population of glutamate 
sites on the common garden snail Helix asperOy and concluded that there were 
two types of glutamate receptors; an excitatory receptor with a preference for 
the folded conformation (resembling L-aspartate), and an inhibitory receptor 
with preference for the extended conformation (resembling ibotenic acid)
(fig. 1.4).
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Fig. 1.4
folded conformation extended conformation
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This tentative hypothesis was further investigated by Duggan^^ who examined 
the relative potencies of N-methyl-D-aspartic acid (15), and kainic acid (18) on 
the same group of feline spinal cells. This researcher found that the relative 
potencies of N-methyl-D-aspartic acid and kainic acid parallelled those of L- 
glutamic acid and L-aspartic acid. Furthermore MCCulloch^^ found regional 
différencies in sensitivity to the amino acids in different regions of the spinal 
cord, glutamate and kainate receptors being more populous in the dorsal horn 
cells than in the Ranshaw cells, which had an increased population of aspartate 
and NMDA receptors. The inference that kainic acid and N-methyl-D-aspartic 
acid acted on different amino-acid receptors led to comparative studies on the
excitations produced by NMDA and kainate receptor agonists42
As soon as the idea of two distinct receptor subtypes became established, the 
possible existence of a third receptor subtype was proposed.^3 This was 
prompted by the observation that iontophoretically applied L-glutamate diethyl 
ester (GDEE) (32) blocked quisqualic acid (20) induced responses but not 
kainic acid-induced responses of the cat spinal neurones."^ Although these 
observations were treated with caution, owing to the non-selectivity of GDEE 
as an antagonist, the findings were substantiated by the evidence^^ that kainic 
acid-induced responses were antagonized by 2-amino-4-phosphonobutyric acid
16
(AP4) (33) to a greater degree than were quisqualic acid-induced responses.
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Furthermore, in cat spinal neurones, kainic acid-induced responses were 
antagonized by y-D-glutamylglycine, (DGG) (29), but those induced by
quisqualic acid (20) were not.'^^
Additionally, Mayer^^’^ ^ found that in cultured neurons, kainate and 
quisqualate activate channels with dissimilar conductance and desensitization 
properties. Since these pioneering discoveries by Curtis, Watkins^ and 
others! 1 considerable evidence^^-S 1 has accumulated indicating that 
excitatory amino acid induced responses may be mediated by up to four 
subtypes of receptors; notably N-methyl-D-aspartate, kainate, quisqualate and 
L-2-amino-4-phosphonobutyrate (L-AP4). The first three of these receptor 
subtypes were defined on the basis of their high selectivity for the appropriate 
agonist; N-methyl-D-aspartic acid, kainic acid, and quisqualic acid 
respectively. The L-AP4 receptor was discovered because a subpopulation of 
synaptically induced excitatory responses were antagonized by L-AP4, but 
those mediated by NMDA, kainate, or quisqualate were not.
Recently however, "quisqualate receptors" have been found to be 
heterogeneous.52»53 xhe term quisqualate receptor is no longer applied to the 
receptor responsible for the mediation of the fast excitatory postsynaptic
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potential and has been termed the AMPA receptor, following the discovery of 
the more selective ligand a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (22). A second type of quisqualate-sensitive receptor is the metabotropic 
receptor. The latter receptor is coupled to the generation of inositol-1,4,5- 
triphosphate (IP3), and the mobilization of calcium ions.
The story is further complicated by the likelihood that kainic acid acts on the
classical quisqualate receptor.^'^
1.9.1. NMDA receptor.
Since it was first recognized as a distinct receptor subtype,^^ the NMDA 
receptor has become undeniably the best characterized, and hence the best 
understood of all the excitatory amino acid receptors.^^ jh e  availability of 
selective antagonists (which distinguish it from other types of excitatory amino 
acid receptors) has contributed to the understanding of this receptor subtype. 
Among these antagonists are a-diaminopimelic acid (34) and D-a-aminoadipic 
acid (35) 3-(2-carboxypiperazin-4-yl)-propyl-l-phosphonic acid (CPP) (36),^6 
the D-isomers of some of the ot-amino-io-phosphono-carboxylic acids, notably
2-amino-5-phosphonopentanoic acid (AP5) (37), 2-amino-5-7-
phosphonoheptanoic acid (AP7) (38), and others.^^
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Based on structure-activity relationships, a model comprising three points of 
attachment was proposed for recognition at the NMD A receptor. Two of these 
points interact with the a-amino acid ammonium and carboxylate functions, 
and are common to both agonists and competitive antagonists.^^ Two further 
points accomodate the (O-acidic group, one for the shorter chain D- and L- 
forms (such as NMDA, L-glutamate), and a separate point for the longer chain 
antagonists which possess the D-stereochemistry, such as D-AP5 (37).
Electrophysiological data do not give conclusive structure-activity information 
for the responses to agonists of the NMDA receptor, because most of the 
NMDA agonists also activate more than one excitatory amino acid receptor.
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However, relative receptor affinities available from combined radioligand 
binding and electrophysiological studies support the view that L-glutamic acid 
has the highest affinity as an agonist at the NMDA receptor. N-methyl-D- 
aspartic acid itself has moderately high affinity. Other agonists include L- 
homocysteic acid (16), ibotenic acid (17), rrcf/w-l-amino-1,3-
dicarboxycyclopentane (39), r/Y7Wi-2 ,3-piperidinedicarboxylic acid (trans-2,3- 
PDA) (24), and N-methyl-L-aspartic acid (40). (a weaker agonist than 
NMDA).58
MeH^N
CO«-
CO«-
(39) (40)
D- and L- forms of short chain, acidic, amino acids have variable preference, 
with the D-enantiomer generally possessing higher affinity than the L- 
enantiomer.^^ The (O-terminal acidic amino acid group preference for agonist 
activity decreases in the order CO2H, > SO2H > SO3H, >>P0 3 H2 .^^
In addition to direct interactions at the NMDA ligand binding site, the NMDA 
receptor system is subject to allosteric control. Evidence^0,61 has 
accumulated which indicates that the dissociative anaesthetics phencyclidine 
(PCP) (41), ketamine (42) and MK801 (43), and a-opiate compounds act as 
non-competitive antagonists at the NMDA receptor. The specific sites have 
been identified by labelling with the PCP analogue (l-(2-
thienyl)cyclohexyl)piperidine (^H-TCP) (44), or with ^H-MK 801^^ and 
shown to lie within the ion channel.
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Autoradiographic experiments showed a high correlation between the 
anatomical distribution of NMDA-sensitive L-glutamate sites and ^H-TCP 
binding sites in the brain. Furthermore, although dissociative anaesthetics had 
no effect on the binding of ^H-glutamate or ^H-CPP, NMDA receptor agonists 
increased ^H-TCP or ^H-MKSOl binding, which suggests^l »22,62,63 that 
PCP and related substances bind to an activated site of the NMDA receptor 
com plex.
Another allosteric site on the NMDA receptor is a binding site which 
recognizes the amino acid glycine (10). Using the patch-clamp technique, 
Johnson and Ascher^^ observed that glycine potentiates NMDA responses by 
increasing the frequency of channel opening. This observation is consistent 
with the finding that the distribution of ^H-glycine binding sites in the CNS
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was similar to that found for NMDA, but quite different from that of ^H- 
strychnine (45) binding sites 6^39,65,66
Anatomically, (as shown by autoradiographical and radioligand binding 
studies), NMDA receptors are localized subcellularly at the postsynaptic 
density (consistent with synaptic rather than extrasynaptic function),67 and are 
present in high density in the cerebral cortex, hippocampus, striatum, septum 
and amygdala.67 Using thin brain slices, Monaghan et al 67. have 
demonstrated that populations of NMDA receptors exists predominantly in the 
stratum oriens and stratum radiatum of the CAl, as well as in the inner areas of 
the dentate gyrus. Lower levels were observed in the stratum oriens and the 
radiatum of CA3, and in the outer molecular layer of the dentate gyrus, and the 
stratum lucidum.68 In support of this, compounds such as D-a-aminoadipic 
acid, ibotenic acid, and D- and L-aspartic acids, which have been shown to 
interact with the NMDA receptor, are all displacers of the NMDA-sensitive 
3H-L-glutamate binding in the stratum radiatum.67
The location and electrophysiological properties of the NMDA receptor 
suggest that it plays a crucial role in pathological conditions and synaptic 
plasticity. Its high concentration in the principal region affected in various
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degenerative diseases has led to the speculation that the receptor may be 
involved in conditions such as Huntington's Chorea and Alzheimer s 
disease.6^’*73 it is also associated with other neuronal injuries such as epilepsy 
and stroke7^
1.9.2. »Ouisatialate receptor”.
The quisqualate receptor was the least understood of the three excitatory amino 
acid receptors originally identified in the 1970's, possibly due in part to the 
unavailability of ^H-quisqualic acid. Quisqualic acid (20) was first described 
as a potent excitant at the crayfish neuromuscular junction,25 and in the frog 
and rat spinal cord.^^ The use of quisqualic acid in binding studies has led to 
the conclusion that the amino acid is not selective for what was initially known 
as the quisqualate receptor subtype. It also exhibits high affinity for other 
excitatory amino acid receptors; namely, the kainate, AMPA, and metabotropic 
receptors, some transport sites, such as the chloride-dependent L-AP4-sensitive 
sites, and certain dipeptide degrading enzymes, such as that responsible for 
cleavage of N-acetyl-aspartylglutamate (NAALADase).^^ A major 
breakthrough in the study of the quisqualate-sensitive ionotropic receptor was 
the isolation of a new class of excitatory amino acid antagonists, the 
quinoxalinediones^^ such as CNQX (46)and DNQX (47).
NC O 2 N
(46) (47)
H
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Binding and electrophysiological studies of this novel group of compounds 
have led to an increased understanding of the function of the quisqualate- 
sensitive receptor subtype responsible for the fast excitatory postsynaptic 
potentials (EPSPs). This receptor is the AMPA receptor, following the 
identification of the more selective ligand a-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid (AMPA) (22). The other receptor which shows high 
sensitivity to quisqualate (CNQX/DNQX-insensitive) is the metabotropic 
receptor, the activation of which is coupled to the generation of inositol 1,4,5- 
trisphosphate (IP3), and the mobilization of calcium ions.76 For the purposes 
of this review the term "quisqualate receptor" will refer to the quis/AMPA 
receptor. The metabotropic receptor will be treated separately.
1.9.3. Ouis/AM PA receptors.
Since its synthesis, isolation, and pharmacological evaluation, the structural 
analogue of quisqualic acid, AMPA (22), has proved a useful tool in advancing 
the understanding of excitatory amino acid receptors. The availability of CH­
AMPA, and its specificity in binding and electrophysiological studies, has 
provided distinct evidence77 of the differences between the NMDA and non- 
NMDA receptors, notably kainate, AMPA and the newly-defined metabotropic 
receptor. To date no specific antagonist for this receptor has been discovered. 
However, two analogues of kynurenic acid (31), the quinoxalinediones CNQX 
(46) and DNQX (47), show some selectivity and relatively high affinity for the 
3H-AMPA binding sites and block AMPA and quisqualate-evoked 
excitation.77 Molecular studies of the AMPA receptor by Honoré et al. 
demonstrated that the use of thiocyanates potentiates 3h -AMPA binding to its
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receptors, possibly due to a shift of a high affinity binding site of the 
receptor7^
Receptor autoradiography using ^H-AMPA in conjunction with kainate and 
NMDA (to prevent binding to other receptor types) suggests that, 
anatomically, the AMPA receptors are localized in the telencephalic regions, 
with high levels in the hippocampus, cortex, lateral septum, stratum, and the 
molecular layer of the cerebellum^^ This distribution corresponds closely to 
that of NMDA receptors, and thus supports the speculation that the two 
receptor subtypes probably act in concert in their mediation of neuronal 
postsynaptic activation.
Physiologically, little is known about the AMPA receptor. There are 
suggestions that it may participate in neurotoxicity in the hippocampus^^ 
neuronal degeneration of the cerebral cortex,^ and ischaemic brain injury. ^ 
However, the mechanism by which these actions may be mediated is not 
clearly understood.
1.9.4. Metabotropic receptor.
The discovery of this newly-defined receptor confirmed a long-held 
hypothesis^^’^ l"^^ that the quisqualate receptor may be coupled to more than 
one site in the CNS. The receptor was identified by the study of
phosphatidylinositol turnover in brain slices, following intracellular injection 
of rat brain .^3 In 1988, the first potent and selective non-NMDA receptor 
antagonists were developed by Honore.^^ Use of these quinoxalinediones, 
particularly (CNQX) (46), in ligand binding as well as in electrophysiological
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studies, by virtue of their blockade of quisqualic acid-induced excitations of 
the AMPA receptor, but not those exhibited by the metabotropic receptor, 
provided evidence in support of the existence of more than one quisqualate 
receptor.
Pharmacologically, metabotropic receptors are preferentially activated by 
quisqualic acid (20), ibotenic acid (28), and L-glutamic acid (1), and not by 
NMDA (15), AMPA (22), or kainic acid (18). There are no specific 
antagonists known, as yet, for these receptor subtypes, although it has been 
suggested that AP4 (33) may be an indirect antagonist.^3
Research into the anatomical localization of metabotropic receptors indicates 
that a subpopulation of ^H-L-glutamate binding sites (quisqualate-sensitive, 
but AMPA-insensitive) may represent their recognition s i t e s . T h e  
development of selective and potent competitive antagonists would facilitate 
further characterization of these receptors.
Little is known of their physiological role in the CNS, although it has been 
suggested that they may be involved in neurodegenerative disorders and 
synaptic plasticity.
1.9.5. Kainate receptOL
Alpha-kainic acid (18), a cyclic analogue of L-glutamic acid (1), was isolated 
from the seaweed Digenea simplex, by Takemoto et al.^^ Its neuroexcitatory 
properties were first described in 1970 by Shinozaki,^^ and it is the prototypic
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agonist of the kainate receptor. Since its identification as an excitatory amino 
acid receptor, only limited progress has been made in kainate neurochemistry, 
possibly due to the lack of specific kainate antagonists. However, some non- 
selective antagonists have been identified including kynurenic acid (31), y-D- 
glutamyl-glycine (29), CNQX (46) and DNQX (47).75 Some progress has 
been made in the identification of potent and selective kainate agonists, 
notably domoic acid,27»86 ( 19) and 5-bromowillardine (21).^7 it would 
appear that the presence of the bromine atom in the latter is significant, since 
willardine has little activity at the kainate site.^7
Moreover, quiscjualic acid has moderate activity at the kainate site, as do L- 
glutamic acid (1). Electrophysiological studies of kainate activity in the CNS 
have indicated that the activation of the receptor may be attributable to the C-4 
unsaturated side chain of kainic acid.^^’^ 7,31 Furthermore, the (S)- 
configuration at C-2, and the c«-relationship between the C-3 and C-4 
substituents, are essential to its activity.^7 Understanding of the kainate 
receptor will be dependent upon the identification of specific and selective 
antagonists for the receptors.
Research into the anatomical distribution of kainate receptors indicated that 
they were predominant in the mammalian C fibres,^7,87,88 but appear to be 
quite diffuse in many regions of the CNS. Autoradiographic studies have 
indicated receptor populations in the cerebral cortex, and high densities in the 
striatum, and nucleus accumbens of the basal ganglia.^^ Localised 
concentrations of the receptor have also been reported in the hippocampus,^^ 
with low levels in the thalamus, hypothalamus, mid-brain, and hind-brain of 
the CNS.90 Only limited investigations ^7 have been made of what appears 
(in view of the lack of NMDA and AMPA selectivity in this region of the
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nervous system to be a pure kainate population, i.e. the C-fibres. It is unclear, 
however, whether or not these kainate receptors are identical to kainate 
receptors in other regions of the CNS.^^ The kainate receptor has also been 
suggested to be involved in neuropathological states such as epilepsy and 
spasticity, neurodegenerative conditions which are associated with strokes, 
Huntingtons Chorea, Alzheimer's disease, and schizophrenia.^^
The excitotoxic effect of kainic acid was first reported by Olney,^^ ^ho 
observed that the amino acid had the same order of potency for its excitatory 
and its neurotoxic activities. Compounds which interact as agonists at the 
kainate receptor, such as domoic acid, also exhibit neurotoxic activity.^^
1.9.6. L-AP4 receptor.
This subpopulation of glutamate receptors was discovered because L-AP4 (33) 
was a potent antagonist of evoked excitatory responses at a subpopulation of 
the glutamate receptor. "^^ ’95 Although the L-AP4 receptor was discovered 
somewhat later than the other excitatory amino acid receptors, it is rather 
surprising that to date very little is known about the mechanism by which it 
mediates its responses.
A number of studies suggest that the effect of L-AP4 is mediated 
presynaptically in the CAl region of the hippocampus, lateral olfactory tract 
and in the spinal cord, where L-AP4 is thought to increase post-synaptic 
excitations induced by NMDA, kainate, quisqualate, and L-glutamate.^^’^ ^ 
However, the precise membrane binding site through which L-AP4 exerts 
these effects has been difficult to elucidate. It has been suggested that its 
actions may be mediated via a chloride-dependent L-glutamate binding
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,i,e.97,98
The anatomical distribution of the the receptor remains equivocal, although 
populations of the L-AP4 receptor in the brainstem, hypothalamus, spinal cord, 
cortex and the cerebellum have been cited.^5,98,99 its precise physiological 
profile has yet to be defined.
A major impetus to the study of excitatory amino acids has been the 
implication of their receptors, particularly the NMDA receptor, in 
neuropathological conditions. Since the discovery in 1957100, ,hat systemic 
administration of L-glutamic acid to mice caused degeneration of retinal 
neurones, research has centred on the role of excitatory amino acids in 
neurodegenerative diseases. These research programmes, coupled with the 
development of selective antagonists for the excitatory amino acid receptors, 
have provided clear evidencelOl-103 of their involvement in 
neuropathological states. The involvement of excitatory amino acids in 
abnormal neuronal activities, such as epilepsy, is well documented.*I*“* They 
are also thought to be associated with chronic neurodegenerative disorders, 
such as Huntington's Chorea.lW senile dementia of the Alzheimer type.105 
Parkinsonism,'OS amyotrophic lateral sclerosis (ALSj.'O^ They are also 
thought to be involved in the pathogenesis of stroke, traumatic brain injury, 
cerebral ischaemia and hypoxia.'"“
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1.10.1. EDilePSY.
Epilepsy is a clinical paroxysmal abnormal electrical activity in the brain, due 
to sudden synchronous high-voltage discharges arising from a number of 
hyperexcitable neurones. Neurochemical and electrical changes occur with 
disturbances of the inhibitory mechanisms and spread of electrical discharges 
beyond the locus. Clinical manifestations include disturbances in sensation, 
alterations in perception and/or coordination, loss of conciousness, convulsive 
movements, and incontinence.!^^
Epileptiform foci may result from many different pathological conditions, such 
as trauma, vascular lesions, neoplasms, infections and atrophy of the brain. 
Metabolic and nutritional factors, such as hypoglycaemia, electrolyte 
imbalances, pyridoxine deficiency, and disturbance of fat metabolism are all 
contributary factors. Various toxic states, including lead and carbon monoxide 
poisoning, uraemia and certain allergic conditions are causative factors. 
Certain endocrine aspects, including changes which occur at puberty, 
premenstrually, and during pregnancy are important. Age is also very 
important, and in young children, febrile convulsions may lead to temporal 
lobe epilepsy later in life. Artificial induction of epileptiform activity in a 
variety of animal models has been reported. 108-110 These inductive methods 
include photic stimulation of the baboon papio papio and of the mouse 
(DBA/2 strain,! 11" 11^); audiogenic stimulation such as bell-ringing; electrical 
stimulation of the brain with externally applied electrodes; i.e a form of 
kindling; and chemical stimulation with known convulsants, such as leptazol, 
and/or excitatory amino acids such as NMDA, kainic acid, L-glutamic acid, L- 
aspartic acid, and quisqualic acid.! !^
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The involvement of excitatory amino acid receptors in the production of 
seizure-like attacks was demonstrated by the use of excitatory amino acid 
antagonists. Often, burst-firing techniques were used for the induction of 
epileptiform seizures in conjunction with metal ions such as potassium. 
Meldrum observed that spontaneous bursts in the region of CA3 region of 
hippocampal slices superfused with 8.5mM potassium ions or with 200nM 
kainic acid were eliminated by 2-5mM CNQX, but were insensitive to 
competitive NMD A antagonists. Furthermore, Aram et al showed that 
NMDA-evoked depolarizations were blocked by NMDA receptor antagonists, 
such as AP7 .112  This was substantiated by Meldrum and his colleagues, who 
observed that photo-induced convulsions in baboons were also blocked by 
113 Corresponding results have been reported for the suppression of 
epileptiform bursts with 7-chlorokynurenic acid (48), a selective antagonist for 
the glycine co-agonist site of the NMDA receptor.^^  ^ The work of Coutinho- 
Netto et al., who identified anti-convulsant effects of locally-applied AP5 in 
cobalt-induced seizure in the rat neocortex, is noteworthy. Antagonism of 
NMDA receptors was also observed by Croucher and his colleagues,^!^ who 
demonstrated that intracerebroventricular administration of AP5 and AP7 
caused potent anticonvulsant effects against audiogenic seizures in DBA/2 
mice. Thus, the NMDA receptor has been seized upon as the ultimate 
mediator of epileptiform seizures. Data on the role of the AMPA receptor is 
rather scanty, although the selectivity of the quinoxalinedione NBQX (49) for 
the AMPA receptor^l^’^l^ over the NMDA receptor should facilitate the 
study of AMPA receptors in epileptiform seizures. The availability of a 
specific non-NMDA receptor antagonist would permit analysis of the role of 
the receptor in the propagation of epileptic seizures.
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1.10.2. H untinnton's disease.
Huntington's disease is a severe neurological disorder, marked by degeneration 
of motor neurones. Usually the disorder is manifest during middle life, with 
the onset of involuntary choreic movements that become more severe with 
time, resulting in death some fifteen years after the onset. The aetiology of 
this genetically inherited disease remains unknown. It is of biochemical 
interest that epilepsy is fairly common when the disorder is first diagnosed. 
Anatomically the greatest atrophy is seen in the basal ganglia, a large group of 
nuclei which controls movement through the thalamus and motor cortex. 
Attempts to discover the biochemical basis for Huntington s disease have 
shown that levels of the inhibitory amino acid y-aminobutyric acid (GABA) 
(2) are lowered. Significantly, the levels of glutamic acid decarboxylase 
(GAD) (an enzyme which catalyzes the synthesis of GABA) were also 
significantly decreased.^
The changes in enzyme concentration were observed in both the postmortem 
tissues of choreic brain and experimental animals in which the disorder had 
been induced by administration of kainic acid.^^^ Interestingly, there appears
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to be no morphological evidence in support of specific excitotoxic neuronal 
damage, nor is there evidence in support of increased levels of quinolinic acid
(25).
Clinical management of Huntington's disease has been fraught with difficulty. 
One choice of treatment would have been to increase the levels of GABA in 
the brain; however since GABA does not cross the blood-brain barrier, this 
mode of treatment is not feasible, unless suitable prodrug forms of GABA can
be produced.
1.10.3. Cerehrnl ischaemia a n d  hvPQXia.
Ischaemic neuronal degeneration is evident after any stress, such as cardiac
120arrest, profound arterial hypotension, focal ischaemia, or hypoglycaemia, 
that critically depletes cerebral energy metabolism. Neuropathologists have 
generally attributed epileptic brain damage to systemic hypoxia, to cerebral 
arterial spasm or to cerebral oedema, leading to compression of the 
arteries.121-123 This is often associated with status epilepticus, involving 
pyramidal neurones in hippocampal CAl and CA3 regions. 1^4 
Microscopically, the brain damage takes the form of nerve cell loss and 
reactive gliosis. 1^5 Excitotoxic mechanisms are thought to contribute to this 
type of neuronal loss, which follows cerebral ischaemia. Postsynaptic 
neuronal changes which characterize excitotoxic damage have been identified 
in the various animal models of ischaemia. ^ 26 Evidence in support of 
excitotoxic involvement in cerebral ischaemia was provided by the finding that 
competitive and non-competitive NMDA receptor antagonists (CPP and TCP 
respectively)^protected  cerebral neuronal cells of adult mice, cats and rats
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from damage, following cerebral artery occlusion. ^  25 jh e  volume of neuronal 
damage in such cases was reduced by 4 0 -6 5%.^25
1.10.4. Aly.heimer*s disease.
Alzheimer's disease is caused by overproduction of fibrous protein in the 
neurones of the brain, and abnormally formed microtubules and 
microfilaments fill the cells, often to such an extent that other vital subcellular 
organelles, such as mitochondria, are excluded, resulting in cell death. 127 The 
cholinergic neurones, which connect the nucleus basilis to the frontal temporal 
cortex, are particularly affected, 128 as are glutamatergic and serotoninergic 
neurones. 129 The involvement of noradrenergic fibres has also been
reported. 1^9
1.10.5. Amvotropic lateral sclerosis.
Amyotropic lateral sclerosis (ALS), also known as motor neurone disease, is a 
progressive degeneration of the corticobulbar, spinal, and lower motor 
neurones. 131 It leads, by encroachment, to a mixture of spastic and atropic 
changes in cranial and spinal musculature. Damage to the myelin sheath 
occurs secondary to damage in the lateral columns. This condition is likened 
to Guam disease, a neuropathological condition sometimes referred to as ALS, 
Parkinsonism or dementia. 131
1.10.6. Guam diseas£>
Like ALS, Guam disease is a chronic neurological disease. It is linked to the
34
dietary consumption of p-N-methylamino-L-alanine (BMAA) (50), an amino 
acid found in the seeds of cycas circinalis.^^^
NHMe
H3 N
(50)
The amino acid BMAA is thought to be an exogenous excitotoxin.132 Under 
normal conditions (in vitro), it is neither excitatory nor toxic. However, in the 
presence of bicarbonate ions it becomes excitotoxic, possibly due to the 
formation of an a-methyl carbamate, excitotoxic activity is thought (by
virtue of its blockade by the NMDA antagonists AP5 and AP7 ), to be 
mediated largely via the NMDA receptor. 1^3,134 However, the observation 
that the amino acid has a weak excitotoxic action on NADPH-diaphorase- 
positive neurones suggests that part of its action may be mediated via a non- 
NMDA receptor. ^
1.10.7 Neiirolathvrism and BOA A
Neurolathyrism is a spastic disorder occurring in East Africa and southern 
Asia. It is associated with the consumption of the chick pea Lathynis sativus, 
which contains the excitotoxin p-N-oxalylamino-L-alanine (BOAA) (23). This 
behaves as a glutamate-like excitant on spinal neurones, acting principally as 
an agonist at AMPA receptors.
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1.11. Theraneutic potential of excitatory amino acids.
There are many mechanisms which control the synaptic release of excitatory 
neurotransmitters. Among these are autoreceptors, whose response is 
analogous to glutamate or its analogues, GABA^ receptors linked to the 
benzodiazepine receptor site, adenosine receptors, and GABAb  receptors. 
Thus, in brain slices or in other in vitro preparations, it is possible to 
demonstrate a decrease in the evoked release of excitatory amino acids in the 
presence of benzodiazepines such as (51), baclofen (52), and excitatory amino 
acid antagonists such as MK801 (43).
Cl
(52)
COo-
The postsynaptic action of excitatory amino acids can be blocked by analogues 
that compete for the particular receptor site. A wide range of glutamate 
analogues has been tested as potential antagonists at postsynaptic NMDA, 
quisqualate, kainate and AMPA receptor sites. The NMDA receptor 
antagonists were more efficacious than the quis/AMPA or kainate receptor 
antagonists. Compounds with a highly potent and selective action on the 
NMDA receptor, such as 2-amino-7-phosphonoheptanoic acid (AP7) (38) and
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3.((+/.)-2-carboxypiperazin-4-yl)-propyl-l-phosphonic acid (CPP) (36), are 
potent anticonvulsants when injected intracerebroventricularly in mice.
To be clinically useful as an anticonvulsant, an NMDA receptor antagonist 
must cross the blood-brain barrier, and should suppress seizures with 
acceptably low toxicity towards physiological systems. The early reports by 
Meldrum and Croucher et that systemic administration of AP7 to mice,
rats, and baboons eliminated seizures at doses devoid of unwanted side-effects, 
engendered considerable optimism for the clinical usefulness of this NMDA 
antagonist. Unfortunately, however, recent reports 1^8-142 suggest that the 
anticonvulsant effect of AP7 may overlap with unwanted behavioural effects. 
The recent identification of the more potent and selective NMDA antagonists 
such as CPP (36) and (+)-5-methyl-10,ll-dihydro-5H-dibenzo[a,d] 
cyclohepten-5,10-imine, (MK801) (43) has provided new insight into the 
therapeutic potential of NMDA antagonists. CPP was found to be 5-12 times 
more potent as an NMDA antagonist than either AP5 or AP7.1^^’^ ^
Electrophysiological studies suggest that MK801 is a potent and 
noncompetitive blocker of NMDA induced responses. The only compounds 
shown to compete effectively at the MK801 binding site were the a-opioid
type drugs, PCP (41), SKF 10047 (53), and ketamine (42).
37
(53)
O ^ N . SO.
H3N CO.
(54)
Furthermore, Foster97 and his colleagues reported that systemic injection of 
MK801 protected against neurodegeneration of cerebral cells following 
intracerebral injection of NMDA. Some compounds with a preferential 
antagonist action at the kainate or quis/AMPA receptors are also 
anticonvulsants. Intracerebroventricular injection of y-D-glutamyl- 
aminomethylsulphonate (54) and various piperazine derivatives (eg BBPP) 
exhibited anticonvulsant effects, although the exact receptor site at which these 
actions are mediated remains equivocal.
It is clear from the above reports that excitatory amino acid antagonists have 
potential value in the search for clinically useful anticonvulsants. However, 
comprehensive biochemical characterization, identification, and isolation of 
the different excitatory amino acid receptors is urgently required for the 
attainment of the full therapeutic potential of such antagonists.
AnOENDUM
Recent advances in molecular biology have led to the cloning and expression 
of glutamate excitatory amino-acid receptors. Thus, the NMDA receptor is
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now divided into two subunits, termed NMDAR-1 and NMDAR-2145,146 
The recent expression and cloning of one of the NMDA receptor subunits, 
NMDAR-1, by Nakanishi et revealed prominent structural similarities
with the classical glutamate NMDA receptor, including Ca '^*' ion permeability, 
voltage-dependent blockade by Mg^+ ions and enhancement by glycine 
Its pharmacological profile was found to be similar to that of the classical 
NMDA receptor; for example, L-glutamate, quisqualic acid, ibotenic acid and 
homocysteic acid were found to be effective agonists, whilst AP5 and CPP 
were antagonists. In contrast, the NMDAR-2 subunit , when co-expressed 
with NMDAR-1, markedly potentiates responses to NMDA or glutamate, but 
shows no intrinsic electrophysiological response to agonist application, 
which suggests that the subunit is distinctively different from NMDAR-1.
The story is further complicated by the findings of Seeburg,!!^^ and 
Nakanishi who reported the existence of at least four additional NMDA 
receptor subunits termed NMDAR-A to NMDAR-D. In addition, cDNA 
cloning of a polypeptide of a putative NMDA receptor has also been
reported.
The recent advances in molecular biology and the identification of a cDNA 
clone for the functional AMPA/kainate receptor has provided evidence of the 
existence of closely related subunits of the classical AMPA receptor. 152 
Cloned cDNA encoding the receptors was obtained via the polymerase chain 
reaction (PCR) from which four molecular subunits termed GluR-A to GluR-D 
or GluR-1 to GluR-4 were fully characterized. 153,154,146 
The pharmacological profile of the recombined expressed receptors was 
studied 155 by ligand binding techniques, using low concentrations of [^H] 
AMPA and [^H] KA. The results demonstrated only specific [^H] AMPA 
binding. Competitive binding to these receptors was most effective with
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quisqualic acid and L-glutamic acid.
In addition, the molecular evidence for the existence of high-affinity kainate 
receptors was provided by the cloning of cDNA for kainate binding proteins 
from frog brain 156 and chick cerebellum. 157 That which was cloned from 
frog brain provided a high affinity binding site, but no ion channel. 1^5 
Additional numbers of the same receptor subclass GluR-6 and GluR-7 have 
also been cloned. 155 GluR-6, which possesses 80% sequence identity with 
GluR-5, was found more predominantly in the CNS than was GluR-5. 
Interestingly, its mRNA distribution was found 158 to resemble that of high 
affinity KA-binding sites in CA3 of the hippocampus, the caudate putamens 
and cerebellar granule cells.
Furthermore, a high affinity KA receptor subunit termed KA-1 was isolated by 
Werner et a/. 159 This clone was found to be abundant in CA3 and dentate 
gyrus of the hippocampal formation, consistent with the localization of certain 
classical high-affinity KA sites in the CNS. A new class of this subunit termed 
KA-2 has also been identified. 15^
Molecular cloning by cross hybridization and polymerase chain reaction 
(PCR)-mediated DNA amplification techniques has provided evidence of the 
existence of at least six subtypes of the metabotropic receptor. These were 
termed mGluR-1 to mGluR-6.160-164 cDNA clones for the six different 
subtypes of the mGluR family were isolated by molecular screening of a rat 
brain cDNA library 1^5 The mGluR's showed distinct signal transduction via 
different G proteins and are expressed in specialized neuronal glial cells in the 
CNS. These six mGluR's were further divided into three subgroups 
according to similarities in their sequences and by their agonist selectivities. 
Nakanishi^"*^ investigated the properties of these individual receptors in
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Chinese hamster ovarian cells and found that mGluR-1 and mGluR-5 
stimulated inositol triphosphate (IP3) formation and intracellular calcium 
mobilization as as the induction of arachidonic acid release. Furthermore, 
these two receptors also showed the same agonist selectivity, being found to be 
most sensitive towards quisqualic acid.^"^^»^^^ However, these receptors 
differ slightly in their sensitivity towards pertussis toxin (PTX). In contrast, 
mGluR-2 is linked to the inhibitory cAMP c a s c a d e a n d  at mGluR-4 
receptors, AP4 is the most potent agonist, being one order of magnitude more 
potent than L-glutamic acid. ^  67-169 Furthermore, mGluR’s-2,3 and 4 were 
found to be more sensitive to PTX, which suggests that these receptors are 
coupled to PTX-sensitiveG (Gi) proteins.
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2.1 ■ Intro ductio n .
The search for new glutamate agonists and antagonists has prompted many 
chemists to synthesize various novel amino acids. The last ten years saw an 
explosion in the field of amino acid research, with particular interest being 
focused on the glutamate agonist, quisqualic acid. This area of research was 
initiated by the observation by Shinozaki et who discovered that
quisqualic acid had powerful neuroexcitant properties.
In 1980 Bycroft and his colleagues commenced a synthetic strategy aimed at 
developing structure activity relationships at the quisqualate receptor. 1^0 
These workers developed the methodology by which quisqualic acid was 
synthesized, in its racemic form. The key intermediates which were 
developed at this time include the enolate (2 :1 ), and the tosylate (2 :2) 
derivatives. While the tosylate undergoes displacement by nucleophiles, 
yielding compounds of the types (2:3), the enolate undergoes condensation 
reaction with hydroxylamine salts yielding compounds such as (2:4). Both 
intermediates have been employed in the synthesis of DL-quisqualic acid 
and related analogues.
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The principal question addressed in this research programme concerned the 
functional group requirements for the maintenance of agonist and/or 
antagonist activity and the development of specific mimetics which act only 
at one defined receptor (the quisqualate receptor being the receptor of
interest).
Receptor models focused on the question of whether two or all three of the 
functional groups in the amino acid moiety were involved in the binding of 
the amino acid to its receptor sites. The alternative models proposed by 
Curtis et alP iov the glutamate receptor comprised a two point receptor 
(possessing a positive and a negative site of attachment) and a three point 
receptor in which there are two positively-charged and one negatively- 
charged binding sites. The question of whether a two or a three point 
receptor is responsible for the mediation of quisqualate responses remains
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unclear, possibly due to the unavailability of agonists and/or antagonists. 
It was on this basis that the decision was made to search for synthetic 
methodology by which tritiated quisqualic acid may be synthesized.
In order to evaluate potential changes in the quisqualate moiety with respect 
to synthetic targets, it is convenient at this point to consider the information 
available in terms of structure activity relationships at the quisqualate 
receptor. To date however, except for preliminary reports by Honore,^^ 
who synthesized a selective antagonist (DNQX) (a non-amino acid), only a 
few analogues of quisqualic acid have been synthesized and tested for their 
pharmacological efficacies; notably Bycroft’s substituted hydantoin (86), 
which showed no activity at the quisqualate receptor, and glutamate diethyl 
ester (32), a non-selective antagonist. The lack of prior investigation into 
the synthesis of quisqualic acid analogues and the paucity of data with 
regards to structure-activity relationships allows the chemist considerable 
scope in the search for novel quisqualic acid analogues
2.1.1. ATMS AND on TECTIVES.
Although the identity of quisqualic acid has been known for a long time, 
very little progress has been made in the study of its receptor, possibly due 
to the lack of tritiated quisqualic acid and the unavailability of selective 
antagonists at the quisqualate receptor. From the foregoing introduction, it is 
clear that of prime importance in the study of the quisqualate receptor is the 
availability of labelled quisqualic acid. Initial efforts were therefore directed
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towards the development of the methodology by which labelled quisqualic 
acid may be synthesized.
Even though the Ferrosan compounds (46) and (47) exhibited selectivity in 
their action as antagonists, it was decided that quisqualic acid analogues (i.e 
compounds possessing the heterocyclic ring systems and the propionic side 
chain) should be synthesized. The reason for this was that whereas the 
Ferrosan compounds, non-amino acids, are selective only at the AMPA 
receptor, analogues which are structurally related to quisqualic acid may act 
not only at the AMPA site, but also at the newly defined metabotropic 
receptor site. Futhermore, since quisqualic acid is a structural analogue of 
glutamic acid, analogues of quisqualic acid may also show some activity at
the NMDA receptor.
It was therefore decided that three types of quisqualic acid analogues would 
be synthesized and tested for their pharmacological effiects. Firstly, 
modification of the heterocyclic side-chain of the amino acid would provide 
a series of p-functionalized L-alanines, such as (2:5) and (2:6).
Secondly, protection of the a-amino or carboxylate function of quisqualic 
acid, or peptide coupling, would provide analogues wherein one or other of 
these groups was no longer charged, for example, dipeptides such as (2:7). 
Thirdly, the acidic NH of the quisqualic acid heterocyclic side-chain would 
be alkylated to give compounds such as (2 .8).
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Pharmacological evaluation of these compounds should hopefully allow 
some conclusion to be reached regarding the functional group requirements 
of the quisqualate receptor.
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2.2. Synthesis of PL-niusniiAUC acid .
The synthetic strategy adopted for the work reported here was based on the 
synthon approach developed by B y c r o f t f o r  the synthesis of DL- 
quisqualic acid. This approach utilizes benzoyl protected glycine (55) which 
was converted to the ethyl ester (56) (scheme 1), by acid-catalyzed 
esterification. The ester, a white solid, was obtained from extractive workup 
in good yield (98%). Its physical and spectroscopic properties were 
consistent with the proposed structure.
Scheme 1.
CO2H
(55)
PhCON
1
H
(56)
COjEt
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^
, CO^E,
”  (58) ”  (57)
Reagents: (i) pi//Y7-toluenesulphonic acid, EtOH, 20^C
(ii) HC0 2 Et, NaOEt, EtOH
(iii) PhCH20NH2.HCl, DCM
ONa
COjEt
Condensation of the ester (56) with ethyl formate and sodium ethoxide afforded N- 
benzoyl-2,3-dehydroserine as its sodium enolate (57). Examination of the 
NMR spectrum showed the olefinic proton in the aromatic region at 5 8.6, with
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concomitant loss of the methylene signals. Structural assignment was completed 
by the mass spectrum which exhibited an [M+H]'*' at "'/e 252.
Condensation of the sodium enolate (57) with 0-benzylhydroxylamine 
hydrochloride in a two phase system (water/dichloromethane) gave the 
benzyl oxime (58) in 63% yield, following flash chromatography. The 
NMR spectrum of (58) exhibited resonances due to the benzyl group at 5 5.1 
(CH2Ph), and 5 7.3. The presence of the methine double doublet at 5 5.41, 
and the olefinic proton of the oxime at 6 7.65, suggested that the sodium salt 
(57) had in fact been converted to the protected oxime (58). The mass 
spectrum exhibited a molecular ion at "^/e 340 which was consistent with the
structure.
Sodium cyanoborohydride reduction of the 0-benzyloxime (58) in 
methanolic HCl at pH 3-4 afforded the protected hydroxylamine (59), The 
reaction was stirred overnight to ensure complete reduction. The yield after 
extractive workup and flash chromatography was 66%. The absence of any 
absorption assignable to the oxime in the infrared spectrum of the product, 
and the absence of the olefinic proton in the NMR, together with the 
presence of a methylene multiplet at 5 3.48, and an upfield shift of the 
methine signals from 5 5.14 in the oxime (58) to 5 4.87 in the 
benzyloxyamine (59), confirmed the structure.
Scheme 2.
Ph
(0
PhCON
H
C02Et PhCON
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(58) (59)
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Reagents: (i) NaBH3CN, MeOH, pH3-4
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The importance of the pH of the reaction deserves some comment. The 
optimum pH for cyanoborohydride reduction of oximes is pH 3-4. This 
ensures that the oxime nitrogen remains protonated, and is therefore more 
susceptible to nucleophilic attack by the borohydride ion. At higher pH, 
reduction is often ineffective because the oxime nitrogen is unprotonated, 
whilst at lower pH the borohydride is solvolyzed.^^^
2.2.1. Construction of the nxadiazolidine ring.
This was initiated by the elaboration of the benzyloxylamine (59). The 
amine was condensed with ethoxycarbonyl isocyanate in dry ether to afford 
the N-benzyloxyureide (60) as an amorphous solid in good yield (68%) 
(scheme 3 ). The base peak in the mass spectrum was the molecular ion 
(m/e 457).
The protected hydroxyurea (60) was debenzylated in ethanol, by facile 
catalytic hydrogenation over palladium on activated charcoal. 
Recrystallization from diethyl ether/ethanol afforded (61) in 74% yield. The 
loss of the benzylic protons in the ^H NMR spectrum of the product showed 
that deprotection of the N-hydroxyl group had occurred.
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Reagents: (i) Et0 2CNC0 , Et20
(ii) H2, Pd-C, EtOH
(iii) 2eqv. NaOH, then HCl aq.
Treatment of the hydroxyurea (61) with two equivalents of sodium 
hydroxide effected both cyclization to the oxadiazolidinedione, and 
hydrolysis of the ethyl ester. The white solid, which precipitated on 
acidification with concentrated HCl, was recrystallized from water and 
ethanol to afford N-benzoylquisqualic acid (62) in 88% yield. The absence 
of ethyl signals in its NMR spectrum, and an [M+H]'*’ at *^/e 294 in the 
mass spectrum, confirmed the structure (scheme 3).
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With the isolation of the benzoyl protected cyclized material, all that 
remained was removal of the N-protecting group to give the racemic 
compound. To this end, treatment of (62) with 6M HCl followed by ion 
exchange chromatography afforded the amino acid (63) in 35% yield. The 
low yield of the final product may be attributable to the vigorous conditions 
required for the removal of the benzoyl protecting group. An interesting 
feature of the NMR spectrum of the product (in NaOD/D2 0 ) was an obvious 
upfield shift of the methine signal relative to that of the methylene protons, 
whereas in DCI/D2O, the methine signal was downfield of the methylene
signal.
Scheme 4.
H
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H
0
0
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(62) (63)
Reagents: (i) 6N HCl, reflux
Initial attempts at synthesis were focused on the methodology by which DL- 
quisqualic acid (63) was prepared, using the intermediate benzyloxime (58). 
The possibility of double bond reduction by facile catalytic hydrogenation to 
give the corresponding protected hydroxylamine derivative (59) was
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considered (scheme 5). Substitution of tritium gas for hydrogen in such a 
reaction would provide a convenient method of incorporating a label into 
quisqualic acid moiety. However, the O-benzyl protecting group would be 
unlikely to survive under such conditions.
Scheme 5
N OCH2Ph OCHgPh
PhCON CO^Et
H <“ > *
PhCON ,5 9 )0 0 2 0  
H
OH
PhCON
H (64)
COjEt
H
Reagents: (i) H2 , Pd-C, EtOH
Thus, in a model reaction, catalytic hydrogenation of the oxime (58) did not 
produce the desired benzyloxylamine (59), but resulted in the loss of the O- 
benzyl group to give (64). Under basic conditions this would simply cyclize 
to a five membered ring system (65) (scheme 5).
In order to circumvent this problem, a new starting material was sought 
which would incorporate a protecting group stable to catalytic hydrogenation 
over palladium. The starting material of choice was the O-t-butyloxime (66), 
prepared by condensation of the sodium enolate (57) with tert- 
butylhydroxylamine hydrochloride in a water/dichloromethane mixture. The 
protected oxime (66), a white solid, was obtained from extractive workup
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and flash chromatography in good yield (62%). The base peak in the mass 
spectrum was the molecular ion ("^/e 306). The absence of the olefinic 
proton, and the presence of the a nine proton singlet in its NMR 
spectrum were consistent with the proposed structure.
The method chosen for the insertion of the "tritium" atom was via 
hydrogenation of the t-butyl protected oxime (66) Thus the oxime was 
dissolved in a mixture of acetic acid (95%) and concentrated sulphuric acid 
(5%). The reaction mixture was hydrogenated over palladium on activated 
charcoal for two hours. Extractive workup gave the t-butyloxylamine (67) in 
40% yield, (scheme 6). The upfield shift of the methine proton in its *H 
NMR spectrum from 5 5.4 in (55) to 5 4.8 in the t-butyloxylamine, coupled 
with the appearance of a signal assignable to the methylene protons, 
suggested that the oxime had been reduced. In principle, tritium gas could 
replace hydrogen in this reaction.
The importance of the concentrated sulphuric acid concentration in this 
reaction is noteworthy. Any increase in the concentration of sulphuric acid 
to greater than 5% results in the acidolysis of the t-butyl group. The yield 
can be improved by the use of 2-3% concentrated sulphuric acid. In the 
absence of concentrated sulphuric acid, the reduction fails, (scheme 6)
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Scheme 6.
NaO
PhCON
H (57)
N
i i l
C 0 2 Et
H
PhCON
H (66)
(ii)
C 0 2 Et
C0 2 Et
OBut
PhCON
H (68)
CO^Et
\ ( i v )
_N —
* r  OH
PhCON CO^Et 
H (67) ^
C0 2 Et
PhCON CO^Et 
H (61) ^
Reagents: (i) B u^N H 2-HCl, H2O-DCM
(ii) AcOH, H2SO4, Pd-C, H2 (or ^H2)
(iii) Et0 2 CNC0 , Et20
(iv) TEA
( * denotes tritium label)
Treatment of the reduced system (67) with ethoxycarbonyl isocyanate in dry 
ether gave the t-butyloxyurea (68), as an amorphous solid, the structure of 
which was confirmed by NMR and mass spectrometry.
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^COgEt
N
OBu'
PhCON
H
C02Et
(68)
(i)
PhCON
H
COjEt
N
OH
COgEt
(61)
Scheme 7.
Reagents; (i) IN HCl in AcOH
Acidolysis of the t-butyl group was effected by treatment of (68) with IM 
hydrogen chloride in acetic acid. After one hour at room temperature, and 
extractive work up, the hydroxyurea (61) was isolated in 52% yield. The 
loss of the t-butyl group was evident from the disappearance of the signal at 
5 1.28 in the NMR spectrum, and an M+. at 367 in its mass spectrum 
confirmed the structure. Cyclization in sodium hydroxide, and hydrolysis of 
the ethyl ester groups, as outlined in scheme 5, gave the protected amino 
acid, which, upon hydrolysis in IM hydrogen chloride in acetic acid, 
followed by ion exchange chromatography, afforded DL-quisqualic acid
(63).
It should be added that, to date, this is still the only reported procedure by 
which a tritium label may be incoporated into the quisqualate moiety. The 
availability of labelled quisqualic acid should facilitate the study of the 
quisqualate receptor.
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2.3. Attempted synthesis of N-m-carhnxvmethvI DL-auisaualic
add (Z2L
The alkylation of quisqualic acid was initiated by the esterification of the 
benzoyl protected amino acid (62) which was converted to its methyl ester 
(69) by treatment with thionyl chloride in methanol (scheme 8). The 
structure of (69) was confirmed by spectroscopic characterization.
N
> = 0
PhCON
N
CO2H
(62)
N
PhCON
N
C02Me
(69)
> = 0
N
PhCON CO^Me
(70)
O.^
> = 0
PhCON CO2H
(71)
Scheme 8.
Reagents: (i) SOCI2» MeOH
(ii) NaH, BrCH2C0 2 Et, DMF, SO^C
(iii) NaOH aq.
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Base induced alkylation of the heterocyclic imide with ethyl bromoacetate in 
DMF at 5QOC produced the alkyl derivative (70) after chromatographic 
purification on silica. The spectroscopic characteristics of this material were 
consistent with its being the desired product.
Treatment of this material with aqueous sodium hydroxide and subsequent 
acidification with 2M HCl gave the diacid (71), which upon hydrolysis in 
refluxing 6M HCl gave what appears to be a decomposed material..
(7 1 )
Scheme 9. 
Reagents:
N
> = 0
H^N CO2H
(72)
(i) 6N HCl, reflux
2 .4  SYNTHF.SIS OF L-OtllSOt)ALlC ACIÜ.
The synthetic approach to L-quisqualic acid was based on that developed by 
Mattingly and Millerl72 for the synthesis of 3-(tert-butoxycarbonyl)amino- 
l-benzyloxy-2-azetidinone (76). This synthon, which possesses a masked ex­
amino acid unit, was synthesized from L-serine (73). The synthesis of (76) 
based on this approach is illustrated in scheme 6. The initial step in the 
synthesis of quisqualic acid entails the conversion of L-serine to its N-t- 
butoxycarbonyl derivative (74) by known methodology. The amino 
group of serine was protected using di-tert-butyldicarbonate ((Boc)20 ) in
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isopropanol and amieous sodium hydroxide at room temperature. The N-t- 
Boc derivative was obtained as a monohydrate, in yields often in excess of 
85%. The NMR spectrum of (74) confirmed that the t-Boc group had 
been incorporated (singlet at 5 1.4). (Scheme 10).
(73) (74) (75)
N
OCHgPh
H
PhCHgON
(77)
COgH
Reagents: (i) (Boc)2 0 , isopropanol, NaOH aq.
(ii) BuiOCOCl, NMM, THF,-250C, 2 min., then 
PhCH2 0 NH2 .HCl, NMM,THF,-150C, 2hrs.
(iii) DEAD, TPP, THF,-780C, then r.t., over night.
(iv) NaOH, aq. MeOH, r.t., 2hrs.
Acylation of 0 -benzylhydroxylamine hydrochloride with the activated N-t- 
Boc protected acid, which was carried out by the repetitive excess mixed 
anhydride (REMA) method, 174 proceeded smoothly in quantitative yield.
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Thus t-Boc protected serine (74) was treated with one equivalent of isobutyl 
chloroformate and N-methylmorpholine in dry THF to give the mixed 
anhydride, which then reacted with O-benzylhydroxylamine to afford the 
hydroxamate (75), in an improved yield compared to that obtained by 
activation with EDC.^’72 jh e  reaction was carried out under anhydrous 
conditions, since the presence of water would have prevented the formation 
of the mixed anhydride, rendering the desired product unobtainable, or 
obtainable only in very low yield. To this end, the monohydrated t-Boc 
protected serine was dehydrated by azeotropic removal of water with 
toluene, prior to formation of the mixed anhydride. The reaction proceeded 
without racemization, presumably because the intermediate azlactone 
(formed after activation of the acid function) was configurationally stable 
under the reaction conditions, unlike the azlactones formed from amide- 
protected amino a c i d s . T h e  benzyl protons in its NMR spectrum 
appeared at 5 5.1 and 6 7.3 respectively, and the characteristic amide signal 
occurred at 6 9.0. This, coupled with an [M-i-H]'*’ (*^/e 311) in the mass 
spectrum, confirmed the structure.
The optically pure hydroxamate was converted to the (3-lactam (76) by the 
modified Mitsunobu^^b reaction (scheme 10). Thus, addition of the 
hydroxamate (75) to a preformed adduct of triphenylphosphine (TPP) and 
diethyl azodicarboxylate (DEAD) at -78®C afforded the desired product (76) 
in an isolated yield of 62%. The reaction was carried out under anhydrous 
conditions in dry THF under nitrogen to prevent hydrolysis of the preformed 
betaine. Thus TPP was dried over phosphorus pentoxide for seventy-two 
hours, and care was taken to ensure that the DEAD was not unnecessarily 
exposed to atmospheric moisture whilst being weighed.
60
Having stirred the reaction mixture at 25^C overnight, the crude product was 
preabsorbed on silica and purified by flash chromatography with ethyl 
acetate/hexane as the eluent. Isolation of the pure (3-lactam (76) was 
complicated by the close similarity in polarity of the by-product diethyl 
hydrazinodicarboxylate. The FAB mass spectrum, with an [M+H]+ at ^ /e  
293, and the characteristic carbonyl stretch (Vco=1720cm‘ ^) in the infrared, 
confirmed that the product was the desired |3-lactam.
The p-lactam (76) was smoothly hydrolyzed to the hydroxylamino acid (77) 
by treatment with one equivalent of sodium hydroxide. The product was 
isolated after acidification with a saturated aqueous solution of citric acid. 
Care was taken to ensure that only one equivalent of base was used, since an 
excess of base would increase the risk of racemization, as suggested by 
Baldwin 177. it was subsequently shown that racemization had not occurred 
during the base hydrolysis of the P-lactam ( or at any at other stage), as the 
final product of the synthesis, L-quisqualic acid, had the same optical 
rotation as that of authentic L-quisqualic acid 177. The mass spectrum of the 
product exhibited an [M+H]+ at ^ /e  311. Final confirmation of the product 
came from the infrared spectrum which demonstrated that the strained p- 
lactam had been converted to the hydroxylamino acid by the lowering of the 
carbonyl stretching frequency (Vqq = 1650 cm 1, compared with 1720cm
for the P-lactam).
During the development of the L-quisqualic acid synthesis, the overriding 
problem which presented itself was the possibility that racemization might 
occur during the base induced hydrolytic opening of the p-lactam ring. 
Having taken the necessary precautions to circumvent this problem, by using 
a minimum amount of base for the ring-opening reaction, an alternative
61
approach to the hydroxylamino acid (77), which would minimize the risk of 
racemization, was considered.
A search of the literature led to a paper by Arnold et which described
a method whereby N-protected a-amino acid -p-lactones (such as (78)) may 
be opened with alkylation using appropriate nucleophiles to give the 
corresponding p-substituted alanine derivatives.
Thus a new synthetic methodology was devised by which enantiomerically 
pure L-quisqualic acid (18) may be obtained, by the alkylation of O- 
benzylhydroxylamine hydrochloride with the N-protected ct-amino-P* 
lactone (78) (scheme 11).
Scheme 11
H
BocN^
(78)
OH
BocN CONHOCH Ph
H
(75)
NHOCH2Ph
COgH
(77)
t = 0 or r.t.
t = 80
Reagents: (i) PhCH2 0 NH2, MeCN
N-t-Boc serine (74) was converted to the p-lactone derivative (78), 
according to the literature precedent of Vederas et by the modified
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Mitsunobu reaction using triphenylphosphine (TPP) and diethyl 
azodicarboxylate (DEAD). The p-lactone was obtained in good yield 
(88%). An examination of the NMR spectrum revealed a downfield shift 
of the methylene signal from 5 3.7-4.1 in the t-Boc protected serine to 5 4.4 
in the P-lactone. The methine resonance appeared at higher field 5 5.1. The 
FAB mass spectrum exhibited an [M+H]+ at the required value of ” /^e 188. 
The elemental analysis of the product was consistent with the desired
structure.
Using O-benzylhydroxylamine as the nucleophile, several attempts were 
made to convert the p-lactone in THF to the corresponding hydroxylamino 
acid (77). These reactions invariably gave the hydroxamate (75), rather than 
the desired hydroxylamino acid derivative (77) (scheme 11). Temperature 
and solvent variation also afforded the acylation product (75). However, at 
40®C in acetonitrile, thin layer chromatography (tic) showed a mixture of 
two products, the more polar of which corresponded to the Rf of the 
hydroxylamino acid (77) obtained by the facile hydrolytic ring opening of 
the p-lactam (76).
Attempts to isolate this polar material by flash chromatography failed, 
nevertheless it was decided that the reaction should be repeated at a higher 
temperature. Thus the reaction mixture was heated under reflux (80^0) in 
acetonitrile. Tic once again demonstrated the presence of two main products, 
which corresponded to the hydroxamate, (75) and the hydroxylamino acid 
(77). These were separated by extractive workup followed by 
chromatographic purification, and isolated in 40% and 60% yield 
respectively. The spectroscopic characteristics and melting point of the less 
polar product were found to be indistinguishable from those of the
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hydroxamate (75) which was prepared directly from t-Boc-L-serine. 
Similarly, the more polar product exhibited identical physical and 
spectroscopic properties to those of the hydroxylamino acid (77). A possible 
explanation for this phenomenon may be attributed to the differences in the 
activation energies for formation of these two compounds. Thus, at lower 
temperatures, the acylation was favoured, whilst at higher temperatures the 
alkylation reaction was predominant, (fig 2 . 1)
Fig. 2.1
free
energy
----- transition state (alkyiation)
-----  transition state (acylation)
beta-lactone
hydroxamate 
hydroxylamino acid
reaction coordinate
Alkylation of O-benzylhydroxylamine with the p-lactone (78) to give the 
benzyloxylamine derivative (77) has not been previously reported. Although 
the nucleophilic ring opening gave both the acyl and the alkyl derivative, 
this approach provides an alternative method by which L-quisqualic acid 
may be synthesized.
Condensation of the benzyloxylamine (77) with ethoxycarbonyl isocyanate 
in dry THF gave the substituted urea (79) (scheme 12). This was 
debenzylated to afford the corresponding N-hydroxy derivative (80) by
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facile catalytic hydrogenolysis over palladium on activated charcoal in 
ethanol. The absence of the benzyl protons in the NMR spectrum, and an 
[M+H1+ at " '/e  336 in the FAB mass spectrum, were consistent with the
proposed structure.
Scheme 12
C02Et
(77)
(79)
C02Et
(80)
(81)
Reagents: (i) Et0 2 CNCO, THF, O^C, then r.t.
(ii) H2, Pd-C, EtOH, Ihr
(iii) NaOH aq. (2 eq.)
(iv) (a) IN HCl in AcOH, (b) ion-exchange
(20)
Ring closure to form the oxadiazolidinedione (81), (t-Boc protected L-
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quisqualic acid), was effected by cyclization with sodium hydroxide, 
(scheme 12).
The product (81) was isolated in good yield (58%) from extractive workup, 
after acidification. The absence of the ester signals in the NMR 
spectrum, and the upfield shift in the signals due to the side chain methylene 
protons, suggested that the cyclized derivative (81) had been isolated. 
Acidolysis of the t-Boc protected L-quisqualic acid (81) in acetic acid 
containing IM hydrogen chloride, followed by ion exchange 
chromatography, afforded L-quisqualic acid (20), in good yield (scheme 8). 
The physical and spectroscopic properties of the amino acid (20) were 
identical to those reported for L-quisqualic acid.^^^
2.,^. SYNTHESIS OF SOME ANAl Or.DRS OF OIJISQUALIC ACID.
Quisqualic acid is a potent analogue of the excitatory neurotransmitter L- 
glutamic acid, exhibiting differing neuronal sensitivities in different regions 
of central nervous system. For example, it is excitatory in the cortex, and 
inactive in the spinal neurones The amino acid and its analogues are 
therefore of potential pharmacological significance. However, if the full 
potential of quisqualic acid activities is to be realized, especially with respect 
to receptor characterization and identification, extensive studies would have 
to be undertaken.
It was therefore considered that a worthy objective would be the synthesis of 
analogues of quisqualic acid, in order to assess the influence of structural 
modification on its neuropharmacological properties. In very simple terms, 
the following types of modifications seemed to present reasonable synthetic
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targets, with a realistic possibility that their synthesis could be achieved:
(a) modification of the nature of the atoms/groups in the ring.
(b) increase or decrease in ring size.
(c) preparation of conformationally less restricted analogues.
(d) modification of the a-amino acid functionalities.
By way of illustration of each of these categories, structures such as (A-D) 
could be regarded as suitable synthetic targets.
N o o
H jN C O jH H j N C O j H
B
V
H j N CO j H
7S1 Svnfhe«snfa.t2.(tetrahvdrn.1.2.5-oxa<1Ía7,Ín-3.6-(IÍOMllL 
alanine (85).
Preparation of a homologue of quisqualic acid (in this case, a six-membered 
ring analogue) would only require modification of the synthesis to allow the 
incorporation of a methylene group into the heterocyclic ring. One obvious
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method would be to substitute ethyl isocyanatoacetate for ethoxycarbonyl 
isocyanate in the step wherein the protected hydroxylamino acid (77) is
acylated.
In considering the best way to approach such a synthesis, it was decided that 
the intermediate (77), in the L-quisqualic acid synthesis already developed, 
would serve as a useful starting material, since it possesses a protected 
hydroxyamino group conveniently placed for acylation with ethyl 
isocyanatoacetate, and hence for construction of the 
tetrahydrooxadiazindione ring, (scheme 13). Reaction of the intermediate 
(77) with ethyl isocyanatoacetate in dry THF afforded the substituted 
urethane (82) in good yield (70%) after extractive work up. The evidence 
that isocyanatoacetate had been incorporated was provided by the presence 
of ethyl and methylene chemical shifts in the^H NMR spectrum, as well as 
an [MH]"^ at m/e 440 in its FAB mass spectrum.
The monoester was debenzylated by facile catalytic hydrogenolysis in 
ethanol, (scheme 13). After workup, and recrystallization, the hydroxyurea 
(83) was isolated in 68% yield. The absence of the phenyl and benzylic 
protons in the NMR spectrum, as well as the FAB mass spectrum, which 
exhibited an [M+Na]+ at ^ /e  372, were taken as structural confirmation of
the product.
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Scheme 13
(77)
^ r -
N
H
(82)
C02Et
HON
C02Et
COgH
(83)
H
(84)
Reagents: (i) Et0 2 CCH2NC0 , THF, O^C, then r.t.
(ii) H2 , Pd-C, EtOH, Ihr.
(Hi) NaOH aq. (2 eq.)
(iv) (a) IN HCl in AcOH (b) ion-exchange.
H
(85)
Cyclization of the hydroxyurea (83) to the tetrahydrooxadiazinedione (84) 
was achieved by dissolution of the intermediate in a minimum amount of 
methanol, followed by the addition of two equivalents of sodium hydroxide. 
The mixture was stirred for four hours to ensure complete cyclization. The 
yield after extractive workup was 59%. Structural confirmation of the
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compound came from the NMR spectrum, which showed a considerable 
downfield shift of the tetrahydrooxadiazine dione methylene to 5 4.2 from 5 
3.7 in the uncyclized material. The FAB mass spectrum of the t-Boc- 
protected amino acid (84) exhibited an [M+H]+ at ” /^e 304.
Removal of the t-butyloxycarbonyl N-protection was effected by acidolysis 
in acetic acid containing hydrogen chloride (IM). Thus, complete 
deprotection of the amino function was achieved by treatment of the 
urethane (84) with the aforementioned acid solution. The amino acid 
hydrochloride, which ensued on evaporation of solvent, was converted to the 
free amino acid (85) by ion exchange chromatography. Interestingly, elution 
of the amino acid from the anion exchange resin (acetate anion) required a 
slightly more concentrated acetic acid solution (5%) than did quisqualic 
acid. Presumably, the tetrahydrooxadiazinedione moiety contributed more 
towards binding to the anion exchange resin than did the 
oxadiazolidinedione of quisqualic acid. The 1h  NMR spectrum of the 
amino acid (85), coupled with the elemental analysis confirmed the
structure.
7 ,«; ? svNTHFSis OF 3-ri -n.3.iM TDAZOUnTN-2.5-DI0NYl.)UhANINE,
Having successfully synthesized the ring expanded analogue of quisqualic 
acid, attention was now directed towards the synthesis of analogues with 
variations in the functional groups of the heterocyclic ring system. The 
initial compound chosen was the hydantoin analogue (87) of quisqualic acid. 
The more obvious hydantoin analogue (86), wherein the ring oxygen of 
quisqualic acid has been replaced by a methylene group, has been prepared.
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in racemic form, by Bycroft.
NH
N N
NH
COjH H^N COM
(86) (87)
In view of the strong structural similarity of (86) to quisqualic acid it was 
somewhat suprising to find that the compound was completely inactive as an 
agonist or antagonist at the quisqualate receptor. The acidity of the 
substituted hydantoin ring system is notably less than that of the 1,2,4- 
oxadiazalidine-3,5-dione system of quisqualic acid; this may be sufficient to 
account for its total lack of activity.
This prompted the search for the methodology by which the hydantoin 
analogue (87) of quisqualic acid may be synthesized.
1 approaches BASF.n ON THF ALKYLATION OF HYDANTQlIil.
It has previously been established that, under suitable conditions, 
nucleophiles may be regiospecifically alkylated by the t-Boc-amino p- 
lactone (78) to yield substituted p-alanine derivatives. Thus it was hoped 
that, using hydantoin (88) as the nucleophile, the P-lactone (78) may be 
converted to the t-Boc protected hydantoin analogue (89) of quisqualic acid.
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(78)
N
N
H
(88)
NH
N
BocN
H
COJi
(89)
Reagents: bases : NaH, NaOH.
It was anticipitated that base abstraction of the proton from the more acidic 
nitrogen would render the hydantoin moiety sufficiently nucleophilic to 
attack and hence open up the (3-lactone, affording the t-Boc protected 
analogue (89). Acidolysis, followed by ion exchange chromatography, 
would then yield the desired amino acid (87).
Initial attempts to synthesize (89) were initiated by alkylation of the 
hydantoin with t-Boc beta-lactone in the presence of sodium hydride in dry 
THF. The product, which was isolated from extractive work-up, was found 
upon characterization to be the elimination product t-Boc-dehydroalanine 
(90).
COgH
(90)
The product was identified by its NMR spectrum, which exhibited 
signals at 6 5.7 and 6.2 , assigned to the olefmic protons, and by an [M+H]+
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in its mass spectrum at *^/el87.
Repeated attempts to synthesize the analogue (89), by the alkylation of 
hydantoin with t-Boc P-lactone (78) under various conditions failed to yield 
the desired product. This approach was abandoned.
Attempts to alkylate hydantoin (88) with t-Boc P-lactone (78) were not 
successful, possibly owing to the preferential reaction of the base at the C2 
hydrogen; base abstraction of the proton simply resulting in an 
intramolecular rearrangment to give the protected dehydroalanine (90). An 
alternative approach was therefore sought for more suitable synthetic 
methodology. A literature search led to the possibility of synthesizing the 
hydantoin analogue by the alkylation of the heterocycle (88) with t-Boc 
serine methyl ester via the modified Mitsunobu reactionl79 (scheme 14).
Scheme 14
OH
CO2H
NH
(74) (91) (92)
Reagents; (i) CH2N2 , Et20
(ii) DEAD, TPP, -780C, then (88)
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Treatment of an ethereal solution of t-Boc serine (74) with diazomethane, 
followed by extractive workup, afforded the methyl ester (91) in good yield 
(87%). The presence of a three proton singlet at 5 3.7 in its NMR 
spectrum, and an [M+H]+ in its mass spectrum at 219, were taken as
structural confirmation of the methyl ester (91). (scheme 14).
N-t-Boc serine methyl ester (91) was added to a preformed adduct of diethyl 
azodicarboxylate and triphenylphosphine in dry THF at -780C, followed by 
addition of hydantoin (scheme 14). A product was isolated which upon 
characterization (1h  NMR) appeared to be the methyl ester of 
dehydroalanine (93). The absence of any resonances assignable to the ring 
methylene of the hydantoin, or of the P-methylene, together with the 
presence of signals due to the olefinic protons, confirmed that the reaction 
had resulted in elimination from the activated serine derivative, rather than 
substitution. No further attempt was made to characterize this product.
COgMe
(93)
Evidently, attempts to synthesize (87), the hydantoin analogue of quisqualic 
acid, by the alkylation of the heterocycle had proved unsuccessful. It was 
therefore decided to explore the possibility of preparing the desired analogue
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by a longer, but unambiguous, route (schemes 15-16).
None of the intermediates prepared thus far was suitable, therefore a new 
starting material had to be sought. L-Asparagine (94) was the starting 
material of choice. The amino acid was converted to its N- 
benzyloxycarbonyl derivative (95). A wealth of literaturel73 exists for the 
synthesis of N-benzyloxycarbonyl protected amino acids. The method 
employed here is a particularly clean and convenient one using benzyl 
succinimidyl carbonate. 180 The use of this ester provides a smooth and 
efficient method for the conversion of L-asparagine (94) to its Cbz-protected 
derivative (95). The reaction, which was carried out in aqueous acetone, 
afforded the N-protected intermediate in an isolated yield of 86% (scheme 
15). The 1h  NMR spectrum of the acid showed the phenyl resonances at 
57.4 and the benzyl methylene singlet at 5 5.1. Structural confirmation came
from the mass spectrum which exhibited an [M-t-H]'*' at *^/e 267. 
Cbz-protected asparagine (95) was converted to Cbz-protected 
diaminopropionic acid (Cbz-DAPA) (96) via the Hoffmann degradationl«! 
using bis(trifluoroacetoxy)iodobenzene in aqueous pyridine/ 
dimethylformamide (DMF) mixture. The amino acid was isolated after 
extractive workup, and recrystallization from water and ethanol, in an 
average yield of 90%. (scheme 15).
The 1h  NMR spectrum of (96) exhibited an downfield shift of the 
methylene from 5 2.5 in the amide to 5 3.5 in the amine. Methine resonances 
also appeared expectedly at a lower field 5 4.4, indicating that the amide 
(95) had been converted to the amine (96). The structural assignment was 
further confirmed by mass spectrometry [M+H]+ ( "^/e 239 ).
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(94)
H
(I)
(95)
(96)
Reagents: (i) N-(benzyloxycarbonyloxy)succinimide, aq. acetone,
NaHC03
(ii) PhI(OCOCF3)2 , aq. DMF, pyridine
(iii) SOCI2 , MeOH
Using thionyl chloride in dry methanol, the amino acid was smoothly 
esterified. The ester (97) was isolated in 78 % yield from trituration under 
ethereal methanol as a hydrochloride salt, (scheme 15). The spectroscopic 
characteristics of the product were consistent with the expected structure.
The most direct route to the construction of the hydantoin ring would be the 
condensation of the amino ester (97) with ethyl isocyanatoacetate, to give 
the substituted urea derivative (98), followed by cyclization on to the amide
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nitrogen (scheme 16). Thus, Cbz-DAPA methyl ester hydrochloride was 
converted to the substituted urea (98). Its NMR spectrum indicated, by 
the presence of ethyl signals and an upfield methylene singlet, that the 
expected product had been isolated.
(97)
COjEt o.
H
(98)
H
N
(99)
:c (lii)
COjH
(87)
Scheme 16
H
( 100)
Reagents: (i) Et02CCH2NC0 (1 eq.), THF, r.t.
(ii) NaOH (2 eq.) MeOH aq.
(iii) EtN=C=N(CH2)3NMe2 .HCl, NMM, HOBT, DMF, r.t.
(iv) H2, Pd-C
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The diester (98) was smoothly hydrolyzed by treatment with two equivalents 
of IN aqueous sodium hydroxide for two hours. The reaction mixture was 
acidified, and the diacid (99) was isolated as a foamy white solid (scheme 
16). The absence of ethyl and methyl signals in its NMR spectrum, 
indicated that the hydrolysis had gone to completion. An [M+H]'*' at ^ /e  
340 in the FAB mass spectrum confirmed the structural assignment.
Structurally, it appeared feasible that cyclization of the intermediate (99) 
using a carbodiimide (a peptide type coupling reaction) in dry DMF would 
effect the desired cyclization. It was envisaged that the reaction would occur 
via amide bond formation between the activated carboxylic acid group 
adjacent to the methylene and the amide NH, (scheme 16). Although the 
intermediate (99) contained two carboxylic acid groups, formation of the 
five membered ring (100) should be kinetically favoured over that of the six 
membered ring (101); at worst, both compounds could be produced, and 
then separated by chromatographic methods.
CbzN
N CO2H
However, attempted cyclization of the adduct (99), using l-ethyl-3-[3- 
(dimethylaminopropyl)]carbodiimide (EDC) in dry DMF, resulted in the 
formation of an intractable mixture, from which no single product could be
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isolated. The mass spectrum of the crude reaction mixture did indicate the 
presence of an ion at *^/e 322 corresponding to the desired product (100) or 
an isomer thereof. However, there were no fragments which could be 
assigned specifically to the hydantoin moiety. It was clear therefore that 
this method was not viable owing to the presence of two free carboxylic acid 
groups, either of which can become activated, and hence undergo chemical 
reaction. This method was therefore abandoned.
It appeared likely that a change in protecting group strategy could furnish 
the desired product. In considering the best way to approach such a 
synthesis, it was thought that the intermediate N-a-Cbz DAPA methyl ester 
(97), which had already been synthesized, would serve as a useful starting 
material. Condensation of this intermediate with benzyl isocyanatoacetate 
would afford a diester adduct. The benzyl ester could then be selectively 
removed by catalytic hydrogenation, yielding one carboxylic acid group 
which can undergo cyclization, after activation with carbodiimide. Initially, 
synthetic interest was focused on the corresponding t-Boc DAPA methyl 
ester hydrochloride (102) as the starting material. However, owing to the 
sensitivity of the t-Boc group to acid, synthesis of this intermediate was not 
undertaken.
NHg.HCI
COgMe
(102)
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The corresponding Cbz-protected DAP A methyl ester(97) was then chosen 
as the starting material (scheme 17).
Scheme 17
(97)
(92)
H
NH2.HCI .  NH
<') ^  \
CO^Me CbzN CO.Me
H
(103)
C02CH2PH
CO 2 H
NH
C 02M e
(104)
Reagents: (i) PhCH202CCH2NC0, THF, 0®c, then r.t.
(ii) (Boc)20, NaHC0 3 , aq. MeOH, Pd-C, H2 , 6 hrs.
(iii) EDC, Et3N, THF, r.t., o.n.
Clearly, from the above scheme, it is quite obvious that the removal of the 
benzyl ester by catalytic hydrogenation would result in the hydrogenolysis of
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the benzyloxycarbonyl group. Attempted cyclization of the resulting amino 
acid could yield an eight membered ring system (105) or, more likely, 
intermolecular condensation products in preference to the desired five 
membered intermediate. As the amine is more nucleophilic than the amide, 
it would undergo reaction with the activated acid more readily.
N
H \ ____ /  ”
COjH
(105)
To circumvent this problem, a search of the literature led to methodology by 
which the Cbz-protected amino acid may be converted to the t-Boc protected 
amino acid in a one pot synthesis by catalytic hydrogenolysis.l^^
Thus, using Cbz-protected DAPA methyl ester as starting material, and 
benzyl isocyanatoacetate as the condensing agent, the intermediate (103) was 
isolated in 62% yield, after purification by flash chromatography. The 
NMR spectrum of the substituted urea (103) showed one methylene singlet 
at 5 3.9 (NHCH2CO2BZI); resonances due to the benzyl ester and the Cbz 
protecting group appeared as two singlets at 6 5.1 (CH2)» and 5 7.4 (C6H5); 
indicating that acylation had taken place. The methyl ester appeared as a 
three proton singlet 5 3.7 , and the ^-methylene and methine protons 
resonated at 5 3.6, and 5 4.4 respectively. The mass spectrum, with an 
[M+H]'*' at m/e 434 confirmed the structure.
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The adduct (103) was successfully debenzylated and reprotected with the t- 
Boc protecting group by catalytic heterogenous hydrogenation over 
palladium on charcoal in the presence of di-tert-butyl dicarbonate and 
sodium hydrogen carbonate in methanol. After six hours the t-Boc protected 
intermediate (104) was isolated in 52% yield. Confirmation of the structure 
came primarily from the NMR spectrum, which exhibited a nine proton 
singlet at 6 1.4 due to the t-Boc group. The absence of resonances in the 
aromatic region, as well as the loss of the benzylic methylene singlet at 6
5.1, showed that the desired exchange of protecting groups had occurred. 
The structural assignment was further confirmed by the mass spectrum of 
the product which exhibited an [M+H]“^  at *^/e 320.
The ease of this protecting group exchange reaction renders the method a 
very useful synthetic tool for the amino acid chemist.
The monoester (104) was stirred in the presence of one equivalent of 1- 
ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC) in dry THF. After 
workup and flash chromatography the cyclized adduct was obtained as a 
white solid. The reaction proceeded in respectable yield (68%), and the 
identity of the cyclized adduct (92) was confirmed by the proton NMR 
spectrum: the ring methylene protons resonated at slightly higher field (5 
3.9), resonances due to the side chain methylene and the methine occurred at 
5 3.3 and 6 4.4. respectively. A three proton singlet at 5 3.7 was assigned to 
the methyl ester, and the t-Boc protons resonated at 5 1.4.
The cyclized intermediate (92) was smoothly hydrolyzed to the 
corresponding acid (89) using one equivalent of IN aqueous sodium 
hydroxide. The protected amino acid was isolated in 71% yield after
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extractive workup (scheme 14). Structural confirmation came from the IH 
NMR spectrum which exhibited loss of the methyl ester signals at 5 3.7.
Acidolysis of the t-Boc protected compound using IM hydrogen chloride in 
acetic acid, followed by ion exchange chromatography, afforded the amino 
acid (87) in an isolated yield of 69%. The loss of the t-Boc group was 
confirmed by 1 H NMR spectroscopy and mass spectrometry (scheme 18).
Scheme 18
(92)
(89) (87)
Reagents: (i) NaOH, aq. MeOH
(ii) (a) IN HCl in AcOH, (b) ion-exchange
SYNTHF.SISOF3-(l-SlirClNlMlDYL) ALANINE.dQgL
Having succesfully synthesized the hydantoin analogue of quisqualic acid, in 
which the oxygen group in the heterocyclic ring was replaced with a 
carbonyl at position two, and the carbonyl with a methylene at position 
three, it was decided that methodology would be sought by which the 
succinimide analogue (109) of quisqualic acid may by synthesized.
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Scheme 19
,  CONHj
f  - J Î1U  f
, NH2 .HCI
CO2 H CbzN' C0 2 H CbzN " C02Me
(95) (96) (97)
CO2H
(108)
Reagents;
(107) (106)
(i) PhI(OCOCF3)2, DMF aq., pyridine, 20^0, 3 hrs.
(ii) SOCI2 , MeOH
(iii) succinic anhydride, THF, reflux
(iv) EDC, Et3N,THF
(v) KOH, MeOH aq.
The synthetic strategy adopted here was based on the synthon approach 
developed for the synthesis of the hydantoin analogue of quisqualic acid.
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The synthon (97) possesses a substituted alanine side-chain with an amino 
group suitably positioned for acylation with succinic anhydride. Acylation 
of the synthon (97) with succinic anhydride proceeded as expected to give 
the acid (106), as a colourless crystalline solid, in 64% yield, (scheme 19).
The NMR spectrum of the product exhibited a four proton double 
doublet (5 2.3) assigned to the succinamide moiety, and the mass spectrum
showed an [M+H]'*' at *^/e 353.
Cyclization of the intermediate (106) was effected by carbodiimide 
activation of the carboxylic acid group. The cyclized product (107) was 
obtained as a colourless oil after extractive workup. The base peak in the 
mass spectrum was the molecular ion [M+H]'*' at * /^e 335.
The ester function of (107) was smoothly hydrolyzed by treatment with one 
equivalent of potassium hydroxide in aqueous methanol for two hours. The 
reaction mixture was acidified and and the acid (108) isolated after 
extractive workup. Spectroscopic characterization of the acid was consistent 
with its being the expected product.
Cleavage of the benzyloxycarbonyl group of (108) was effected by 
heterogeneous catalytic hydrogenation over palladium on carbon in ethanol. 
The crude material, which was insoluble in ethanol, was dissolved in hot 
water, and the product (109), a white solid, was obtained on evaporation of
solvent (scheme 20).
The absence of aromatic and benzylic methylene protons in the NMR 
spectrum of the product suggested that débenzylation had gone to 
completion. The mass specmim exhibited an [M-i-H]+ at "^/e 187, 
confirming the structure.
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(108)
Scheme 20.
(109)
Reagents: (i) Pd-C, H2, EtOH.
2.S.S. 3 -r 2 -n -2-oxAZOLlDlNF.-3.5-D10NYL)l ALANINEi
Continuing the series of analogues of quisqualic acid with changes to the 
heterocyclic ring system, it was decided that a synthetic methodology should 
be sought for the preparation of the carbon analogue (113), wherein the NH 
was replaced by a methylene group. It was considered that the synthesis of 
(113) would provide a useful analogue for comparative pharmacological 
investigation into the effect of the acidic NH at position 4 in the quisqualic
acid molecule.
Functionally, the imide with its sp2 hybridized nitrogen would be replaced 
with a tetrahedral carbon atom. Since the Van der Waals radius of nitrogen 
is close to that of the carbon atom, the replacement of nitrogen by carbon is 
a suitable way to change the electron distribution pattern without 
substantially changing the shape or size of the molecule. The loss of the 
lone pair of electrons on the nitrogen may have pharmacological
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significance. Furthermore, the loss of the very acidic N-H which ionizes at 
physiological pH could provide an interesting pharmacological outcome.
Scheme 21
NOCH2Ph
COgH
(i) (route 1)
C02Et
NOCH2Ph
CO2H
(77) ( 1 1 0 )
(i) (route 2)
H
C02Et
Reagents: (i) Ethyl malonyl chloride, PhMe, reflux
The synthetic strategy adopted for the synthesis of the carbon analogue (113) 
utilizes the same synthon (77) developed for L-quisqualic acid synthesis 
(scheme 10). Thus the benzyloxyamine (77) was acylated with ethyl 
malonyl chloride in toluene under reflux to give the corresponding 
hydroxamate (110). The mechanism by which the reaction occurred is
87
unclear. The reaction may have proceeded via the formation of a mixed 
anhydride (route 2), or may have occurred by direct acylation of the 
hydroxylamine (route 1) (scheme 21)
The product was collected as a colourless oil, after extractive workup and 
flash chromatography, in an isolated yield of 62%. The NMR spectrum 
of the product (110) exhibited signals due to the ethyl malonyl moiety, 
together with downfield shifts of the methine and P-methylene signals. This 
indicated that acylation of the hydroxylamino nitrogen had occurred. The 
mass spectrum, which gave an [M+H]+ at *^/e 425, confirmed the structure.
The O-benzyl hydroxamate (110) was converted to the hydroxy derivative 
(111) by facile catalytic hydrogenolysis over palladium on charcoal in 
ethanol, (scheme 22). The NMR spectrum of the product showed the 
disappearance of the aromatic and benzyl methylene protons.
Interestingly, the loss of the benzyl group induced an upfield shift of the 
methylene from 5 4.2 to 5 3.6, due probably to shielding by the aromatic 
ring in the benzylated material. Structural confirmation came from the mass 
spectrum which exhibited an [M+H]"^ at *^/e 335.
Cyclization of the synthon (111) was effected by treatment with potassium 
hydroxide in methanol. The basic solution was acidified, and the
isoxazolidinedione (112) was obtained from extractive workup in 64% yield. 
The loss of the ethyl protons in the NMR spectrum as well as a 
downfield shift of the side chain methylene signal from 5 3.4, to 5 3.9 
suggested that cyclization had taken place. This, coupled with the an 
[M+H]"** at *^/e 289 in its mass spectrum, was taken as structural
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confirmation.
Scheme 22
(77)
(i)
COJEX
(110)
C02Et
NOH
CO2H
r \ 0
/
r
^ 0 (iv)
------ X -^
X
^ C 0 2 H H2 N" C0 2 H
(113)(111) (112)
Reagents: (i) Ethyl malonyl chloride, PhMe, reflux
(ii) H2, Pd-C, EtOH
(iii) KOH, MeOH aq.
(iv) IN HCl in AcOH, then ion-exchange chromatography
The t-Boc protected amino acid (112) was treated with IM hydrogen 
chloride in acetic acid to effect deprotection. Ninhydrin development of the 
thin layer chromatogram gave the characteristic a-am ino acid reaction.
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suggesting that the t-Boc group had been cleaved. However, evaporation of 
solvent and subsequent ion exchange chromatography gave an off-white 
solid, which appeared to have decomposed. The NMR and mass spectra 
of the product were inconclusive. No attempt was made to purify this
product.
Having synthesized analogues of quisqualic acid which incorporated 
different functional groups into the heterocyclic ring, it was considered that 
an appropriate modification to the system would be to add a basic centre to 
the heterocyclic ring, by the introduction of an amino function at position 4 
of the heterocyclic system. This is not unreasonable, as the potent NMDA 
antagonist CPP (cf. chapter 1) possesses a basic amino function (in addition 
the a-amino group). The methodology adopted for this synthesis (scheme 
24) also introduces another chiral centre to the compound, but initial work 
was carried out on a simplified analogue based on glycine (scheme 23).
Svntbp^is of i.f(3s^-i-AininoDvrroii(lin-2,5-diftnYl1-ac€tic acid
a m .
L-aspartic acid p-benzyl ester was the starting material for this non- 
genetically coded amino acid. The amino ester was converted into its t-Boc 
derivative by treatment with (Boc)20 and sodium hydroxide (scheme 23). 
Spectroscopic characterization confirmed the structure.
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Scheme 23
C02CH2PH
(i)
C O ^C H ^Ph
(»1
BocN CO«H
H ^
(114)
BocN
(115)
C 0 2 E t
C 0 2 E t
N
(116)
BocN
H O
(117)
C 0 2 E t
N
(V)
BocN
H O
(118)
CO 2 H
(119)
C O jH
Reagents: (i) (a) mixed anhydride (IBCF), NMM, THF,-25®C; then
(b) H.Gly.OEt.HCl, NMM, THF, -150C
(ii) H2, Pd-C, EtOH
(iii) EDC, THF
(iv) NaOH aq.
(v) IN HCl in AcOH; then ion-exchange chromatography
The adduct (114) was converted to the protected dipeptide by treatment with
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glycine ethyl ester hydrochloride via a mixed anhydride reaction using 
isobutyl chloroformate and N-methylmorpholine. The presence of the 
methylene doublet at 5 4.0 and the chemical shifts assigned to the ethyl ester 
of the glycine moiety, as well as an [M+H]'*' at m/e 409 in its mass spectrum, 
confirmed the structure.
Deprotection of the benzyl group by catalytic hydrogenolysis gave the acid 
(116). Spectroscopic characterization confirmed the structure. Treatment of 
the adduct (116) with EDC in THF afforded the cyclized adduct (117) in 
isolated yield of 63%. Structural confirmation came primarily from nmr 
and mass spectrum which exhibited an [M+H]"*' at * /^e 301
Treatment of the adduct with aqueous sodium hydroxide gave the acid (118), 
which was deprotected using IM hydrogen chloride in acetic acid, to give 
the amino acid hydrochloride, which was converted to the free amino acid 
(119), by ion exchange chromatography.
The starting material for this synthesis , as for the model chemistry, was L- 
aspartic acid P-benzyl ester. This was converted to its t-Boc derivative (114) 
by reaction with (Boc)20 and sodium hydroxide. The product was isolated 
after workup in 86% yield. The presence of a nine proton singlet in its 
NMR, and an [M+H]+ at *^/e 324 in its mass spectrum confirmed that the t- 
Boc group had been incorporated.
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Scheme 24
BocN
C02CH2Ph . . NH2 .HCI
J C  ^  J C
1 CO^H CbzN 
2 1 
H
' C02Me
(114) (97)
(I)
(120)
C02CH2PH
Nt
C02Me
C02Me
(121) (122)
Reagents: (i) mixed anhydride (IBCF), NMM, THF, -25®C.
(ii) (Boc)20, NaHC0 3 , Pd-C, H2 , MeOH aq., 6 hrs.
(iii) EDC, NMM, THF, r.t., o.n.
C02Me
The synthon required for the construction of the heterocyclic nucleus was 
the intermediate ot-N-Cbz-DAPA methyl ester hydrochloride (97) 
synthesized for the preparation of the hydantoin analogue (scheme 14). This 
adduct (97) and t-Boc p-benzyl aspartate (114) were coupled by standard 
peptide methodology using isobutylchloroformate and N-methylmorpholine, 
via a mixed anhydride intermediate (scheme 24). The amide (120) was
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obtained from extractive workup in 66% yield. Structural confirmation 
came from its NMR spectrum, which exhibited resonances, in addition to 
those present in the aspartate moiety, which were assignable to the protected 
DAPA moiety. An [M+H]+ at 558 in its mass spectrum confirmed the
structure.
Catalytic hydrogenolysis of the Cbz group in the presence of (Boc)20 
resulted in the reprotection of the amino function with a t-Boc group and 
also in cleavage of the benzyl ester. The reaction proceeded smoothly to 
afford the acid (121) in 59% yield. The NMR spectrum of this product 
confirmed the loss of the benzyl groups by the absence of the aromatic and 
benzylic methylene signals, and the presence of a second nine proton singlet 
at 6 1.4 demonstrated that reprotection by the t-Boc group had taken place.
The importance of the above Boc exchange reaction is that it ensures that 
there are no free amino groups available for reaction with the carbodiimide- 
activated carboxylic acid. Cyclization to give the five membered ring was 
effected by the reaction of the adduct (121) with EDC. The protected 
cyclized product (122) was obtained as a colourless oil after extractive 
workup. Structural confirmation came primarily from its infrared spectrum 
which exhibited absorptions assigned to the imide carbonyls at 1680cm" 1. 
The absence of the carboxylic group was evident by the loss of a broad 
stretch at 2750cm" 1. The mass spectrum, which gave an [M+H]+ at ^ / t  
416, confirmed the structure.
Treatment of the cyclized adduct (122) with potassium hydroxide in 
methanol effected the ester hydrolysis (scheme 25). The product (123) was 
isolated after acidification followed by extractive workup. The loss of the
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methyl ester group was confirmed by the absence of the a three proton 
singlet at about 5 3.7 in its NMR spectrum.
Scheme 25
COgH COgH
(124)(123)
Reagents: (i) KOH, aq. MeOH.
(ii) IN HCl in AcOH, then ion-exchange chromatography.
The t-Boc-protecting groups were smoothly acidolyzed by treatment of 
(123) with IM hydrogen chloride in acetic acid solution at room temperature 
(scheme 25). The resulting amino acid dihydrochloride was converted to the 
monoacetate by ion exchange chromatography (acetate anion). A more 
concentrated acetic acid solution was required to elute the amino acid from 
the ion exchange resin. This may be attributable to the increased binding of 
the diamino acid to the resin bed. The loss of the t-Boc group was 
confirmed by NMR spectroscopy .
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The objective was to develop synthetic methodology whereby various 
aromatic and non-aromatic heterocyclic analogues of quisqualic acid could 
be synthesized.
It was considered that alkylation of a variety of heterocycles with suitably 
activated derivatives of L-serine would provide a versatile approach to 
quisqualic acid analogues bearing a variety of functionalized chains. The 
synthesis of analogues which incorporate the pyrazole, pyrrolidine, triazole, 
and pyrrolidinone rings was investigated. The synthetic strategy adopted was 
based initially on alkylation of the heterocycle with the t-Boc a-amino P-
lactone (78).
Vederas et reported several examples of synthetic routes whereby
chiral p-lactones may be opened by nucleophiles to give pure enantiomers of 
N-protected P-substituted alanines. Using this synthetic methodology, 
attempts were made to alkylate pyrazole with (78). The reaction was carried 
out initially at room temperature, and then at 50®C, in dry acetonitrile. After 
workup, the colourless oil which ensued was found upon characterization to 
be a mixture of the starting material and t-Boc serine. The latter product 
presumably arose from hydrolysis of the P-lactone by adventitious water
(scheme 26).
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Scheme 26
BocN.
X ^
N
N
CO2H
(78) (125)
Reagents: pyrazole, MeCN, r.t., then 50^C
Several attempts were made to alkylate pyrazole with the heterocycle (78). 
Reactions which were carried out in the absence of base led predominantly 
to the formation of t-Boc serine even at increased temperatures. It was 
decided therefore that the reaction should be repeated in the presence of 
base, in the hope that the preformed anion (by base abstraction of the acidic 
proton on the heterocycle) would undergo alkylation by the (3-lactone more 
readily than neutral pyrazole (scheme 27). This hope was unfounded, 
reaction of pyrazole and the t-Boc p-lactone in the presence of sodium 
hydride at room temperature gave a colourless oil which upon 
characterization (^H NMR) was found to be the elimination product (90). 
The presence of the olefinic protons at 5 5.7 and 5 6.2, and the absence of 
methylene and methine protons at 5 3.8, and 5 4.2, respectively, and the 
absence of signals in the aromatic region assignable to the pyrazole moiety, 
supported the case for elimination rather than alkylation. Confirmation 
came from the mass spectrum which exhibited an [M-i-H]+ at "^/e 187. 
Repetition of the reaction at higher temperature gave an intractable mixture. 
The use of different solvents (THF, DMF, or EtOAc) under various
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experimental conditions also failed to yield the desired product.
Scheme 27
(125) (78)
(i)
COgH
(90)
Reagents: (i) pyrazole, NaH, MeCN, r.t.
Attempts to circumvent this problem by the use of a more hindered base, 
such as DABCO or potassium tert-butoxide, under different experimental 
conditions, also afforded the elimination product (90). An alternative 
approach was therefore sought for the synthesis of the pyrazole analogue of 
quisqualic acid.
In view of the failure to alkylate pyrazole with the p-lactone (78), attention 
was directed towards the use of different starting materials with other 
leaving groups. N-protected |3-substituted alanines became the starting
materials of choice.
Initial interest was directed towards the alkylation of the heterocycle with N- 
t-butyloxycarbony 1-0-acetyl serine (126), which was prepared according to 
the procedure of Vederas et The acetate was obtained in 78% yield
after extractive workup.
Reaction of the acetate (126) and pyrazole in acetonitrile at room
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temperature gave the starting materials only. The reaction mixture was 
heated at SO^C for two hours. Tic showed the presence of mainly starting 
material, hence the reaction was heated under reflux for four hours. An 
intractable mixture was obtained after extractive workup; this method was 
abandoned (scheme 28).
Scheme 28
-X—^
(127)
Reagents: pyrazole, MeCN, r.t., then 50®C
A new synthetic methodology was sought. It was considered that perhaps the 
mesylate(128), or the bromide (129), may be a better leaving group than the 
acetate in trying to effect an alkylation of this type.
Initially, attempted alkylation of pyrazole with the mesylate (128) (prepared 
as outlined on page 170) in acetonitrile at room temperature, then at SO^C, 
resulted in a colourless oil which upon characterization was found to be the 
elimination product, the protected dehydroalanine (130) (scheme 29).
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Scheme 29
CbzN
H
CO^Me
(128)
Reagents: pyrazole, MeCN, r.t., then 50®C
(130)
The final attempt at pyrazole alkylation involved the use of N- 
benzyloxycarbonyl-p-bromo-L-alanine(129) The bromide was synthesized 
from the N-benzyloxycarbonylamino (3-lactone (131) according to Vederas 
et (scheme 30).
Scheme 30
H
CbzN«
(i)
H
(131) (129)
Reagents; (i) MgBr2.0Et2, dry Et20
The initial reaction of pyrazole with the halide (129) was carried out in 
toluene at room temperature in the presence of sodium bicarbonate. The 
apparent lack of reaction after two hours suggested that more vigorous 
conditions would be neccessary to facilitate the reaction. To this end, the 
reaction mixture was heated under reflux for four hours. The mass spectrum
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of the product (a colourless oil), and the NMR spectrum clearly indicated 
that some form of reaction had taken place, although evidence for the 
proposed structure was equivocal. Owing to the difficulties encountered in 
the synthesis of the pyrazole analogue of quisqualic acid, further approaches 
were not considered.
2.5.8. Synthesis of a-N-t-hutoxvcarbonvl-3-ri-triazolvl1 alanine (1321
During the course of our studies in the attempted preparation of the pyrazole 
analogue, it was decided that the 1,2,4-triazole analogue of quisqualic acid 
should also be synthesized. As with the pyrazole, the aromatic nature of this 
amino acid (133) makes it an interesting synthetic target, from the 
pharmacological viewpoint. A synthetic approach to this system was 
therefore sought.
It was considered that the best approach to the synthesis of the triazole 
analogue would be to alkylate the heterocycle with the acetate (126), even 
though this method proved unsuccessful in the pyrazole synthesis. The 
triazole moiety, being more nucleophilic than pyrazole, might possibly 
undergo alkylation more readily (scheme 31).
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Scheme 31
OAc
Boc^^ C 02M e CO 2 H
C 02M e
^  H
(126) (132) (93)
Reagents: (i) triazole, tetramethylguanidine, MeCN, reflux
The heterocycle and the acetate (126) were heated under reflux in 
acetonitrile, in the presence of tetramethylguanidine.
Chromatography gave the product as the acid (132) in 35% yield (scheme 
31). The methyl ester had effectively been hydrolyzed in situ to the acid, 
possibly vio. a mechanism involving intramolecular attack of the triazole N-2 
on the ester carbonyl (scheme 32).
Scheme 32
(work-up)
(132)
The rather low yield may be attributable to the competing formation of the 
elimination product t-Boc-dehydroalanine methyl ester (93), which was 
removed by chromatographic separation. Structural confirmation of the
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product came from its NMR spectrum, which exhibited two aromatic 
singlets at 5 8.0, and 5 8.4 respectively, due to the triazole moiety. The loss 
of the of the three proton singlet at 5 3.7 was a clear indication that the 
methyl ester had been hydrolyzed. The structural assignment was completed 
by the mass spectrum, which exhibited an [M+H]"*" at m/e 257. Future work 
would have included removal of the t-Boc group to give the amino acid
(scheme 33)
Scheme 33
N
N
N
CO2H
(132)
N
N
N
H2N CO2H
(133)
Reagents: IN HCl in AcOH, then ion exchange chromatography.
Deprotection was achieved on a small scale, albeit without spectroscopic 
characterization (positive ninhydrin test), which suggests that the approach 
may be feasible.
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Having synthesized the triazole analogue of quisqualic acid ( albeit t-Boc 
protected ), by alkylation of the heterocycle, the decision was taken that 
compounds (134) and (135) should become synthetic targets.
N
HgN COgH
(134)
The pyrrolidinone system (135) would be an analogue in which all but one 
of the functional groups on the quisqualic acid ring had been replaced by a 
methylene, while the pyrrolidine analogue (134) incorporates a side-chain 
devoid of any functional group other than the basic tertiary amine. 
Pharmacologically these two compounds, in conjunction with previously 
described analogues of quisqualic acid, represent an interesting research tool 
for the investigation of the ligand/receptor interactions of the quisqualate
receptor.
With some idea of the reaction conditions required, it was decided that 
preliminary work should be carried out on the reaction between pyrrolidine
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and t-Boc ^ lac tone  (78). The reaction, which was carried out at room 
temperature in acetonitrile in the presence of l,4-diazabicyco[2.2.2]octane 
(DABCO), gave a mixture of the alkylated material (136), and the 
elimination product (90). Chromatographic purification afforded the t-Boc- 
protected amino acid (136) in 28% yield. Spectroscopic characterization of 
the product was consistent with the proposed structure.(scheme 34).
The adduct (136) was subsequently deprotected by treatment with a solution 
of IM hydrogen chloride in acetic acid. The amino acid was collected as the 
hydrochloride salt in 76% yield (scheme 34). Structural confirmation came 
from spectroscopic characterization.
Scheme 34
(i)
H
(78) (136)
(134)
Reagents: (i) pyrrolidine, DABCO, MeCN
(ii) IN HCl in AcOH, then ion-exchange chromatography
105
In parallel with the synthesis of (136) , preparation of the protected 
pyrrolidinone analogue (137) was in also progress. In this case, however, 
alkylation was effected by the use of the bromide (129) in toluene, (scheme
35).
Scheme 35
CbzN
H
N w
COgH
(137)
Reagents: (i) pyrrolidinone, Et3N, PhMe, reflux
(ii) H2, Pd-C, EtOH.
Heating pyrrolidinone and the bromide (129) in toluene effected the
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alkylation. The product, a Cbz-protected amino ester (137), was obtained 
after extractive workup.
Unfortunately, however, deprotection of the pyrrolidinone analogue of 
quisqualic acid was not carried out, owing to lack of time.
2..S.12. NQN-rvrur ANAl onilESOFOIlISOUAUC ACm.
It was considered that less conformationally restricted analogues of some of 
the systems described above could be of interest as excitatory amino acid 
agonists and antagonists. Compounds (138)-(141)) were chosen as initial
targets.
NH NH
CO2H
H2N CO2H
(138)
H^N CO2H
(139)
NH,
(140)
NH
H2N CO2H
(141)
NH,
The synthetic routes chosen were directed towards the acylation of Cbz- 
protected diaminopropionic acid (96) with protected reagents derived from a
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range of amino or dicarboxylic acids. Some of the compounds are non- 
cyclized analogues of systems already synthesized. Specifically, compound 
(138) is an acyclic analogue of the hydantoin (87), while (139) is a non- 
cyclized analogue of the succinimide (109). Compounds (140) and (141) 
were chosen as examples wherein the terminal side-chain functionality was 
complementary to that in (138) and (139), and hence would provide a 
comparative study of the two non-cyclized structural types.
The analogues were synthesized via the same general route (scheme 36). A 
solution of a-N-Cbz-DAPA (96) in dry THF was treated with the 
appropriate acylating agent. Extractive workup and flash chromatography 
gave the corresponding protected amide (142) in variable yields. See table 2 
for a summary of the reactions undertaken.
The intermediates were subsequently deprotected under standard conditions. 
De-esterification was effected by treatment with sodium hydroxide to give 
the corresponding acids, followed by cleavage of the t-Boc group by 
treatment with hydrogen chloride in acetic acid. Ion-exchange 
chromatography (acetate resin), gave the amino acids. The individual amino 
acids were all satisfactorily characterized by NMR, mass spectrometry 
and elemental analysis.
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Scheme 36
NH
CbzN CO H 
H 2
(96)
acylation
THF CbzN CO H 
H 2
(142)
Table 2 ( see scheme 36)
acylating agent product after hydrolysis
H1
H
1
O N CO Et 
2
O >v.N
NH NH
r
CO Me CbzN CO H
2 (98)
final prod.
EtO CCH NCO 
2 2
(99)
(138)
NH
CbzN CO Me
u 2 (106)
NH
CbzN CO H 
H ^ (139a)
(139)
Cbz.Gly.OH
EDC
NHCbz
NH
CbzN ^  CO Me
i
NHCbz
NH
(140a)
CbzN CO H
. 2 (140b)
(140)
NHCbz
CbzN CO Me (141a) 
H 2______________
O NHCbz
NH
CbzN CO^H 
H
(141)
Having completed the synthesis of a series of quisqualic acid analogues in 
which various changes were introduced in the heterocyclic ring system, the 
emphasis now fell on the search for the methodology by which analogues 
with modification of the amino acid functions may be prepared.
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2.5.13. SYNTHESIS OF SOME PEPTIDE ANALOGUES OF QUISQUALIC ACID.
An attempted synthesis of the peptide (144) employed N-benzoyl quisqualic 
acid, (62) which was converted to the the acid chloride by treatment with 
thionyl chloride. The acid chloride was not isolated, and hence not 
characterized, but was treated with glycine ethyl ester hydrochloride in 
dimethylformamide, in the presence of trie thy lamine. The reaction gave an 
intractable mixture, from which no single product could be isolated 
(scheme 37).
Scheme 37
PhCON COgH PhCONI
H
N
N COgEt
(62) (144)
Reagents: (i) SOCI2» then H.Gly.OEt.HCl, Et3N, DMF
no
2..S.13.2. Synthesis of L-OuisaualvI-leucine (147).
The amino acid leucine was chosen on the basis of its increased lipophilicity.
A carboxyl-activated derivative of quisqualic acid was required, and 
therefore the carboxyl function of leucine was protected as its methyl ester.
The reaction was carried out via the repetitive excess mixed anhydride 
(REMA) method. Thus, t-Boc protected quisqualic acid (81) was activated 
by conversion to the mixed anhydride with isobutyl chloroformate and N- 
methylmorpholine in DMF, then treated with leucine methyl ester 
hydrochloride and NMM in THE. After work-up and flash chromatography 
on silica, the protected peptide (145) was collected in 45% yield (scheme 
38).
The NMR spectrum of the peptide exhibited resonances assignable to the 
leucine ester moiety, in addition to those due to the quisqualic acid portion 
of the molecule. The base peak in the mass spectrum was the [M-t-H]+ at m/e 
417.
Base hydrolysis of the ester was effected by treatment of (145) with sodium 
hydroxide at room temperature. The acid (146) was obtained in 68% yield.
Its structure was confirmed by NMR, and mass spectrometry. Acidolysis 
of the t-Boc group with IM hydrogen chloride in acetic acid solution, 
followed by ion exchange chromatography (acetate resin), afforded the 
dipeptide (147) in quantitative yield.
Ideally, comparative study of the peptides would have demanded the synthesis of 
several dipeptides incorporating different amino acid moieties coupled to 
quisqualic acid. Unfortunately, owing to lack of time, further peptide syntheses 
were not undertaken.
I l l
Scheme 38
(81)
Reagents: (i) mixed anhydride (IBCF), then
H. Leu.OMe.HCl,NMM, DMF
(ii) NaOH aq. (1 eq.)» MeOH, 1 hr.
(iii) IN HCl in AcOH, then ion-exchange chromatography
3.3. SVNTHRSIS OF tS)-F.-N-r  ARBOXYMETHYL QUISOFALIC ACID(1S0L
The alkylation of quisqualic acid was initiated by the conversion of t-Boc 
quisqualic acid to the corresponding disodium salt by treatment with two
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equivalents of sodium hydride in dry DMF. Alkylation was effected by 
treatment (in situ) of the sodium salt with ethyl bromoacetate. Chromatography 
gave the pure alkyl derivative (148) in 40% yield (scheme 39). Structural 
confirmation came primarily from its NMR spectrum.
Scheme 39
N
> = 0
BocN
H
N
CO2H
(81)
(i)
> = 0
N
C02CH2C02Et
(148)
> = 0 > = 0
N
BocN  ^ CO,H 
(149)
N
^ 2*^" CO2H
(150)
Reagents: (i) NaH, DMF, Et0 2 CCH2Br
(ii) KOH (3 eq.)
(iii) IN HCl in AcOH, then ion-exchange chromatography
Hydrolysis of the ester (148) with three equivalents of potassium hydroxide to 
the corresponding diacid (149), and cleavage of the t-Boc group with IM
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hydrogen chloride in acetic acid solution gave, after ion-exchange 
chromatography, the alkylated amino acid (150). Interestingly, elution of the 
alkylated derivative from the ion exchange resin required a stronger 
concentration of the acetic acid (10%) than that (3%) used for the elution of 
quisqualic acid. This was presumably due to the carboxylic acid function in the 
N-e side-chain.
2.S.14. MlSCKl.LANKOUS SYNTHESES.
2.5.14.1. 1.2.4-Oxadiay.ondine-3.5-diQne (153),
Prior to the successful synthesis of quisqualic acid, it was anticipated that a 
novel approach to the synthesis of quisqualic acid would be to alkylate the 
heterocycle (153) with the t-Boc (3-lactone (78) to the corresponding t-Boc 
protected quisqualic acid. This would provide a convenient methodology by 
which the amino acid may be synthesized in its L-enantiomeric form.
Hence the heterocycle l,2,4-oxadiazolidine-2,5-dione (153) was synthesized 
according to the method of Srivastava et by the condensation of O-
benzylhydroxylamine hydrochloride with ethoxycarbonyl isocyanate. The 
reaction, which was carried out in dry THF, gave the hydroxamate (151) in 
good yield (92%). Spectroscopic characterization of the product confirmed 
the structure (scheme 40).
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Scheme 40
PhCHgONHg.HCI ♦ EtOgCNCO PhCH-ON2 I
H
NCO^EtI 2H
(151)
N — 0
(153)
Reagents: (i) dry THF, r.t.
(ii) H2 , Pd-C, EtOH
(iii) NaOH aq. MeOH, then ion-exchange chromatography
Débenzylation by catalytic hydrogenolysis in ethanol produced the hydroxyl 
derivative (152), which was cyclized to the heterocycle in aqueous sodium 
hydroxide. The structure of (153) was confirmed by mass spectrometry 
([M+H]"*" at m/e 103) and elemental analysis which gave the empirical
formula as C2H2N2O3 .
NCO^EtI c
H
(152)
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2.5.14.2. Attempted alkylation of the heterocvcle (153) with t-BoC-P- 
lactone (78).
The reaction of the the heterocycle (153) with t-Boc ^-lactone in dry ACN 
at room temperature, which would have been expected to give t-Boc 
protected quisqualic acid (81), resulted in the hydrolysis of the |3-lactone to 
the protected serine derivative (74) (scheme 37 ). The presence of base led 
to the formation of the elimination product (90). Attempts to synthesize this 
compound under different conditions also failed to yield the desired product.
Scheme 41
BocN^
(78)
(i) or (h)
Reagents:
N
N — O
(153)
COgH
(90)
(i) MeCN
(ii) MeCN, base
(74)
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In a different approach, attempts were made to alkylate the heterocycle by 
treatment with t-Boc serinyl-acetate methyl ester (126). At room 
temperature in dry ACN, the reaction gave protected serine and 
dehydroalanine, and at elevated temperatures, intractable mixtures were 
obtained. The use of different solvents, bases and experimental conditions 
also failed to yield the desired product, (scheme 42).
Scheme 42
OH
Bocf^
H
C 0 2 Me
(154)
Boc^ jl
H
(126)
OH
Boc^ )l
(154)
C 02M e Bocr^  C02Me
H (93)
Reagents: (i) Ac2 0 , pyridine, DCM
(ii) (153), dry MeCN, room temp.
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It was hoped that the mesylate, being a better leaving group than the acetate, 
would furnish the alkylated material. Unfortunately, starting materials and 
protected serine (156) were obtained from the treatment of the heterocycle 
with the mesylate under neutral conditions in dry ACN. Base induced 
alkylation gave the elimination product .(130) (scheme 43).
Scheme 43
Cbzr^
H
(128)
0 S 02M e
_ J D ____ ^
X
C 02M e Cbzr^'^
H
(
(156)
1«)
Reagents: (i) (153), dry ACN
(ii)(153), base, dry ACN
OH
Cbz j^l C02Me
H (130)
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In a different approach, a literature search 1^4 led to the possibility that the 
desired alkylation might be achieved by the use of the para-toluene 
sulphonic acid (PTSA) salt (157) of the p-lactone (78).
Thus the t-Boc (3-lactone was converted to its PTSA salt (157) by the 
reaction with anhydrous p-toluenesulphonic acid in trifluoroacetic acid. 
Treatment of this with the heterocycle (153), in dry ACN at room 
temperature gave a white solid tentatively assigned as the protected 
quisqualate salt (158) (scheme 44). The chemical shift in its nmr 
spectrum suggested that alkylation may have taken place; the expected shift 
of the methylene from 5 4.95 in the lactone to 5 4.33 in the desired alkylated 
derivative was observed. Unfortunately, however, lack of time prevented 
further characterization of the product.
Scheme 44
(78)
H3 N .
OTs-
D
(157)
Reagents: (i) TFA, anhydrous para-toluenesulphonic acid
(ii) (153), dry ACN
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2.5.15. Synthesis of 1.2-Oxazolidine-3.5-diQne (159L
The unsuccessful attempt at deprotection of the carbon analogue (112) to the 
desired product (113) prompted the decision for the development of the 
methodology for an alternative method by which the analogue may be prepared. 
It was decided therefore that the heterocycle (159), should be synthesized. 
Alkylation of this with PTSA propiolactone (157) would then yield the tosylate 
salt of the carbon analogue (scheme 45).
Scheme 45.
HgN.
+ OTs-
(157) OTs- (113) tosylate
Reagents: (i) (159), base
To this end, 0 -benzylhydroxylamine hydrochloride was treated with ethyl 
malonyl chloride to afford the corresponding hydroxamate (160). Spectral 
characterization by nmr, mass spectrum and elemental analysis were 
consistent with the desired product. Catalytic hydrogenation in ethanol, using 
10% palladium on activated charcoal gave the product as a foamy solid. An 
[M+H]'*' at m/e 149 in its FAB mass spectrum suggested the desired product 
(161) had been isolated. Cyclization of this intermediate by treatment with 
potassium hydroxide gave the heterocycle (159) as a white solid (scheme 46). 
Its FAB mass spectrum and elemental analysis confirmed the structure.
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Materials and methods.
Nuclear magnetic resonance spectra were recorded on a Bruker AC200 
Spectrometer.
The recorded chemical shifts are relative to tetramethylsilane (TMS) and the 
values are expressed as parts per million (ppm).
Mass spectra were recorded on a Kratos MS50TC.
Infrared spectra were recorded on a Bruker IPS 66
Elemental analyses were recorded on an Elemental Analyzer Model 1106.
Melting points were recorded on an Electrothermal Melting Point apparatus and 
are uncorrected.
Chemicals were obtained from the Aldrich Chemical Company.
Solvents were dried for reactions by the appropriate methods 1^3.
Flash chromatography was carried out on silica gel (Merck Kieselgel 60 )
(Art. 9385) (230-400 mesh ASTM).
Tic was carried out on Merck Kieselgel 60 F252 (Art 5719).
Ion-exchange chromatography was performed on Dowex AG50-X8 cation 
exchange resin in the hydrogen form and Bio-Rad analytical grade anion 
exchange resin in the acetate form (200-400 mesh).
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SYNTHESIS OF DL-OmSOUALIC ACID.
3.1.1. Preparation of ethvi hinDurate.f56)
A catalytic amount of para-toluenesulphonic acid (0.3Ig, 1.62mmol) was added 
to a solution of hippuric acid (50g, 0.28mol) in ethanol (180ml). The solution 
was heated under reflux for twenty hours and excess ethanol was evaporated in 
vacuo to give a clear oil which was taken up in dichloromethane (60ml), washed 
with 2M sodium bicarbonate solution (3x20ml). The organic solvent was dried 
over sodium sulphate, filtered and the solvent was evaporated reduced pressure 
to afford a light oil. Crystallization from diethyl ether afforded ethyl hippurate 
as white crystals.
Yield: 49g. (84%).
m.p. 67OC.(Lit.l70 67.50Q
Rf: 0.76 ( solvent hexane/ethyl acetate 2:1 v:v)
1h  nmr (CDCI3): 6 1.29 (t, 3H, £ii;jCH 2); 4.2 (m, 4H, CH3£H2 andOl2);
7.5 -7.9 (m, 5H, (PhCO).
13c nmr (CDCI3): 13.9 (s, 3H, CH2 CH2); 42.6 (s, 2H, HN£H2);
63.2 (s, 2H, CH3CH2); 127.8-133.4 (s, 5H, EhCO);
171.9, and 172.4 (Ph£Q, and CQ2CH2CH3).
Infrared spectrum: (nujol) v^ax  3340, 1760, 1640, 1580cm 1.
3.1.2. Alternative method of preparation of ethvi hiDDurate (56L 
A solution of hippuric acid (9.6g, 0.05mol), and triethyl orthoroformate (8.9g,
0.6mmol) in dimethylformamide (DMF) (6ml), was heated under reflux 
overnight at 1250C. The oil bath temperature was increased to 1760C, and the 
mixture was heated for another four hours. The brown solution was distilled.
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and the fraction collected at b.p.l40-142OC was chromatographed on silica gel 
(40g) eluted with hexane /ethyl acetate (1:3 v:v). On evaporation of solvent 
ethyl hippurate was collected as white crystals. Recrystallization from diethyl 
ether gave the ester in 62% yield, (on a larger scale, yields were markedly 
decreased).
Rf: 0.76 (solvent EtOAc/hexane.
1h  nmr (CDCI3): 5 1.3 (t, 3H, 4.2 (m, 4H, £H 2™ 3 and
V.4-7.9 (m, 5H, EhCO).
^,1.3. N.Benzovl-2.3-dehvdroserine ethyl ester sodium salt (571 
Ethyl formate (14.8, 0.2mol), was added to a stirred and cooled solution of 
sodium ethoxide, (sodium 4.6g, 0.2mol) in dry ethanol (60ml). The resulting 
mixture was stirred for thirty minutes, and ethyl hippurate (43.7g, 0.21 mol), was 
added over thirty minutes. The mixture was stirred at room temperature for 
forty hours. The yellow slurry was pour into a large volume of diethyl ether 
(600ml), and stired for a further hour, and filtered. The product, a cream solid, 
was air dried, powdered and dried in vacuo over P2O5.
Yield: 29.6g (55%). 
m.p. 128^0 (decomposed).
nmr: (D2O): 5 1.24 (t, 3H, CH3CH2): 4.14 (q, 2H, CH3,CH2);
7.4- 7.6 (m, 5H, PhCO); 8.6. (s, IH, CH=C).
Mass spectrum: molecular ion at m/g 257.
Anal, calcd. for C i2H i2N0 4 Na requires C 56.03; H 4.67; N 5.45.
Found: C 55.85; H 4.82; N 5.34.
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^1.4. Preparation of the enol from the sodium salt.
2M HCl (3ml) was added to a solution of the sodium salt (57) (150mg, 2mmol), 
in water (25ml) and the mixture was extracted with diethyl ether (3x25ml). The 
extracts were combined, dried over sodium sulphate, filtered and the filtrate was 
evaporated in vacuo to yield a light yellow oil which crystallized on standing. 
Yield: 40mg, (87%).
1h  nmr ( CDCI3): 5 1.3 (t, 3H, £ ^ ¿ ^ 2); 4.25 (q, 2H, CH3£H2)’
7.43-7.51 (m, 4H, EhCO, and £H=C); 7.78-7.87 (m, 2H, PhCO);
8.48 (broad s, lH ,JiH ); 12.2 (broad s,lH,HQC=C).
3.1.5. N-Benzovl-3-oxo-alanine O-benzvl oxime ethvl CStcr (5&L
A solution of the sodium salt (57), (13g, 0.05mol), in water and 
dichloromethane (70ml), was stirred at O^C, for fifteen minutes. O- 
Benzylhydroxylamine hydrochloride (7.34g, 0.046mol.) was added, and the 
mixture was warmed to room temperature and was left stirring overnight. 
The aqueous phase was separated and then extracted with dichloromethane 
(3x60ml). The combined extracts were dried over sodium sulphate, filtered 
and the filtrate was evaporated in vacuo to yield a light yellow oil which 
solidified on standing. Recrystallization from ether/hexane gave the oxime as 
a white solid.
Yield: 10.5g, (63%). 
m.p.85-870C, 88-890Q.
Rf: 0.76 ( solvent: hexane/ethyl acetate (2:1 v:v).
1h  nmr (CDCI3): 5 1.28 (t, 3H, £H2 ,CH2); 4.26, (q, 2H, CH3£H 2 );
5.11 (s, 2H, 5.41 (dd, IH, CHC0 2 C2H5); 7.1-7.51 (m, 5H,
EI1CH2); 7.65 (d, IH, N=£H); 7.76-7.89,(m, 5H, £liCO)
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Mass spectrum: molecular ion at m/g 340.
Anal, calccl. for C l9H20N2O4 requires: C 67.04; H 5.92; N 8.28.
Found: C 67.09; H 6.12; N 8.41.
3.1.6. ii-N-Ben7nvl-3-benzvloxvamino alanine ethvi ester (52L
A trace of bromocresol green indicator was added to a solution of the oxime 
(58) (6.8g, 0.02mol), in methanol (50ml). The basic solution was acidified 
(yellow) with 2M methanolic HCl and sodium cyanoborohydride (1.26g, 
0.02mol) was added in the one potion. The reaction mixture was maintained 
at pH2 by the gradual addition of methanolic HCl and was left stirring at 
room temperature overnight. The solvent was evaporated in vacuo and the 
residue was partitioned between chloroform and saturated sodium bicarbonate 
solution. The aqueous phase was extracted with chloroform (3x50ml) and 
the combined extracts were dried over sodium sulphate, filtered and the 
solvent was evaporated under reduced pressure to yield a yellow oil (6.6g). 
After column chromatography on silica gel (30g) eluted with hexane/diethyl 
ether (2 :1 ), the product was collected as a white solid on evaporation of 
solvent. Recrystallization from diethyl ether/hexane gave the pure 
hydroxylamine as a white crystalline solid.
Yield: 4.52g (66%). 
m.p. 62-64®C.
iH nmr (CDCI3): 6 1.28 (t, 3H, £H 2CH2); 3.48 (m, 2H, C U ^z)'^
4.26 (q, 2H, CH2 CH3); 4.67 (s, 2H, £H 2 Ph); 4,87 (m, 1H ,I:H C 0 2 C2H5); 
6.77 (broad s, IH . NHCHo); 7.26-7.28, (m, lOH, 2x£li).
Mass spectrum: m/g 342.
Anal, calcd. for C l9H22N2O4 requires: C 66.50; H 6.48; N 8.18.
Found: C 66.87; H 6.90; N 8.43.
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3.1.7. Diethvl-2-benzovlaminQ-4-benzvlQxv-5-oxo-4.6-diay.aheptane-
l. 7-dioate (60).
Ethoxycarbonyl isocyanate (0.3g, 2.5mmol) was added (dropwise) at SO^C, to 
a stirred solution of the hydroxylamine (59) in dry ether. After five to ten 
minutes, a colourless crystalline product began to separate out. Stirring was 
continued for another hour at room temperature and the product was collected 
by filtration, washed with cold ether and air dried. Recrystallization from 
diethyl ether gave a colourless amorphous solid.
Yield: ( 0.72g, 80%).
m. p. 98-lOQOC, (Lit.*'?0 98-lOOOC).
Rf. 0.5 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 1.1-1.3 (m, 6H, 2xCH2Pl^);
3.5-4.4.3 (m, 6H, CHCHo+(CH2CH3)2 4.5 (m, IH, £HCH2);
5.1 (s,2H ,£ H 2 Ph); 5.8 (d, lH ,iiH ); 6.7 (s, lH ,im );
7.3-7.8 (m, lOH, CH2EIl-t-P!lCO);
Mass spectrum: molecular ion at m/e 457.
3.1.8. Diethvl-2-ben7.ovlamino.4-hvdroxv-5-QXQ-4.6-diay^heDtane-]«7- 
dioate (61).
A suspension of the benzyloxyureide (0.9g, 2mmol), in ethanol (20ml) and 
5% palladium on activated charcoal (0. 12g), was hydrogenated at room 
temperature and atmospheric pressure for two hours. The catalyst was 
removed by filtration through keiselguhr and the filtrate was evaporated to 
dryness, yielding a foamy solid (0.7g,96%). Recrystallisation from ethanol 
gave colourless plates.
Yield: (0.7 Ig, 74%).
128
m.p. 146-1480C
Rf. 0.36 (solvent ethyl acetate/hexane 1:1 v:v).
1h  nmr (CDCI3): 5 1.15 (t, 3H, CH2CH^); 1.39 (t, 3H, CH2£H^);
3.5 (m, 2H, CH£H2)’ 7.6 (m, 5H, EhCO);
9.02 (s, 1H,QH-N).
Anal, calcd.: C 16H2 1N3O7; requires C 52.32; H 5.72; N 11.44.
Found: C52.01; H 5.96; N 11.12.
Mass spectrum: molecular ion at m/e 367.
3.1.9. N-Benzovlauisaualic acid (62).
The diester (61) (5.5g, 0.015mol), was dissolved in 4N sodium hydroxide 
solution (15ml), diluted with water (15ml). The mixture was left standing at 
room temperature for three hours and the solution was filtered, the filtrate was 
carefully acidified to pH3 with concentrated hydrochloric acid at O^C. The 
precipitated product was collected, washed with water and dried in a 
desiccator over P2O5.
Yield: 4.12g, (94%). 
m.p. 191-193®C.
1h  nmr (DMSO): 5 4.0 (m, 2H, CH£H2); 4.3 (m, IH, OiCH2);
7.3 (d, IH, NH); 7.5-7.S (m, 5H, £hCO).
3.1.10 DL-Ouisaualic acid (63).
N-Benzoylquisqualic acid (62) (5.68g, 0.02mol), was dissolved in 6N 
hydrochloric acid (240ml) and the solution was heated at 80^0 for twenty 
hours. On cooling, the benzoic acid which separated was removed by 
filtration and the aqueous phase was extracted with ethyl acetate (3x30ml) to 
remove residual benzoic acid, and the aqueous phase was concentrated in
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vacuo. The resulting quisqualic acid hydrochloride was converted to the 
amino acid by ion exchange chromatography (Dowex 1X2-400, acetate resin). 
The column was first eluted with water (100ml), then with 3% acetic acid 
solution (200ml). The acidic eluates were combined and evaporated to 
dryness to afford DL quisqualic acid. Recrystallization from water and 
ethanol gave the amino acid as colourless plates.
Yield; 1.8g 48%, (Lit. 170 30%).
m.p. 1920C (decomposed with effervescence) (Lit.170 190-191OC).
Rf: 0.17 (solvent: BuOH; AcOH: H2O; 3:1:1 v.v).
iH  nmr (D2 0 /NaOD): 5 3.4 (m, IH, I/2  CH£H2); 3.7 (m, 2H, £H+1/2£H2)- 
Anal, calcd.: C5H7N3O5; C 31.75; H 3.70; N 22.22.
Found; C 31.03; H 3.78; N 21.67. (Calcd. for 0.25 H2O: C 31.01, H 3.87, 
N 21.70)
vmax; (KBr), 3420, 3210, 2980, 2720. 1825, 1700, 1620.
A solution of the sodium salt (57) (2g, 7 .8mmol), in water (25ml) and 
dichloromethane (25ml), was treated at OOC, with tert-butylhydroxylamine 
hydrochloride (1.07g, 8.6mmol). The mixture was warmed to room 
temperature and was left stirring overnight. The aqueous phase was 
separated, washed with dichlomethane (3x20ml) and the combined organic 
extracts were washed with brine, dried over sodium sulphate, filtered and the 
filtrate was evaporated under reduced pressure to afford a light yellow oil. 
Crystallization from ether/hexane gave the oxime as a white solid.
Yield: 1.5g, (60%).
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m.p. 105-107OQ
Rf: 0.44 (solvent EtOAc/hexane 2:1 v:v).
1r  nmr (CDCI3); 5 1.28 (s, 9H, t-butyl); 1.29 (t, 3H, CH2£H¿);
4.26 (q, 2H, CH2CH3V. 5.42 (d, IH, CHCOOEt); 7.28 (s, IH, MH); 
7.41-7.88 (m, 5H,EhCO).
13c nmr (CDCI3): 14.02 (3H, CH2O Í 2 ); 27.48 (9H,
53.26 (IH CHCQOEO: 62.26 (2H,_Cil2^^3)’ 127-133.66 (5H, Ell); 
142.16 (IH, -N-CH): 166.92 (£QOEt); 168.55 (Ph£Q).
Mass spectrum: molecular ion at m/e 306.
Anal, caled, for C 16H22N2O4 requires: C 62.75; H 7.19; N 9.15. 
Found: C 62.87; H 7.21; N 9.23.
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T 1.11 .2 . N.Benyovi-3-t-butvlaminoalanine ethvl ester (^ZL
N-benzoyl-3-oxoalanine-t-butyl oxime ethyl ester (66) (2g, 6.5mmol) was 
dissolved in a solution of acetic acid (95ml), and concentrated sulphuric acid 
(5ml). The mixture was hydrogenated at room temperature and a pressure of 
40psi in the presence of 5% palladium on charcoal (0.2g). The reaction was 
followed by thin layer chromatography, which showed complete 
disappearance of the starting material after two hours The catalyst was 
removed by filtration, and the acidic filtrate was neutralised with sodium 
hydroxide pellets. The product was extracted into chloroform (2x60ml) and 
the combined extracts were dried over sodium sulphate, filtered and the 
solvent evaporated in vacuo to yield a light yellow oil, which solidified on 
standing. Recrystallization from diethyl ether /hexane gave the 
hydroxylamine as colourless crystals.
Yield: 0.8g, 40%. 
m.p. 64-66®C.
Rf: 0.29 (solvent: hexane/ethyl acetate 1:1 v:v).
1h  nmr (CDCI3): 5 1.17 (s, 9H, t-butyl ); 1.33 (t, 3H, £H 2 CH2);
3.39-4.46 (m, 2H, CH2 -NOBut); 4.28 (q, 2H, 7.27 (s, IH, HN-
CH) 7.49-7.90 (m, 5H, PbCO).
13c nmr (CDCI3) 5 14.98 (CH2 CH2); 26 55 (t-lMyl); 52.67 ( £HCH2);
53.05 ( C H £tl2)’ 61.49 (£H 2™ 3); 77.6 (HN£ti); 127.1 (PbCO);
167.19 (PhCQ); 171.42, (£Q2 Et).
Anal cacld for C]^ 5H24N204  requires C 62.34; H 7.79; N 9.09.
Found: C 62.13; H 7.81; N 8.60.
Vmax  ^ (nujol); 3330, 2950, 1780, 1760, 1740, 1720, 1520.
(The work reported above provides a method by which tritiated quisqualic
acid can be synthesized).
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3.1.11.3. Diethvl-2-benynvlamino-4-t-butvloxv-5-oxQ-4.6-diazaheDtane^
l. 7-dioate (68).
A solution of the hydroxylamine (67) (3.5g, O.Olmol) in dry ether (20ml), 
was treated dropwise with ethoxycarbonyl isocyanate (1.4g, O.Olmol), at 
After stirring for an hour, the white solid which precipitated was filtered, 
washed with ice-cold ether, and air dried. Recrystallization from ether gave 
the diester as a white crystalline solid.
Yield: 4.1g, 94%.
m. p. 135-136®C.
R f:0  .68 (solvent hexane/EtOAc 1:1 v:v).
nmr (CDCI3): 5 1.1 (s, 9H, t-butvl): 1.2 -1.4 (m, 6H, (CH2£ i i2 )2 ;
3.6-4.4 (m, 6H, CH£H2+(CH2CH3)2 ; 4.5 (m, IH, £HCH2).5.8 (d, IH, M i); 
6.8 (s, IH. NH).
3.1.11.4. Diethvl-2-benzovlamino-4-hvdroxv-5-oxo-4.6-diazaheDtane
l .  7.dioate (61)
The tert-butoxy amino derivative (68) (0.5g, 1.62mmol), was dissolved at 
O^C, in a solution of trifluoroacetic acid (20ml). The solution was left 
standing at room temperature for two hours. On evaporation of solvent, the 
residue was taken up in ethyl acetate and washed with 2M sodium bicarbonate 
solution (3x40ml) and then with saturated brine, dried over sodium sulphate, 
filtered and the solvent evaporated in vacuo to give the product as a white 
solid.
Yield: 0.28g, 68%.
m. p. 148-150®C.
Rf: 0 .36 (solvent'.hexane/ethyl acetate)
1h  nmr (CDCI3): 81.14 (t, 3H, CH2CH2 ); 1-4 (t, 3H, CH2CU2 );
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3.6, (m, 2H, CH£H2 ); 4.3 (m, IH, O IC H 2); 7.4-7.6 (m, 5H, £h);
9.00 (s, 1H,NH).
Synthesis of" ^H" DL quisqualic acid was carried out as outlined in (3.1.9.) 
and (3.1.10.).
3 .2 . A l k y l a t io n  o f  D L -q u is o u a l ic  a c id .
3.2.1. N-Ben/ovI auisaualic acid methvi ester (69).
Thionyl chloride (5ml) was added (dropwise) under nitrogen, to dry methanol 
(40ml), at -40^C. The solution was stirred for fifteen minutes and N- 
benzoylquisqualic acid (3.46mmol) was added. The mixture was warmed to 
room temperature, then heated under reflux for three hours. On cooling, the 
solvent was evaporated and the residue was taken up in water and washed 
with ethyl acetate (3x30ml). The combined washings were dried over sodium 
sulphate, filtered and the solvent was evaporated under reduced pressure to 
afford a clear oil. Crystallization from ether and methanol gave the ester as a 
white solid.
Yield: 0.65g, 62%.
Rf: 0.28 (solvent DCM/MeOH 9:1 v:v). 
m.p. 128-130OC.
1h  nmr (CDCI3): 5 3.7 (s, 3H, O O l^);
4.1-4.3 (m, 4H, CHCH2 +CH2COOEt): 4.9 (m, 1H,_01CH2); 6.9 (d, IH, 
NHk 7.3-7.6 (m, 5H, EhCO).
Mass spectrum: [M+H]'*' at m/e 308.
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 ^? 1 ».N.Benynvl-£-N-e>hnxvcarbonvlmettlvl QuiSQUaiiC acid iilgth.Yl 
ester (70).
A solution of the methyl ester (69) (0.5g, 1.6mmol) in DMF was treated with 
sodium hydride (0.04g, l.Tmmol). The mixture was stirred for thirty minutes 
at room temperature, followed by the addition of ethyl bromoacetate (0.28g, 
1.7mmol). Stirring was continued for another fifteen minutes and the mixture 
was heated under at 50^C for four hours. On cooling, the solvent was 
evaporated and the residue was partitioned between dichloromethane and 
aqueous sodium bicarbonate solution. The crude product was extracted into 
the organic phase (3x20ml), washed with brine, dried over sodium sulphate, 
filtered and the filtrate was evaporated under reduced pressure to give a light 
yellow oil. Purification by flash chromatography on silica gel (15g) and 
elution methanol/dichlomethane 2:98 v:v gave the diester as a very light
yellow oil.
Yield; 0.3Ig, 53%.
Rf. 0.40 (solvent EtOAc/Hexane 1:1 v:v).
1h  nmr (CDCI3): 5 1.3 (t, 3H, CH2O I 2 )’
3.7 (s, 3H, OCH^): 4.2-4.5 (m, 4H,
5.1 (m, IH. CHCH2): 7.1 (d, lH ,N il); 7.4-7.8 (m, 5H, PhCO).
Mass spectrum: [molecular ion-C02] at m/e 349
fY-N-RenynvI-F.-N-cflrhoxvinethvI auisaiialic acid (711i
The diester (70) (0.29g, 0.8mmol), was dissolved in methanol (5ml) followed 
by the addition of sodium hydroxide (0.07g, 1.7mmol) in water (15ml). The 
mixture was stirred at room temperature for two hours and alcohol was 
evaporated under reduced pressure. The aqueous phase was acidified to pH3 
with 2M HCl and then extracted with ethyl acetate (3x20ml). The combined
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extracts were dried over sodium sulphate, filtered and the solvent was 
evaporated in vacuo to afford the acid as a foamy oil.
Yield: 0.13g, 50%.
Rf: 0.5 (solvent DCM/MeOH/AcOH 44:5:1 v:).
1h  nmr ( DMSO): 5 3.6-3.7(m, 2H, CH£H2); 3.8 (s, 2H, CH2COOH);
4.3 (m, IH, 01CH2); 6.9. (d, IH, NH);
7.3 (m, 5H, Ph).
3.2.4. Atemnfed synthesis of e-N-carhoxvmethvI DL-quisQualic acid (72L
A solution of the adduct (71) (lOOmg, 0.28mmol) in 6M HCl was heated at 
80®C for twenty hours. Benzoic acid which precipitated was collected by 
filteration and the residue was evaporated to dryness to afford an oily residue. 
Ninhydrin developed tic showed the presence of several products. These were 
neither isolated nor characterized.
3.3. SYNTHRSIS OF L-QIIT-SODALIC ACID (20).
3..3.1. N-t-Biitoxvcarbonvl serine (74).
Di-tert-butyl dicarbonate (155.g, 0.71mol) in isopropanol (50ml) was added 
dropwise over an hour to a well stirrred solution of L-serine (73) (50g, 
0.48mol) and sodium hydroxide (21g, 0.52mol), in water (50ml) and 
isopropanol (100ml). After a short period the temperature rose to 
approximately 40^0, and a further 100ml of isopropanol was added. The 
turbid solution was stirred overnight, and the solvent was evaporated in 
vacuo. The residue was taken up in water, washed with petrol to remove 
residual (Boc)2 0 , then acidified with 5% citric acid solution to pH3. The
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aqueous phase was saturated with sodium chloride and the product was 
extracted into ethyl acetate (3x60ml), dried over sodium sulphate, filtered and 
the solvent evaporated in vacuo, to afford a colourless oil which solidified on 
standing to give the monohydrated t-Boc serine.
Yield: 86g 87%. 
m.p.74-770C (lit. 75-780C 202)
Rf. 0.55 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 1.4 (s, 9H, t-Boc): 3.8-4.1, (m, 2H, £H 2CH);
4.2-4.4 (m, IH £HCH2); 6.2 (d, IH, m i) .
Mass spectrum: [M+H]'*' at m/e 206.
r3SV3-t.Butoxvcarhnnvlaminn-nxetan-2-one (78L 
Triphenylphosphine (15.5g, 0.06mol) was dissolved in 150ml of dry THF. 
The solution was stirred under nitrogen at -78°C, followed by the dropwise 
addition of diethyl azodicarboxylate (11.32g, 0.065mol). Stirring was 
continued and the off-white slurry which ensued was treated with a solution 
of t-Boc-L-serine (12.1g, 0.05mol) in 100ml of dry THF. The mixture was 
stirred overnight and concentrated in vacuo, to a give light brown/orange 
residue which was (pre-absorbed on silica gel), purified by flash 
chromatography using ethyl acetate/ hexane (40/60 v:v) as the eluent. The 
product, a white solid, was collected on evaporation of solvent.
Yield: 58%. (Lit 176 7 1%)
m.p. 119-120OC (Lit 176 119.5-120OC).
Rf: 0.4 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 6 1.4 (s, 9H. t-Boc); 3.9 (m, 2H, C H O I2 );
4.3 (m, IH, C H O i2 ); 4.9 (s lH ,m i) .
Mass spectrum: [M+H]"*" at m/e 188.
Anal, calcd. for CgH i3N04  requires C 51.34 H 6.95 N 7.48
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Found: C 51.04 H 6.93 N 7.24.
3.3.3. N-t-Butoxvcarbnnvlserine-0-benzvlhvdroxamic acid (75). 
N-tert-butoxycarbonyl-L-serine monohydrate (1.115g, 5mmol), was 
dehydrated by the azeotropic removal of water using toluene/ethyl acetate. 
The anhydrous oil which ensued was dissolved in dry tetrahydrofuran (THF) 
(20ml), cooled to -25^C, and N-methylmorpholine (505mg, 5mmol) was 
added The mixture was stirred at -250C for five minutes and isobutyl 
chloroformate (682.5mg, 5mmol) was then added, and the mixture was stirred 
at -25®C for two minutes then treated with a cooled (-15®C) suspension of
O-benzylhydroxylamine hydrochloride (1.6g, lOmmol), and N- 
methylmorpholine (l.Olg, lOmmol), in dry THF (50ml). The reaction 
mixture was stirred for two hours at -15®C, then poured into 400ml of semi- 
saturated brine. The solution was acidified (pH3) by the gradual addition of 
5% citric acid solution. The precipitated product was isolated by filtration 
and the filtrate was extracted into ethyl acetate, (3x20ml), dried over sodium 
sulphate, filtered and the solvent was evaporated in vacuo. The white solid 
which ensued was added to that obtained by filtration, and recrystallized from 
hexane and ethyl acetate to afford the product as a white crystalline solid. 
Yield: 1.2g, 62%. 
m.p. 129-130OC.
Rf: 0.44 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 1.4 (s, 9H, t-Boc): 3.6-4.41 (m, 2H,
4.9 (s, 2H, CHoPh): 5.5 (s, IH, HN-t-Boc); 7.4 (m, 5H, Eh); 9.3 (s, IH, U iL  
OCH2).
Mass spectrum [M+H]"*" at m/e 311
Anal, calcd. for C 15H22N2O5 requires: C 58.06; H 7.10; N 9.03.
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Found: C 57.57; H7.06; N 8.82.
3.3.4. (3S)-l-Benzvloxv-3-tert-butoxvcarbQnvlainino-azeti(lin-2-Qne(76).
Diethyl azodicarboxylate (3.06g, 0.02mol) was slowly added at -780C to a 
solution of triphenylphosphine (5.1g, 0.019mol), in dry THF (100ml). A light 
yellow slurry which ensued was treated by the slow addition of a solution of 
the hydroxamate (75), (5.92, 0.019mol) in dry THF (100ml). The mixture 
was stirred at -78^0 for twenty minutes, then overnight at room temperature. 
The solvent was evaporated and the residue preabsorbed on silica gel (3g), 
then chromatographed on silica gel (30g), eluted with hexane/ethyl acetate 
2:1. The product, a white crystalline solid, was collected on evaporation of 
solvent.
Yield: 2.3g 41% (Lit. 172 66%).
Rf: 0.42 (solvent EtOAc/hexane 1:2 v:v). 
m.p.91-920C (Lit.l72m.p91-920C).
1h  nmr (CDCI3): 5 1.4 (s, 9H, t-Boc): 3.2-3.5 (m, 2H,
4.5 (m, 2H, CH2£H); 4.9 (s, 3H, Q i^P h  +HN t-Boc); 7.4 (m, 5H, £li)
Mass spectrum: [M+H]"*" at m/e 293.
Anal, calcd. for C 15H20N2O4 requires: C 61.64, H 6.85, N 9.59.
Found: C 61.28, H 7.12, N 9.96.
Infrared spectrum: Vn^x 3210, 2925,1720 cm’ l
3.3..S. lSl-nt-N-tert-Butnxvcarbonvl-3-benzvloxvainino alanine (77).
A solution of sodium hydroxide (0.15g, 3.75mmol) was added to a solution of 
N-a-tert-butoxycarbonyl-L-serine P lactam (76) (Ig, 3.42mmol), in methanol 
(10ml). The mixture was stirred at room temperature for two hours and the 
basic solution was acidified (pH3), with saturated citric acid solution at 0®C. 
The precipitated product was collected by filtration, and the aqueous phase
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was extracted with ethyl acetate (3x20ml), dried over sodium sulphate, 
filtered and the solvent was evaporated under reduced pressure to afford a 
colourless oil. This was combined with the precipitated solid, and then 
recrystallized from ethyl acetate/hexane to give the product as a white solid. 
Yield: 0.64g, 64%. 
m.p. 62-64^C.
Rf: 0.79 ( solvent:DCM/MeOH/AcOH 45:5:1 v:v).
1h  nmr (CDCI3): 5 1.4, (s, 9H, t-Boc); 3.1-3.4, (m, 2H, £H 2CH);
4.35-4.5 (m, IH, £HCH2); 4.7, (s, 2H, QiiPh)-. 4.8-5.0 (s, IH, HM t-Boc)
7.3, (s, 5H, Ph),
Mass spectrum: [M+H]"*" at m/e 311.
Anal, calcd. for C 15H22N2O5 requires: C 58.06 H 7.1 N 9.03.
Found: C 58.26 H 7.31 N 9.23.
Infrared spectrum: v^ax
3.3.6. Synthesis of ( 77)  bv alleviation of O-ben/.vIhvdroxYlamine with 
B-lactone (78).
A solution of t-Boc p-lactone (Ig, 5.3mmol) and O-benzylhydroxylamine 
hydrochloride (0.95g, 5.9mmol) in dry acetonitrile (40), was heated at SO^C 
for eight hours. The reaction which was followed by tic showed the presence 
of two products. The solvent was evaporated in vacuo, and the residue was 
taken up in ethyl acetate, washed with water (3x25ml). The organic extract 
was dried over sodium sulphate, filtered and evaporated under reduced 
pressure to afford the acylated material (75) as a colourless oil. 
Crystallization from ethyl acetate/hexane gave the hydroxamate as a white 
solid.
Yield: 40%.
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m.p. 129-130OC.
Rf: 0.45 (DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 1.4 (s, 9H. t-Boc): 3.6-4.1 (m, 3H, O i  and Qig)',
4.9 (s, 2H, 5.5 ( d, IH, M i); 7.4 (s, 5H, Eh);
9.3 (broad s, IH, NH).
Mass spectrum: [M+H]"*" at m/e 311.
The aqueous phase was acidified to pH3 with 0.5M HCl at 0®C and then 
extracted with ethyl acetate (3x20). The extracts were combined, dried over 
sodium sulphate, filtered and evaporated in vacuo to afford the aklylated 
product (77) as a colourless oil which solidified on standing.
Yield: 60%. 
m.p. 62-64®C.
Rf: 0.8 (DCM/MeOH/AcOH 45:4:1 v:v).
1h  nmr (DMSO): 5 1.4 (s, 9H. t-Boc): 3.1-3.4 (m, 2H, CH£H2 );
4.4 (m, IH, CHCH2); 5.5 (s, 2H, Q iz ^ ^ y  5-8 (s, IH, NH); 7.3 (s, 5H, Eh). 
Mass spectrum: [M+H]"*" at m/e 311.
3.3.7. (2)-N-t-butoxvcarbonvl-3-benzvloxvamino-alanine methvl ester.
Freshly prepared diazomethane ^  85 in ether was slowly added to an ethereal 
solution of the acid (74) (2.7g, 8.37mmol), in diethyl ether (100ml), until the 
evolution of nitrogen had ceased and the solution remained permanently 
yellow. A small amount of acetic acid solution was slowly added to destroy 
residual diazomethane. The ethereal solution was washed with cold water 
(3x30ml), dried over sodium sulphate, filtered and evaporated in vacuo to 
afford a colourless oil.
Yield: 2.8g, 92%.
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Rf: 0.55 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 6 1.4 (s, 9H, t-Boc^: 3.2-3.5 (m, 2H, O I 2CH)
3.7 (s, 3H, O C m ): 4.45 (m, IH, O IC H 2); 4.6 (s, 2H, £H 2Ph);
5.4 (broad s, IH, HN-t-Boc); 5.8 (broad s, IH, HN): 7.35 (s, 5H, Ph). 
(Although the pilot synthesis of quisqualic acid utilized the methyl ester, it 
was found that on subsequent synthesis, esterification was not neccessary. 
Acylation of the acid (77) proceeded smoothly to yield the desired product).
3.3.8. r2S)-2-t-Butoxvcarbonvlaniino-4-benzvloxv-5-oxo-4.6-dia/a- 
heptan-lJ-dioic acid-7-ethvl ester (79).
A solution of the benzyloxyamine (77) (0.5g, 1.6mmol) in dry THF (30ml) 
was treated with a dropwise addition of with ethoxycarbonyl isocyanate 
(0.19g, 1.7mmol.) at 0®C. The mixture was stirred at O^C for ten minutes, 
then at room temperature for one hour. The product which precipitated was 
collected by filtration and the aqueous filtrate was extracted with ethyl acetate 
(3x20ml), dried over sodium sulphate, filtered and the solvent was 
evaporated under reduced pressure, to afford a white solid which was 
combined with that obtained by filtration, and recrystallized from ether and 
hexane.
Yield: 0.5g, 74%. 
m.p. 119-1210C.
Rf: 0.64 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 6 1.3 (t, 3H, i£H 2CH2 ); 1.4 (s, 9H, (t-Boc):
3.8-4.1 (m, 2H, CH2 CH3); 4.6 (m, IH, £HCH2);
4.85 (s, 2H, CH2P*^  ^ HH-t-Boc); 7.4 (s, 5H, Eh); 7.8 (s, IH , NH).
Mass spectrum: [M+H]"*" at m/e 426.
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3.3.9. r2S)-2-t-Butoxvcarbonvlamino-4-hvdroxv-5-oxo-4.6-diaza-heDtan-
1.7-dioic acid-7-ethvl ester (8QL
A suspension of the acid (79) (200mg, 0.47mmol) in ethanol (25ml) and 5% 
palladium on charcoal catalyst (20mg) was hydrogenated at room temperature 
and atmospheric pressure for one hour. The catalyst was removed by 
filtration, and the solvent was evaporated in vacuo. The residue was taken up 
in ethyl acetate, washed with O.IM HCl, dried over sodium sulphate, filtered 
and the solvent was evaporated in vaciiOy to afford the desired product as a 
colourless oil.
Yield: 0.12g, 76%.
Rf: 0.63 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 1.3 (t, 3H, CH2CH2 ); 1.4 (s, 9H, t-goc);
3.6 (s, 3H, OCH^); 3.6 and 4.2 (m, 2H, CHlCH); 4.2 (q, 2H, £H 2 CH3);
4.8 (m, IH, CHoCH): 5.7 (d, IH, NH-t-Boc); 8.2 ) (s, IH, NU);
9.0 (s, 1H,QH).
Mass spectrum: [M+H]"^ at m/e 336.
3.3.10. (2Sl-a-N-t-Butoxvcarbonvl auisQualic acid (811
Sodium hydroxide (0.35g, 8.75mmol), in water (10ml), was added to the acid 
(80) (1.5g, 4.3mmol). The mixture was left standing at room temperature for 
three hours and filtered. The filtrate was acidified with saturated citric acid 
solution to pH3 at O^C. The product was extracted into ethyl acetate 
(3x30ml) and the combined extracts were dried over sodium sulphate, filtered 
and the solvent was evaporated in vacuo to yield a foamy oil. Crystallisation 
from dichloromethane and ether gave the cyclized acid as a white solid.
Yield: 1.2g,97%. 
m.p. 96-98®C
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Rf: 0.11 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (DMSO): 6 1.4 (s, 9H, t-BocV. 3.8 -4.1 (m, 2H, £H 2 CH);
4.3 ( m, IH, £HCH2); 7.2 (d, IH, HH-t-Boc).
Mass spectrum: [M+Na] at m/e 312.
3.3.11. L-OuisQualic acid (20).
t-Boc L-quisqualic acid (500mg, 1.7mmol) was dissolved in IM HCl in acetic 
acid solution (10ml). The solution was left standing at room temperature for 
one hour, during which time the amino acid hydrochloride began to 
precipitate out. On evaporation of solvent, the solid which ensued was taken 
up in water and washed, then with ether. The aqueous phase was 
concentrated in vacuo and converted to the free amino acid by ion exchange 
chromatography (acetate anion resin Dowex X8) eluted with water (100ml), 
then with 3% acetic acid solution (200ml). On evaporation of solvent, L- 
quisqualic acid was collected as a white solid.
Yield: 203mg,62%
m.p. 192-193 decomposed with effervescence.
Rf: 0.22 (solvent: BuOH/H20 /AcOH 3:1:1 v:v).
1h  nmr (D20 /NaOD): 6 4.0.(m, IH, I/2O I 2 ™ ) ’
4.1-4.2 (m, 2H, + I/2  Q iz )
Mass spectrum: [M+H]**" at m/e 190
Anal, calcd for C5H7N3O5 requires: C 31.75: H 3.70; N 22.22.
Found: C 31.72: H 3.72: N 22.38.
[a]o  +17.2 (c= 1.0, IM HCl).(Lit.l77 + 17.0 (c=2.0, 6M HCl)).
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.^.4. SYNTHESIS OF SOME ANALOGUES OF OIIISQUALIC ACID.
. .^4.1.1. rS)-2-t-Butoxvcarhonvlainino-4.6-diaza-5-QX0-0Ctan-1.8-diQi£ 
acid-8-ethvl ester (821
A solution of the protected hydroxylamine (77) (3.4g, 0.01 Imol), in dry THF 
(50ml), was treated dropwise at O^C, with ethyl isocyanatoacetate (1.5g, 
0.02mol) in dry THF (20ml). The colourless solution was stirred for fifteen 
minutes at 0<^ C, then at room temperature overnight. The solvent was 
evaporated in vacuo, and the residue was partitioned between 0.5M HCl and 
ethyl acetate. The product was extracted into the organic phase, dried over 
sodium sulphate, filtered and the solvent was evaporated in vacuo to give a 
foamy oil.
Yield: 3.43g, 70%.
Rf: 0.64 (solvent: DCM/MeOH/AcOH 45:5:1: v:v).
1h  nmr (CDCI3): 5 1.1-1.25 (t, 3H, £H 2CH2); 1.4 (s, 9H, ( k t o ) ;
3.6-4.3 (m, 6H, CH£H2’ a n d ^ 2 ^ 2 ^ ^ 3 > ’ (m» IH, O IC H 2);
6.0 (s, IH, HNCHoCOOEt): 6.4 (s, IH, jM  t-Boc.);
13-1.5  (s, 5H, PhCH2 ).
Mass spectrum: [M+H]"^ at m/e 440.
Vmax (KBr): 3540 (broad), 1620, 1730cm-l.
3.4.I.2. r2Sl-2-t-Butoxvcarhonvlamino-4-hvdroxv-4.6-diaza-5-QXik 
octan-1.8-dioic acid-8-ethvl ester (83L
10% Palladium on activated charcoal (0.3g), was suspended in a solution of 
the O-benzylhydroxamate ester (82) (2.9g, 6.9mmol.) in ethanol (60ml). The 
suspension was hydrogenated at room temperature and atmospheric pressure 
for two hours. The catalyst was removed by filtration and the filtrate was
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evaporated in vacuo to yield a foamy oil.
Yield: 2.36g, 96%.
0.35 (solvent DCM/MeOH 3:1 v:v).
1h  nmr (CDCI3): 5 1.2 (t, 3H, £H 2CH2); 1.4 (s, 9H, t-Boc);
3.8 (m, 2H, CH£H2 ); 4.2 (m ,4H, £ 1 1 2 ^ 3  and NH£H2);
4.5 (m, IH £HCH2); 6.1 (d, IH, HN); 6.5 (m, IH, M i).
Mass spectrum: [M+H]"*" at m/e 350, [M+Na]+ at m/e 372
3.4.1.3. (2Sl-2-t-Butoxvcarhonvl-3-r2-Metrahvdro-l,2.4-Qxadia7jn-
3.6-dionvli1alanine (84).
The hydroxyl derivative (83) (2.4g, 6.86mmol) was added to a solution of 
sodium hydroxide (0.6g, 15mmol) in water (20ml) and the solution was 
stirred at room temperature for two hours. (The reaction was followed by 
ferric chloride indicator). The solution was filtered and the filtrate was 
acidified by the gradual addition of 0.5M HCl to pH3. The product was 
extracted into ethyl acetate, dried over sodium sulphate, filtered and the 
solvent was evaporated in vacuo to yield a foamy white solid.
Yield: 1.6g, 60%. 
m.p. 11-1 A^C.
Rf: 0.57 (solvent DCM/MeOH/AcOH 44:5:1 v:v).
1h  nmr (d-6 DMSO): 5 1.4 (s, 9H, t-Boc): 3.7 (m, 4H, CH£H2 and 
CHoCQOH): 4.2 (m, IH, CHCHo): 6.6 (d, IH, M l); 7.1 (m, IH, M l).
3.4.1.4. 3-(2-Tetrahvdrn-l,2.4-oxadiazin-3.6-dionvl)alanine (85L
The t-Boc protected system (84) (500mg, 1.7mmol), was dissolved in IM HCl 
in acetic acid (20ml). The solution was left at room temperature for one hour, 
during which time amino acid hydrochloride began to precipitate out. On
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evaporation of the solvent, the white solid which resulted was taken up in 
water and passed down an anion exchange column (acetate anion Dowex X8) 
eluted with 100ml of water, followed by 5% acetic solution, (200ml).The 
solvent was evaporated under reduced pressure and the product was collected 
as a white solid.
Yield: 280mg, 84%.
m.p. 191-193^C (decomposed 185®C then melted).
Rf:0.17 (solvent Bu0H/Ac0H/H20 3:1:1 :v:v)
1h  nmr (D2O): 6 3.5 (s, 2H,
4.0 (m, 1H ,£H C H 2).
Mass spectrum: [M+H]"^ at m/e 204.
Anal, calcd. for C5H9N3O5 requires: C 41.37; H 4.43; N 20.69.
Found: C 41.85; H4.71; N 20.90.
[a ]o -  10.0 (c 0.1 , IMHCl).
3.4.2. SYNTHESIS OF THF. HYDANTOIN ANALOGUE OF QUISQUALIC ACID.
3.4.2.I. Attempted synthesis of 3-i1-(U-imidazolidin-2.5-diQnYl)l 
alanine (87).
A solution of hydantoin (O.lg, 1.18mmol) in dry THF was added under 
nitrogen to a solution of the t-Boc (3-lactone (78) (0.2g,1.07mmol) in dry 
THF. The mixture was stirred at room temperature for four hours. Tic showed 
the presence of starting materials only, and the reaction was heated at 50®C 
for another two hours. On cooling, solvent was evaporated and the residue 
was taken up in water, acidified to pHethyl acetate (3x20ml). The combined 
extracts were dried over sodium sulphate, filtered and the solvent was
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evaporated under reduced pressure to afford a colourless oil, which was 
identified as t-Boc serine.
Yield: 0.12g, 55%.
1h  nmr (CDCI3): 5 1.5 (s, 9H, t-Boc): 3.8 (s, 3H, OCH^);
5.7 (d, IH, O i) ;  6.2. (d, IH, £H); 7.0 (broad s, IH, MH).
3.4.2.2. Synthesis of N-t-Biitoxvcarbonvl serine methvl ester (91).
A solution of t-Boc L-serine (2g, 9.76mmol) in ether (30ml) was treated with 
the slow addition of freshly distilled diazomethane in ether. Excess 
diazomethane was destroyed by the addition of a small amount of acetic acid 
solution. The ethereal solution was washed with cold water (3x40ml), dried 
over sodium sulphate, filtered and evaporated in vacuo to afford the ester as a 
colourless oil.
Yield: 1.8g, 84%.
Rf: 0.42 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 1.4 (s, 9H, t-Boc): 3.5-3.6 (m, 2H, CHOi2);
3.7 (s, 3H, O O I2 ); 4.2 (m, IH, £HCH2); 6.0 (d, IH, m i) .
Mass spectrum: [M+H]"*" at m/e 220
2 4.2.2. Attempted synthesis of 3-ri-n J-imiday.Qlidin-2t5-diQnYiH 
alanine (87) hv the Mitsnnohu method.
A solution of triphenylphosphine (0.26g, Immol) in dry THE was stirred 
under nitrogen at -780C, for 10 minutes, followed by the dropwise addition of 
diethyl azodicarboxylate (0.17g, Immol). The off-white slurry which ensued 
was treated with t-Boc serine methyl ester (0.2g, 0.94mmol) and hydantoin 
(O.lg, Immol). The mixture was stirred at -780C for another fifteen minutes, 
warmed to room temperature, and stirred for two hours. The crude product
148
was purified by preabsorbed flash chromatography on silica eluted with 
hexane/ethyl acetate (2:1 v:v). The product, a colourless oil, was obtained on 
evaporation of solvent. (The product was identified by its nmr spectrum as 
the elimination product (90).
3.4.2.3. (2S)-2-Ben7.vloxvcarbonvlamino-3-ammQ-prODionic add (L-Cbfc 
DAPA.OH (96).
N-Benzyloxycarbonyl-L-asparagine (2.66g, 0.01 mol) was added to a stirred 
solution of bis[trifluoroacetoxy]iodobenzene (6.5g, O.OlSmol) in 
dimethylformamide (DMF) (40ml) and water (40ml). The mixture was 
stirred for fifteen minutes at room temperature, followed by the addition of 
pyridine (1.6ml, 0.02mol). After stirring at room temperature for three hours, 
the solvent was evaporated in vacuo. The residue was dissolved in water 
( 100ml) and washed extensively with ether to remove residual 
bis[trifluoroacetoxy]iodobenzene and iodobenzene. The aqueous phase was 
concentrated in vacuo to afford the crude L-Cbz-DAPA, which was 
crystallized from ethanol/ether to give the compound as a white solid.
Yield; 1.89g, 79%. (Lit. 181 84%)
m.p 225-226 «C (Lit. 181 m.p 228-230OC )
Rf: 0.18 (solvent DCM/MeOH/AcOH 44:5:1 v;v).
1h  nnu (DMSO): 5 2.5 (m, 2H, CH£H2)’ ^ ^ 1 ^ 2 )^
5.1 (s, 2H, O l 2 Ph); 6.9 (s, IH, HH); 7.4 (s, 5H, Eh); 7.5 (s, 2H, 2?^NH).
Mass spectrum: [M+H]"*" at m/e 239
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l .  4.2 4. Methvl-(2S)-2-Benzvloxvcarhonvlammo-3-aminQ propionate
Thionyl chloride (10ml) was slowly added to dry methanol (70ml), under 
nitrogen, at -40OC. The solution was stirred for a further fifteen minutes, 
followed by the addition of the acid (5g, 0.02mol). The mixture was stirred at 
-40OC for fifteen minutes, then warmed to room temperature. After ten 
minutes at room temperature, the reaction mixture was heated under reflux for 
three hours. The solvent was evaporated in vacuo and the residue was was 
triturated under ether, to give a colourless solid. Recrystallization from 
methanol/ether gave the methyl ester hydrochloride as a white solid.
Yield: 4.5g, 85%.
m. p. 152-1540C (decomposed, then melted).
Rf! 0.24 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (DMSO): 5 3.0-3.3 (m, 2H, CHCH2 ): 3.7 (s, 3H, QCH^);
4.4 (m, 1H. CHCHo :^ 5.1 (s, 2H, £H 2El); 7.4 (s, 5H, Ph); 7.9 (d, IH, HH);
8.4 (s, 2H, 2xNH).
Mass spectrum: [M+H]'*' at m/e 253.
The adduct (97) (4g, O.Olbmol) in dry THF was treated at O^C, under 
nitrogen, with ethyl isocyanatoacetate (2.24g, 0.017mol) in dry THF. The 
reaction mixture was warmed to room temperature, and was left stirring for 
two hours. The solvent was evaporated and the residue was taken up in ethyl 
acetate (35ml), washed with saturated sodium bicarbonate and then with 
brine, dried over sodium sulphate, filtered and the filtrate was evaporated in 
vacuo, to afford the amide as a colourless oil.
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Yield: 5.1g, 84.%.
Rf. 0.48 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 1.2 (t, 3H, 3.6 ( m, 2H, CH£U2);
3.7 (s, 3H, OCH3) 4.2 (m, 2H, CH2COOEt); 4.4 (m, IH, CHCH2);
5.1 (s, 2H, CHoPh): 5.3 (s, IH, NH); 6.2 (d, IH, NH); 7.3 (s, 5H, £h).
Mass spectrum: [M+H]"*" at m/e 382.
3.4.2.6. (2Sl-2-Ben7vloxvcarhonvlamino-4.6-diay^-5-QXQ- 
octan-1.8-di<ic acid (99).
The amide (98) (4.8g, 0.013mol) was treated with a solution of sodium 
hydroxide (1.06g, 0.026mol) in water (60ml). The mixture was stirred at 
room temperature for one hour, acidified to pH3 with 0.5M HCl and extracted 
with ethyl acetate (3x25ml). The combined extracts were dried over sodium 
sulphate, filtered and the solvent was evaporated under reduced pressure to 
afford the diacid as a colourless oil.
Yield: 3.7g, 84%.
Rf: 0.63 (solvent DCM/MeOH AcOH 44:5:1 v:v).
1h  nmr (DMSO): 5 3.1-3.6 (m, 2H, CH£H2); 3.7 (d, 2H, £H 2COOH);
4.0 (m, IH, £HCH2); 5.0 (s, 2H, 6.3 (m, 2H, 2xNH);
7.4 (s, 5H,JPh); 7.5 (d, 1H,HH).
Mass spectrum: [M+H]'*’ at m/e 340.
3.4.2.7. Attempted cvcli/ntinn to (100).
EDC (0.29g, 0.15mmol) was dissolved in a solution of dry THE (30ml) 
containing the diacid (99) (0.5g, 1.45mmol) and triethylamine (0.15g, 
1.53mmol). The mixture was stirred at room temperature for two hours and
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the solvent was evaporated in vacuo. The resulting light yellow residue was 
taken up in water, acidified to pH3 with 2M HCl and extracted with ethyl 
acetate (3x20ml). The combined extracts were dried over sodium sulphate, 
filtered and the solvent evaporated under reduced pressure to afford a light 
yellow oil which was found by tic to contain multiple products. Attempts 
were not made to separate these products. The method was abandoned.
X d l . f i .  f2Sl-1-Methvl-8-hpn7vl-2-ben7vlnxvcarbonvlamino-4»6-diaKa:i: 
nxo-octan-1.8-dioate (103.L
Benzyl isocyanatoacetate (0.3g, 1.99mmol) in dry THF (10ml), was added 
dropwise at O^C, to a solution of (2S) l-methyl-2-benzyloxycarbonylamino-
3-aminopropionic acid hydrochloride (97) (0.5g, 1.98mmol) and
triethylamine (0.8g, 1.12ml) in dry THF (50ml). The mixture was stirred at 
O^C for fifteen minutes, then at room temperature overnight. The precipitated 
triethylamine hydrochloride was removed by filtration, and the filtrate was 
evaporated in vacuo to give a yellow oily residue which was partitioned 
between dichloromethane and aqueous sodium bicarbonate solution. The 
product was extracted into the organic phase (3x40ml), dried over sodium 
sulphate, filtered to remove the desiccant, and then evaporated in vacuo. The 
resulting residue was taken up in a minimum amount of ethyl acetate/hexane 
2:1 and purified by flash chromatography on silica gel (30g) The product was 
isolated as a colourless oil following gradient elution with hexane/ethyl
acetate ( 1:2 v:v).
Yield: 0.52g, 62%.
Rf: 0.55 (solvent DCM/MeOH 9:1 v:v).
nmr (CDCI3): 6 3.6 (m, 2H, 3.7 ( s,3H,OOi^)’
3.9 (d, 2H ,O l2COOCH2Ph); 4.4 (m, IH, £HCH2); 5.1 (s, 4H, 2x0 1 2 ^^);
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5.2 (m, 2H, 2xNH); 6.1 (d, IH, M l); 7.4 (s, lOH, 2xPh).
Mass spectrum; [M+H]"*" at m/e 444.
3.4.2.9. (2Sl-1-lVlethvl-2-t-hiitoxvcarhonvl-4.6-diaza-5-oxo-OCtan-L8T 
dioic acid (104).
Palladium on activated charcoal 10% (0.2g) was suspended in methanol 
containing the diester (103) (0.5g, 1.13mmol.), followed by the addition of a 
solution of sodium bicarbonate (0.5g, 5.95mmol) in water (10ml), and di-tert- 
butyldicarbonate (Boc)2 0 ) (1.3g, 5.96mmol) in methanol (70ml). The 
suspension was hydrogenated at room temperature and atmospheric pressure 
for six hours. The catalyst was removed by filtration, and the filtrate was 
concentrated in vacuo, the resulting residue was taken up in water (30ml), 
washed with petrol to remove residual (Boc)20  and then acidified by the slow 
addition of 0.5M HCl at O^C, to pH3. The product was extracted into ethyl 
acetate (3x40ml), and the combined extracts were dried over sodium sulphate, 
filtered to removed the dessicant and the solvent was evaporated in vacuo to 
afford the product as a foamy solid.
Yield; 0.33g, 68%.
1h  nmr (DMSO); 5 1.4 (s, 9H, t-Boc): 3.3 (m, 2H, CH£H2);
3.7 ( s, 3H, OCH^): 3.8 (d, 2H, f f l ™ 2 )’
6.3 (m, 2H, 2xNH); 7.1 (m, IH, M l).
Mass spectrum; [M+H]"*" at m/e 320.
3.4.2.10. fi.N.t-Butoxvcarbonvl-3-ri-(imidaznlidine-2-dionvmalaninfi
(92k
The t-Boc protected adduct (104), (0.3g, 0.94mmol) was dissolved in dry 
THF (60ml), followed by the addition of l-ethyl-[3-
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(dimethylamino)propyl]carbodiimide (EDC) (0.7g, 1.02mmol), and
triethylamine (O.lg, 1.02mmol). The suspension was stirred at room 
temperature overnight, and the precipitated triethylamine hydrochloride was 
removed by filtration and the filtrate was evaporated in vacuo. The residue 
was taken up in 60ml of ethyl acetate, washed with three 20ml portions of 
sodium bicarbonate and then with brine, dried over sodium sulphate, filtered 
and the solvent was evaporated in vacuo to afford the crude (92). Purification 
by chromatography on silica gel (25g), eluted with ethyl acetate/hexane 2.1, 
gave the cyclized product as foamy oil.
Yield; 0.18g, 65%.
Rf! 0.39 (solvent DCM/MeOH 9:1 v;v).
1h  nmr (CDCI3): 5 1.4 (s, 9H. t-Boc); 3.5 (m, 2H, CH£H2 );
3.7 (s, 3H, OCH^): 3.9 (s, 2H, £H 2COOH); 4.5 (m, IH, O ÌC H 2);
5.5 (d, l H ,m ) ;  6.0 (s, 1H,M1).
Mass spectrum: [M+H]"’" at m/e 302.
Sodium hydroxide (0.02g, 0.50mmol) in water (20ml), was added to a 
solution of the cyclized hydantoin (92) (0.15g, 0.50mmol), in methanol (5ml). 
The solution was stirred at room temperature for two hours. Alcohol was 
evaporated in vacuo and the aqueous phase was carefully acidified with 0.5M 
HCl to pH3 at O^C and extracted with ethyl acetate (3x30ml). The organic 
extracts were combined, dried over sodium sulphate, filtered and the solvent 
was evaporated in vacuo to gave the t-Boc protected acid as a foamy solid.
Yield: lOOmg, (71%).
Rf: 0.56 (solvent DCM/MeOH/AcOH).
1h  nmr (CDCI3); 6 1.4 (s, 9H, t-Boc): 3.8 (m, 2H, CHCil2)’
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4.2 (d, 2H, CH2NH): 4.4 -4.6 (m, IH, O IC H 2); 5.5 (s, IH, NH);
5.9-6.0(s, 1H,NH).
Mass spectrum; [M+H]"*" at m/e 288.
^ 41,12. 3.ri-M^^-ImidazQiidin-2.5-dionvmalanine (87).
The-t-Boc protected acid (89) (72mg, 2.5mmol) was dissolved in a solution of 
IM HCl/acetic acid solution (10ml). The solution was left standing at room 
temperature for one hour, during which time amino acid hydrochloride began 
to separate out. The solvent was evaporated and the residue was taken up in a 
minimum volume of water and converted to the free amino acid by ion 
exchange chromatography (acetate anion resin) eluted primarily with water 
50ml, followed by 10% acetic acid solution. The amino acid was collected as 
a white solid on evaporation of solvent.
Yield: 0.3 Ig, 66%. 
m.p. 224-226®C.
Rf. 0.19 (solvent BuOH/H20 /AcOH 3:1:1 v:v).
nmr (D2O): 5 3.6-3.8 (m, 2H, C H O I2)’
4.2 (m, IH, £HCH2).
Mass spectrum: [M+H]'*' at m/e 188.
Anal, calcd. for C6H9N3O4 requires C 38.50; H 4.81; N 22.43.
Found: C 38.72; H 5.00; N 22.61.
[a lp  - 11.76 (cO.2, IM HCl).
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^4.3. PRKPARATIQN OF 3-H-SI irriNlMIDYL)-ALANINE (1091
3.4.3.1. (2S)-2-Benzvloxvriirhonvlamino-4-aza-S-OXO-OCtan-l «S-diOiC 
acid-1-methyl ester (106).
Succinic anhydride (l.lOg, 11 mmol) was added at O^C, under nitrogen, to a 
stirred solution of Cbz-L-DAPA.OMe.HCl (97) (2.4g, 9.5mmol), and 
triethylamine ( l.lg , 10.9mmol) in dry THF (50ml). The mixture was stirred 
at room temperature overnight and the solvent was evaporated in vacuo, to 
give a light yellow oil, which was partitioned between ethyl acetate and water. 
Excess succinic anhydride was extracted into ethyl acetate, and the aqueous 
phase acidified with IM HCl, to pH3, and the product was extracted into 
ethyl acetate (3x40ml), the combined extracts were dried, over sodium 
sulphate, filtered and the filtrate was evaporated in vacuo to afford the amide 
as a colourless oil, which crystallized on standing.
Yield: 2.6g, 64%. 
m.p. 92-94^C.
Rf. 0.18 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 2.4 (d, 2H, CH2CH2); 2.6 (d, 2H, CH2CH2);
3.5-3.7 (m, 5H, CH£H2_and 0£il;^); 4.4 (m, IH, O IC H 2);
5.1 (s, 2H,
6.0 (d, IH, NH); 6.6 (d, IH, jm ); 7.3 (s, 5H, Eh)
Mass spectrum: [M+H]"*" at m/e 353.
3 4.3.2. (lSl-N-RenzvloxvcarbnnvlaminQ-3-(1-succinimidvn-alanine
methyl ester (107).
N,N-Diisopropylethylamine (0.57ml, 4.7mmol) and 1-hydroxybenzotriazole 
(HOBT) (0.7g, 5.18mmol), were added, under nitrogen, to a stirred solution
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of the ester (1.67g, 4.7mmol) in dry THF (40ml). The solution was stirred at 
room temperature for fifteen minutes, followed by the addition of EDC, (Ig* 
5.22mmol). The reaction, which was followed by thin layer chromatography 
(tic), was stirred for a further four hours. On evaporation of solvent the 
resulting residue was partitioned between aqueous sodium bicarbonate and 
ethyl acetate. HOBT was removed in the aqueous phase and the organic layer 
was washed with O.IM HCl (to remove the urea by-product), then with brine. 
The solvent was dried over sodium sulphate, filtered and the filtrate was 
evaporated in vacuo, to give the cyclized product as a white solid.
Yield: 1.2g, 76% 
m.p. 88-90OC.
Rf: 0.6 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (DMSO): 5 2.3 (dd, 4H, 2x£ti2)’ CH£H2)’
3.7 (s, 3H, OCfcl^);
4.1 (m, 1H ,£H C H 2); 5.0 (s, 2H ,O l2Ph); 7.3 (s, 5H,£ll); 7.9 (d, IH, NH). 
Mass spectrum: [MH+] at m/e 335.
3.4.3.3. (2Sl-N-Benzvlnxvcarbonvlainino-3-(l-SUCCiniinidYl)alaninfi
i i m
Potassium hydroxide (0.2g, 3.56mmol), in water (10ml), was added to a 
solution of the ester, ( l.lg , 3.6mmol) in isopropanol (30ml). The solution 
was stirred at room temperature for two hours, and alcohol was evaporated in 
vacuo. The resulting residue was partitioned between ethyl acetate and IM 
hydrochloric acid. The product was extracted into ethyl acetate (3x40ml), and 
the combined organic extracts were dried over sodium sulphate and the 
solvent was evaporated in vacuo. The product was collected as a white solid 
after crystallization from ethyl acetate/hexane.
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Yield: 900mg, 79%. 
m.p. 142-144®C.
Rf: 0.26 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (DMSO): 5 2.3 (dd, 4H, 2x£Ii2)’
4.1 (m, IH, £HCH2); 5.0 (s, 2H, Q iiP h)\ 7.3 (s, 5H, Eh); 7.9 (d, IH, MH). 
Mass spectrum: [M+H]"*" at m/e 321.
3.4.3.4. 3-(1-SiiccinimiHvn.alanine (109).
A suspension of (2S)-benzyloxycarbonylamino-3-succinimidopropanoic acid
(108) (700mg, 2.18mmol) and 10% palladium on charcoal (70mg), in ethanol 
(25ml), was hydrogenated at room temperature and pressure for one hour. 
The catalyst was largely removed by filtration, and the product, which 
precipitated from the alcohol, was dissolved in hot water, and refiltered to 
remove residual catalyst. The product, a white solid, was collected on 
evaporation of solvent in 55% yield, 
m.p. 240-242OC.
Rf: 0.25 (solvent BuOH/AcOH/H20 3:1:1 v:v).
1h  nmr (D2O/DCI): 5 2.4 (m, 2H, 2x£il2)’ CH£il2^’
4.1 (m, IH, O iCH2).
Mass spectrum: [M+H]"^ 187.
Anal, calcd. for C7H 10N2O4 requires: C 45.16 H 5.38 N 15 05.
Found: C 45.35 H 5.58 N 14.97.
[a]D -29.0 (c 1.0 IM HCl).
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^■4.4. SYNTHRSIS QF ■^-r2-n.2-OXA7QLIDIN-3.5-DIQNYL)1 ALANINE (113)i
■^4.4.1 r2S^-7.pthvl-2-t-hutoxvcarhnnvlammo-4-ben/vloxv-4-a7.a-5-QXlI: 
heptandioic acid mO).
Ethyl malonyl chloride (1.5g, 9.7mmol) was added (dropwise) under 
nitrogen, to a solution of the benzyloxyamine (77) (2g, 6.5mmol) and 
potassium hydroxide (1.8g, 0.013m), in toluene (60ml). The mixture was 
stirred at room temperature for ten minutes, then heated under reflux for two 
hours. On cooling, solvent was evaporated in vacuo, and the residue was 
taken up in water, acidified to pH3 with saturated citric acid solution and then 
extracted with three 30ml portions of dichloromethane. The combined 
extracts were dried over sodium sulphate, filtered and the solvent was 
evaporated under reduced pressure to afford the crude ( 110 ) as a light yellow 
oil. Purification by chromatography on silica gel (25g) eluted with 
DCM/MeOH (9:1 v:v) gave the amide as a foamy oil.
Yield: 1.4g: 51%.
Rf: 0.75 (solvent DCM/MeOH/AcOH 44:5:1 v:v).
1h  nmr (DMSO): 5 1.1 (t, 3H, 1.4 (s, 9H, izfiflc);
3.5 (s, 2H, £H 2COOEt); 3.S-4.2 (m, 4H, CH£H2 and £ £ ¡ 2 ^ 3 ) ’
4.3 (m, IH, £HCH2); 4.9 (s, 2H, O ilP h ); 6.9 (d, IH, MH); 7.4 (s, 5H, Eh). 
Mass spectrum: [M+H]"^ at m/e 425.
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3.4.4.2. (2S>-7-ethvl-2-N-tert-butoxvcarbonvl-3.6.tetrahvdrQ-4.-N= 
hvdroxvl-5-oxo-heDtan-1.7-dioic acid (1111
A solution of the amide (110) (1.2g, 2.8mmol) in ethanol (50ml), was 
hydrogenated at room temperature and atmospheric pressure in the presence 
of 10% palladium on activated charcoal. After one hour, the catalyst was 
removed by filtration and the filtrate was evaporated under reduced pressure 
to afford the hydroxyl derivative as a clear oil.
Yield: 0.8g, 86%.
Rf: 0.24 (solvent DCM/MeOH/AcOH 44:5:1 v:v).
1h  nmr (DMSO): 5 1.0 (t, 3H, CH2£ tl;^ ; 1.4 (s, 9H ,t-Bo£);
3.4 (s, 2H, CHoCOOEt): 3.6-4.0 (m, 2H, CH£H2)’
4.2 (m, 3H, CH0CH3 and £HCH2); 6.6 (d, IH, NH).
Mass spectrum: [M+H]"^ at m/e 335.
3.4.4.3. N-t-Biitnxvcarbonvi.3-(1.2-oxay.olidin-3.5-dion-2-vl)-alanine
m2).
Potassium hydroxide (0.3g, 5.42mmol), in water (20ml) was added to a 
solution of the hydroxamic acid (111), (0.9g, 2.70mmol) in methanol (2ml). 
The reaction, which was followed by thin layer chromatography, (developed 
with ferric chloride solution) was stirred at room temperature for one hour. 
Alcohol was evaporated, and the aqueous phase was acidified with 0.5M HCl 
to pH3 and extracted with ethyl acetate (3x20ml). The combined extracts 
were dried over sodium sulphate, filtered and the solvent was evaporated in 
vacuo to afford the cyclized acid as an off-white solid.
Yield: 0.5g, 64%. 
m.p. 147-150OC.
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Rf: 0.59 (solvent DCM/MeOH/AcOH 44:5:1: v:v).
1h  nmr (DMSO): 5 1.4 (s, 9H, t-Boc): 3.2 (s, 2H, £H 2CO);
3.8-4.1 (m, 2H, CH£H2 ); 4.3 (m, IH, 01CH2); 7.2 (d, IH, M l).
Mass spectrum: at m/e 289.
3.4.4.4. 3-n.2-nxazolidin-3J>-dinn.2-vn alanine.
N-tert-butoxycarbonyl-oxazolidine adduct (112) (0.3g, 1.04 mmol) was 
disolved in a solution of IM HCl in acetic acid (15ml). The solution was left 
standing at room temperature for one hour and the solvent was evaporated 
under reduced pressure. The off-white residue which ensued was taken up in 
water and converted to the free base by ion exchange chromatography (acetate 
anion resin) eluted primarily with water followed by 3% acetic acid solution 
(120ml). The solvent was evaporated under reduced pressure to give the 
product as an off-white solid. (The product appeared to have decomposed, as 
shown by T.L.C. using ninhydrin development.)
3.4.5.I. r5S)-1-Ethvl-7-benzvl-5-t-butoxvcarbonvlamino-3-axa-4-QXlk 
heptan-U-dioate (115).
N-tert-butoxycarbonyl-L-aspartic acid -4-benzyl ester (114) (3g, 9.32mmol) 
in dry THF was treated at -15^0, with N-methylmorpholine (0.04g, 
9.32mmol and isobutylchloroformate (1.27g, lOmmol). The solution was 
stirred under nitrogen for two minutes, followed by the addition of a 
suspension of glycine ethyl ester hydrochloride (1.4g, lOmmol) and N- 
methylmorpholine (Ig, lOmmol), in 50ml of dry THF. After being stirred for
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two hours at -15®C the solution was poured into 500ml of semi saturated 
brine, and extracted with three 30ml portions of ethyl acetate. The combined 
extracts were dried over sodium sulphate, filtered and evaporated. The light 
yellow oil which ensued was purified by chromatography on silica gel (30g), 
eluted with hexane/ethyl acetate (2:1 v.v) to afford the product as a colourless
oil.
Yield: 3g, 72%.
Rfi 0.2 (solvent DCM/MeOH 9:1 v:v).
1h  nmr ( CDCI3): 5 1.3 (t ,3H, CH2£H^); 1.4 (s, 9H, iz to ) ;
2.7-3.1 (m, 2H, CH£H2)’ £H 2 COOEt); 4.2 (q, 2H, £H 2 CH3);
4.6 (m, IH, CHCH2); 5.1 (s, 2H, £112^^^’
7.4 (s, 5H, Ph).
Mass spectrum: [M+H]"*" at m/e 409.
3.4..S.2. (5 SV5 -t-Butoxvcarhonvlamino-3-aza-4-OXO-hePtan-1 «7-diOC acid
1-ethvl ester (1161
The diester (115) (2.8g, 6.68mmol) in ethanol (60ml), was hydrogenated in 
the presence of 10% palladium on activated charcoal (0.28g), at room 
temperature and atmospheric pressure. After one hour, the catalyst was 
removed by filtration, and the alcohol was evaporated in vacuo. The resulting 
residue was partitioned between ethyl acetate and 0.5M HCl. The product was 
extracted into the organic phase (3x30ml), dried over sodium sulphate, 
filtered and evaporated to afford the product as a colourless oil.
Yield: 1.89g 89%.
Rf: 0.35 (solvent Hex/EtOAc 2:1 v:v).
1h  nmr (CDCI3): 5 1.2 (t, 3H, CH2CH2 ); 1-4 (s, 9H, tEiiC);
2.42.7 (m, 2H, CHoCOOEt); 3.8 (m, 2H, CH£H2)’
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4.4 (m, IH, £HCH2);7.0 (s,1H, MH); 8.1 (s, IH, HH).
Mass spectrum; [M+H]'*’ at m/e 319.
t3Sl-1-Ethoxvcarhoxvlmethvl-3-t-hutoxvcarbonvl- 
amino-Dvrrnlidine-2^-dione (117).
The adduct (116) 2.0g, 6.3mmol), and triethylamine (0.70g, 6.93mmol), was 
dissolved in 50ml of dry THF. The solution was stirred under nitrogen for ten 
minutes followed by the addition of (EDC) (1.33g, 6.94mmol), and the 
mixture was left stirring overnight. The precipitated triethylamine 
hydrochloride was removed by filtration, and the filtrate was evaporated 
under reduced pressure. The oily residue which ensued was taken up in 
dichloromethane (60ml), washed with three 30ml portions of saturated 
sodium bicarbonate, dried over sodium sulphate, filtered and evaporated in 
vacuo to give the crude (117) as a yellow oil. Purification by chromatography 
on silica gel, with DCM/MeOH (9:1 v:v) as the eluent provided the cyclized 
product as a colourless crystalline solid.
Yield: 1.2g,63%. 
m.p. 89-910C.
Rf: 0.35 (solvent EtOAc/Hex 1:1 v:v).
1h  nmr (CDCI3): 6 1.3 (t, 3H, CH2£H¿); 1.4 (s, 9H, kBfíc);
2.8-3.2 (m, 2H, CH£Ü2)’ ^ ^ (9’ ^H, O Í 2CH3); 4.3 (s, 2H, £H 2 COOEt);
4.4 (m, IH, £HCH2); 5.2 )s, IH, NH).
Mass spectrum: [M+H]"*" at m/e 301.
3.4.S.4. (3Sl-1-Carboxvmethv|.3-t-butoxvcarbonYlamino-PYrrplÍdÍn£:
2.5.dione(118).
A solution of potassium hydroxide (0.2g, 3.5mmol) in water (25ml) was
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added to the ester 117) 0.9g, 3.02mmol), in methanol (10ml). The mixture 
was stirred at room temperature for one hour. The alcohol was evaporated, 
and the aqueous phase was acidified with 0.5M HCl to pH3, and extracted 
with ethyl acetate (3x30ml). The extracts were combined, dried over sodium 
sulphate, filtered and evaporated under reduced pressure to give the acid as a 
colourless oil.
Yield: 0.62g, 68%.
Rf: 0.74 (solvent DCM/MeOH) 9:1 v:v).
1h  nmr (DMSO): 5 1.4 (s, 9, t-Boc): 2.8 (m, 2H, CHCH2 )’
3.7 (m, 2H, O I 2 COOH); 4.1 (m, IH, CHCH2); 7.2 (s, IH, KH)- 
Mass spectrum: [M+H]"*" at m/e 273.
.SYNTHESIS QF rr3Sl-3-AMINOPYRRQLIDIN-2,5-DI0N-l-YLl ACETIC
ACID a m
The t-Boc protected acid (118) (0.52g, 1.88mmol), was dissolved in 15ml of 
IM HCl in acetic acid solution. After one hour at room temperature, the 
solvent was evaporated in vaciio, and the resulting amino acid hydrochloride 
was converted to the free base by ion exchange chromatography (acetate 
anion resin), eluted primarily with water (50ml), followed by 10% acetic acid 
solution. The amino acid was collected as a white solid on evaporation of 
solvent.
Yield: 0.29, 89%.
m.p. 205®C (decomposed).
Rf: 0.14 (solvent BuOH/AcOH/H20  3:1:1 v:v).
1h  nmr (D2O): 6 2.9 (m, 2H, CHOi2); 3.8 (m, 2H, CH2 COOH);
4.2 (m, IH, O IC H 2).
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Mass spectrum: [M+H]'*' at m/e 173.
Anal, calcd. for C6HgN204  requires: C 41.86 H 4.65 N 16.28. 
Found: 41.68 H 4.32 N 16.12.
N-t-Butoxvcarhnnvl aspartic acid 4-benzvl ester (114L
Di-tert-butyl dicarbonate (Boc)20  (14.7g, 0.067mol) was added to a solution 
of L-aspartic acid 4-benzyl ester (lOg, 0.045mol) and sodium hydroxide 
(1.8g, 0.045mol), in isopropanol (200ml). The mixture was stirred at room 
temperature overnight. Alcohol was evaporated in vacuo and the aqueous 
phase was carefully acidified with 0.5M HCl solution and extracted with ethyl 
acetate (3x40). The organic extracts were combined, dried over sodium 
sulphate, filtered and the filtrate was evaporated in vacuo to afford the t-Boc 
protected ester as a white solid.
Yield: 13g 89%. 
m.p. 94-96®C.
Rf: 0.48 (DCM/MeOH 9:1 v:v)
nmr (DMSO): 5 1.4 (s, 9H, t-Boc): 2.6-2.9 (m, 2H, C H Q i2) \
4.3 (m, IH, £HCH2); 5.1 (s, 2H, 7.1 (s, IH, NH); 7.4 (s, 5H, Eh).
Mass spectrum: [M+H]"*" at m/e 324.
14 6.2. r2S.6Sl.l-Methvl-8-henzvl-2-henzvloxvcarbonYlaniinQ-6=k 
hiitnxvcarbonvlamino-4-a7.a-5-QXO"OCtan-l«8-dl0at€ (120)i
A solution of the t-Boc L-aspartic acid-p-benzyl ester (114) (4.04g, 0.013mol) 
in 70ml of dry THF was cooled to -250C, and N-methylmorpholine (1.2ml,
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1.05eqv), and isobutyl chloroformate (1.8g, 0.013mol) was added with 
stirring. The mixture was stirred at -25^C for two minutes, then treated with a 
cooled (-I50C) suspension of Cbz-L-DAPA-methyl ester hydrochloride (97) 
(3g, 0.012mol), and N-methylmorpholine (1.2ml, 1.05eqv) in 50ml of dry 
THF. The mixture was stirred at -IS^C for two hours, and then poured into 
600ml of semi-saturated brine, stirred for fifteen minutes at room 
temperature, and extracted with dichloromethane (3x30ml). The combine 
organic extracts were dried over sodium sulphate, filtered, and evaporated in 
vacuo to give the crude (120). Purification by chromatography on silica gel, 
(30g) eluted with dichloromethane/methanol (9:1 v:v) gave the product as a 
foamy oil.
Yield: 4.8g 66%.
Rf. 0.73 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 1.4 ( s, 9H, t-Boc): 2.6 3.0 (m, 2H, CH2 CO);
3.6-3.8 (m, 5H, OCH3 andCH£H2); 4.4 (m, IH, CHCH2);
5.1 (2s, 4H, 2xCH2 Ph); 5.6 (d, IH, HH); 5.8 (d, IH, MH); 6.8 (m, IH, HH);
7.3 (2s, lOH, 2x£h).
Mass spectrum: [M-hH]"  ^at m/e 558.
(2S.6S1.1.niethvl-2.6-di-(t.butQxvcarbonvlamino)-4-aza-5-QXQ= 
octan-1.8-dinic acid (121).
10% Palladium on activated charcoal (0.4g) was suspended in ethanol 
(150ml) containing the diester (120) (4.00g, 7.2mmol), (Boc)20  (2.49g, 
l.lm m ol), and sodium carbonate (0.94g, 7.56mmol). The mixture was 
hydrogenated at room temperature and atmospheric pressure for six hours. 
The catalyst was removed by filtration and the solvent was evaporated under 
reduced pressure, to afford an oily residue which was taken up in water.
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washed with three 50ml portions of petroleum ether to remove residual 
(Boc)2 0 . The aqueous phase was acidified to pH3 with 0.5M HCl at 0®C, and 
the product was extracted into ethyl acetate (3x50ml), dried over sodium 
sulphate, filtered and evaporated in vacuo to afford the t-Boc protected acid as
a foamy oil.
Yield: 1.8g 59%.
Rf: 0.49 (solvent ethyl acetate/hexane 2:1 v:v).
1h  nmr (DMSO): 5 1.4 (s, 18H, 2xt-Boc): 3.3 (m, 2H, O I 2 COOH);
3.7 (s, 3H, OCH^): 3.8 (m, 2H, CH£H2); 4.0-4.2 (m, 2H, 2x£HCH2);
6.9 and 7.1 (s, 2H, 2xMi); 8.1 (m, IH, MiCO).
Mass spectrum: [M+H]"*" at m/e 434
:^.4.6.4. (y.N-f.Riitnxvlcarbonvlainino-3-ri-f(3SV3-t-hiitOXYCarbQnYL 
aminnlnvrrnlidin-2.5-dionvll-alanine methvl ester (122^
A stirred solution of the adduct (121) (0.9g, 2.14mmol), in 30ml of dry THF, 
was treated under nitrogen with l-ethyl-3-[3-(dimethylamino)- 
propyllcarbodiimide (0.45g, 2.4mmol), and N-methylmorpholine (0.24g, 
2.4mmol). Stirring was continued overnight at room temperature, and the 
solvent was evaporated in vacuo^ to yield an oily residue which was taken up 
dichloromethane, washed with saturated sodium bicarbonate, then with brine, 
dried over sodium sulphate, filtered and evaporated in vacuo to afford the 
cyclized adduct as a foamy oil.
Yield: 0.45g, 56%.
Rf: 0.54 (solvent Hex/EtOAc 2:1 v:v).
1h  nmr (CDCI3): 5 1.4 (s, 18H, 2xlzEtQ£); 2.6-3.0 (m, 2H, CO£H2)’
3.5 (m, 2H, CHCH2 ); 3.7 (s, 3H, QCH^); 4.4 (m, 2H, 2x CHCH2);
5.7 (s, 2H, 2x]m ).
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Mass spectrum; [M+H]'*' at m/e 416.
3.4.6.5. a-N-t-Butoxvcarbonvl-3-rM(3Sl-3-t-butoxvcarbonYlaminQlr 
nvrrnlidme-2.5-dionvl1 alanine (123).
The methyl ester (122) (0.32g, 0.77mmol) was dissolved in 15ml of methanol 
containing potassium hydroxide (0.034g, 0,613mmol). The solution was 
stirred at room temperature for one hour. The solvent was evaporated in 
vacuo, and the residue was taken up in 20ml of water, acidified to pH3 with 
0.5M HCl at O^C and extracted with ethyl acetate (3x20ml), dried over 
sodium sulphate, filtered and evaporated under reduced pressure to give the 
product as a foamy oil.
Yield: 0.23g 74%.
Rf: 0.49 (solvent DCM/MeOH).
nmr (DMSO): 5 1.4 (2s, 18H, 2xt-Boc); 2.6 (m, 2H, CH£H2)’
3.3 (m, 2H, CH£H2 ); 3.9 (m, IH, £HCH2); 4.2 (m, IH, £HCH2);
6.9 (s, IH, NH).
Mass spectrum: [M+H]"*" at m/e 402
3.4.6.6. 3-i1-(3Sl-3-amino-Dvrrolidine-2.5-dionvl1 alanine (124).
The t-Boc protected acid (123)(0.23g, 0.55mmol), was dissolved in a solution 
of IM HCl in acetic acid (15ml). The solution was left standing at room 
temperature for one hour. On evaporation of the solvent, the amino acid 
hydrochloride which ensued was taken up in a minimum amount of water, 
and converted to the free base by ion exchange chromatography, (acetate 
anion resin ) eluted initially with 60ml of water, followed by 10% acetic acid 
solution. The diamino acid was collected as the diacetate salt as a white solid 
on evaporation of solvent.
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Yield: 73mg, 61%. 
m.p. 2 1Q0C (decomposed).
Rf: 0.12 (solvent Bu0 H/Ac0 H/H20  3:1:1 v:v).
1h  nmr (D2O): 6 3.5-3.7 (m, 4H, 2xCH£Ü2)’ ^ 2x£HCH2).
Mass spectrum: [M+H]"^ at m/e 262.
Anal, caled, for C9H 15N3O6: requires C 41.38 H 5.75 N 16.09.
Found: C 41.91: H 5.88; N 16.40.
[a]D+1101 (c 0.25, IM HCl).
3.4.7.I. Reaction of the t-ButoxycarbonvIamino-B-lactonc (78) with 
Dvrazole.
A solution of pyrazole (0.04g, 0.59mmol), in ACN (15ml) was treated under 
nitrogen with the t-Boc-amino-|3-lactone (78) (O.lg, 0.54mmol). The mixture 
was stirred at room temperature for two hours, followed by the addition of 
sodium hydride (0.014g, 0.59mmol). The resulting mixture was then stirred 
for another two hours and solvent was evaporated under reduced pressure. 
The residue was taken up in water, acidified to pH3 with 0.5M HCl, extracted 
with ethyl acetate (3x15ml), dried over sodium sulphate, filtered and the 
filtrate was evaporated in vacuo to a clear oil, which was identified by its 
nmr spectrum as the elimination product (90).
The above reaction was repeated in different solvent ( THF, DMF, EtOAc) 
and at different temperatures (25®C-100®C), but these conditions gave
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intractable mixtures.
1 d  7 1 Reartinn of the g.N-t-hutoxvcflrhnnvIamino-fi-lactone (78) 
pvrazole in the presence of a tertiary amine»
DABCO (0.066g, 0.59mmol) was added to a stirred solution of pyrazole 
(0.04g, 0.59mmol).in dry THF (15ml). After stirring at room temperature for 
thirty minutes, the t-Boc-amino p-lactone (78) (O.lg, 0.53mmol) was added 
and the mixture was stirred for another two hours. The solvent was 
evaporated, the residue was acidified to pH3 with 0.5M HCl and extracted 
with ethyl acetate (3x20ml). The combined extracts were dried over sodium 
sulphate, filtered and the filtrate was evaporated under reduced pressure to 
give a colourless oil, which was found upon characterization to be the 
elimination product (90).
14.7.3. N.RenzvIoxvcarhonvI-L-serine
L-serine (5.25g, 0.05m) was dissolved in a mixture of water (70ml) and 
acetone (70ml), containing sodium bicarbonate (4.2g, 0.05m). The mixture 
was stirred at room temperature, and benzyl succinimidyl carbonate (12.4g , 
0.05m) was added. Stirring was continued overnight. Acetone was evaporated 
in vacuo, and the aqueous phase was washed twice with dichloromethane 
(30ml), then acidified to pH3 with concentrated HCl. The product was 
extracted into ethyl acetate (3x50ml), washed with water, dried over sodium 
sulphate, filtered and the solvent was evaporated under reduced pressure to 
afford the product as a white solid. Recrystallization from ether gave the 
protected amino acid as a white crystalline solid.
Yield: 9.8g 82%.
Rf: 0.23 (solvent DCM/MeOH 9:1 v:v).
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m . p .  1 1 8 - 1 2 0 O C . ( L i t . l 8 0  U Q O Q .
iH nmr (CDCI3): 5 3.7 (m ,2H, CHOI2 )’ (m, IH, £HCH2);
5.1 (s, 2H, 1.2>-1A (m, 6H, EL+ HH).
3 4.7.4. N-Benyvioxvcarbnnvl serine methvi ester>
Thionyl chloride (10ml) was slowly added at O^C to 70ml of methanol. The 
solution was stirred for twenty minutes, followed by the addition of N- 
benzyloxycarbonyl serine (5g, 0.02mol). The reaction mixture was warmed to 
room temperature, then heated under reflux for three hours. The solvent was 
evaporated, the residue, a colourless oil, was taken up in ethyl acetate and 
washed with water and sodium bicarbonate solution, dried over sodium 
sulphate, filtered and the filttrate was evporated under reduced pressure to 
afford the product as a colourless oil.
Yield: 4.3g, 85%
Rf: 0.58 (solvent DCM/MeOH 9:1 v:v).
( L i t .  1 8 6  m . p . 3 3 - 3 5 0 0
iH  nmr (CDCI3): 5 3.7 (s, 3H, 0 0 1 2 ); 3.8 (m ,2H, CHOI2 );
4.2 (m, IH, 0 1 CH2); 5.1 (s, 2H, O l2Ph); 7.3 (s, 5H, Phi; 7.4 (d, IH, NH).
3 4,7..<>. cx-N-BenzvIoxvcflrhnnvI-O-methvlsulphonvl serine methll 
ester ( 128).
A solution of Cbz-L-serine methyl ester (Ig, 4.57 mmol), in dichloromethane 
(30ml), was treated with methanesulphonyl chloride (0.58g, 5.07mmol) and 
triethylamine (0.5 Ig, 5.07mmol. The mixture was stirred overnight, at room 
temperature, washed with saturated sodium bicarbonate and then with brine. 
The organic solvent was dried over sodium sulphate, filtered and evaporated 
under reduced presssure to afford an oily residue. Crystallization from
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dichloromethane and ether gave the product as a white solid. 
Yield: l.lg,73% % .
Rf: 0.47 (solvent hex/EtOAc 2:1 v:v). 
m.p. 99-lO loc.
1h  nmr (CDCI3): 5 2.8 (s, 3H, £H lS); 3.7 (s, 3H,
4.4-4.6 (m, 3H. CHCH2 ); 5.2 (s, 2H, 5.7 (d, IH, MH);
7.4 (s, 5H, Eh).
Mass spectrum: [M+H]"*" at m/e 332.
^.4.7.6. ix-N-t-Butoxvcarhnnvl serine acetate methvi ester (1261
Acetic anhydride (3.09g, 0.03mol, lOeq), was added to a solution of t-Boc L- 
serine methyl ester (91) (0.65g, 3.02mmol), and pyridine (2ml) in 
dichloromethane (30ml). The mixture was stirred overnight at room 
temperature, washed with aqueous sodium bicarbonate, followed by 0. IM 
HCl to remove residual pyridine, and finally with brine. The organic solvent 
was dried over sodium sulphate, filtered and the filtrate was evaporated under 
reduced pressure to afford the acetate as a colourless oil.
Yield: 0.67g, 86%.
Rf: 0.52 (solvent ethyl acetate/hexane 2:1 v:v).
1h  nmr (CDCI3): 5 1.4 (s, 9H, t-Boc); 2.0 (s, 3H, CH^); 3.7 (s, 3H, 0£ü ;j);
4.4. (m, 2H, CH£Ü2)’ (m, IH, £HCH2); 5.3 (s, IH, M i).
Mass spectrum: [M+H]'*' at m/e 262.
3.4.7.7. Reaction of the acetate (126) with Dvrazolf.
t-Boc-serine O-acetate methyl ester (0.5 Ig, 2mmol), was added to a stirred 
solution of pyrazole (0.06g, 2.3mmol) in dry ACN (15ml) and the mixture
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was stirred at room temperature for two hours and then at 50^C for two hours. 
Tic showed presence of starting materials mainly, hence the mixture was 
heated under reflux for another two hours. The reaction gave an intractable 
mixture.
Attempted synthesis of the analogue(127) under the above conditions with 
Cbz serinyl-mesylate (128) also gave an intractable mixture.
3.4.7.8. (3Sl-3-Ben7.vloxvcarbonvlaminooxetan-2-one (1311
Cbz-P-lactone was prepared as described for the synthesis of t-Boc p-lactone 
(78) (page 136). The crude product was purified by flash chromatography, 
with AcOH/ hexane (40/60 v;v) as the eluent. The white solid was obtained in 
65% yield following recrystallization from ethyl acetate/hexane. 
m.p. 130-133OC. (Lit.176 133-1340C)
1h  nmr (CDCI3): 5 3.8 (m, 2H, CH£H2); 4.4 (m, IH, £HCH2);
5.2 (s, 2H, £H 2Ph); 6.2 (d, IH, HH); 7.3 (s, 5H, Eh).
Mass spectrum: [M+H]"*" at m/e 222.
3.4.7.9. N-(Benxvloxvcarbonvll-B-bromo-L-alanine iI2^h
Magnesium bromide etherate (1.2g, 4.6mmol) (Aldrich) was added to a 
solution of Cbz-L-serine p-lactone (131) (0.3g, 1.3mmol.) in ether (70ml) 
and dry THF (7ml). The mixture was stirred at room temperature for fifteen 
minutes. The solvent was evaporated in vacuo and the residue was taken up in 
water, acidified with 2M HCl to pH3, and extracted with ether (3x40ml). 
After drying over sodium sulphate and filtration, the solvent was evaporated 
under reduced pressure to afford the crude bromide which was recrystallized 
from dichloromethane/hexane to give the pure bromide as a white solid.
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Yield: 0.24g, 59%.
m.p. 7 I-73OC (Lit.>76 70-71OC).
Rf; 0.49 (solvent (DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 3.5-4.0 (m, 2H, C H £ii2)’
5.1 (s, 2H, CHoPhl: 5.6-5.S (d, IH, MH); 7.3 (s, 5H, Eh).
Mass spectrum: [M+H]"^ at m/e 302,304.
3.4.7.10. Reaction of the bromide with PYray,Qk>
A stirred solution of pyrazole (0.04g, 0.59mmol) and sodium bicarbonate 
(0.5g, 0.59mmol) in ACN (15ml) was treated with the Cbz-protected bromide 
(129) (0.18g, 0.59mmol). The mixture was stirred at room temperature for 
two hours, then heated under reflux for four hours. The solvent was 
evaporated under reduced pressure and the residue was taken up in ethyl 
acetate and partitioned between the organic solvent and aqueous sodium 
bicarbonate. The product was extracted into ethyl acetate (3x20ml), the 
combined extracts were dried over sodium sulphate, filtered and the solvent 
was evaporated in vacuo to give a light yellow oil, which was purified by 
flash chromatography on silica gel eluted with ethyl acetate/hexane 60:40 v:v. 
The product, a colourless oil, which was identified as the elimination product 
(130b) on the basis of its nmr spectrum, was collected on evaporation of
solvent.
3 4.R. PRFPARATiONQF(Sl.«-N-ri.2.4-TRIAZQl,-1-YLl ALANINE (132L
2^ 4 s  1 iQi_rf-N-#-Riitoxvcarbonvl-3-*^ -^^^  ^4-#rin7.nl-l-vni alanincTOi
Triazole (0.32g, 0.46mmol) and tetramethylguanidine (0.53g, 0.46mmol) 
were disssolved in 20ml of dry acetonitrile. The solution was stirred under
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nitrogen, at room temperature, followed by the addition of t-Boc L-serine 
acetate methyl ester (126) (0.1 Ig 0.42mmol). The mixture was stirred for 
another fifteen minutes at room temperature, then heated under reflux (SO^C) 
for three hours. On cooling solvent was evaporated at reduced pressure, and 
the residue was taken up in water and washed with two 25ml portions of ethyl 
acetate to remove residual triazole. The aqueous phase was acidified with 
saturated citric acid solution to pH3 and extracted with ethyl acetate 
(3x20ml). The combined extracts were dried over sodium sulphate, filtered 
and the solvent was evaporated under reduced pressure to afford the adduct as 
a colourless oil which solidified on standing. Recrystallization from ethyl 
acetate/hexane gave the compound as a white solid.
Yield: 41mg, 35%.
Rf: 0.12 (solvent DCM/MeOH/AcOH 33:10:5 v:v). 
m.p. 176-170C>C.
1h  nmr (DMSO): 5 1.4 (s, 9H, t-Boc); 4.4-4.6 (m, 3H, CHCH2);
7.2 (s, IH, NH); 8.0 (s, IH, £H); 8.4 (s, IH, £H).
Mass spectrum: [M+H]"*" at m/e 257.
3.4.S.2. (Sl-3-n.2.4-tnazol-l-vl) alanine (133).
The t-Boc protected adduct (132) (50mg,0.2mmol) was dissolved in a solution 
of IM HCl in acetic acid. This was left standing at room temperature for one 
hour and the solvent was evaporated under reduced pressure. The amino acid 
hydrochloride gave a ninhydrin positive spot on tic. Owing to lack of time, 
this product was not characterized.
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1.4.9. SYNTHESIS OF (S)-3-n.PYRROLlDINYLl ALANINE_(134L
.1.4.9.!. rS)-N-t-butoxvcarbonvl-3-il-Dvrrondinvl1 alanine (1361
The N-t-Butoxycarbonylamino P-lactone (78) (O.lg, 0.54mmol) was added 
under nitrogen to a solution of pyrrolidine (0.04g, 0.513mmol), and DABCO 
(0.06g, 0.56mmol) in 25ml of dry THF. The mixture was stirred overnight at 
room temperature and the solvent was evaporated under reduced pressure. 
The residue was taken up in water and acidified with 0.5M HCI to pH3 and 
extracted with ethyl acetate (3x20ml). The combined extracts were dried over 
sodium sulphate, filtered, and the solvent was evaporated under reduced 
pressure to afford as a colourless oil. Crystallization from hexane and ether 
gave the product as a white solid, 
yield: 90mg, 33%.
Rf: 0.63 (solvent DCM/MeOH/AcOH 44:5:1 v:v). 
m.p. 142-143®C.
1h  nmr (DMSO): 5 1.4 (s, 9H, t-Boc): 1.6-2.0 (m, 4H, CH2CH2);
2.9-3.6 (m, 6H, Q l 2 f ^ Z  and CH£H2>’ £HCH2);
6.7 (d, 1H,NH).
Mass spectrum: [M+H]"*" at m/e 259.
1.4  9 .2 . . l - r i-P v r ro l id in v I l  a la n in e  (134),
The t-Boc protected adduct (136) (50mg, 0.2mmol) was dissolved in IM 
solution of HCI acetic acid (10ml). After one hour at room temperature, the 
solvent was evaporated and the resultant amino acid hydrochloride was taken 
up in water and then evaporated off to remove residual acetic acid, (this was 
repeated three times). Excess acetic acid was then removed by high vacuum. 
The product was taken up in a small amount of water and freeze-dried to yield
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the product as a sticky solid.
Yield: 200mg, 11%.
m.p. The compound is hygroscopic, therefore the melting point was not 
obtained.
Rf: 0.4 (solvent BuOH/ AcOH/ H2O 3:1:1 v:v).
1h  nmr (D2O): 5 1.9-2.1 (m, 4H, 3.4-3.T (m, 4H, 2x£H2li); 3.9-
4.0 (m, 2H, CH£H2 ); 4.4 (m, IH, £HCH2).
3.4.10. Synthesis of (S)-3.ri-Dvrrolidin-2-onvl1 alanine il35k
3.4.10.1. N.henzvloxvcarhonvl-3-ri-Dvrrolidin-2-Qnvl1-alanine(13ZL
A solution of N-Cbz-P-bromo-alanine (129) (0.5g, l.Tmmol) and
triethylamine (0.18g, l.Smmol) in toluene (20ml) was treated with pyrrolidin-
2-one (0.15g, l.Tmmol). The mixture was heated under reflux for four hours, 
cooled and the solvent was evaporated under reduced pressure to afford an 
oily residue which was taken up water, acidified to pH3 with 2N HCl and 
extracted with ethyl acetate (3x25ml). The combined extracts were dried over 
sodium sulphate, filtered and evaporated under reduced pressure to give the 
Cbz-protected amino acid as a white solid.
Yield: 0.12g, 24%.
Rf: 0.53 (DCM/MeOH/AcOH 44:5:1 v:v).
1h  nmr (CDCI3): 5 2.2 (m, 2H ,0 1 2 ^^2 ); 2.4 (m, 2H, CH2CO);
3.6 (t, 2H, CH2N): 3.7-4.0 (m, 2H, CH£H2)’ (n™’ IH, £HCH2);
5.1 (s, 2H, O l 2 Ph); 5.7 (d, IH, MH); 7.4 (s ,5 H ,^ ) .
Mass spectrum: [M+H]"*" at m/e 307.
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.1.4.11. NON-rv c i  ir  AMINO ACIDS.
.1.4.11.1, (2S)-2-Amino-4.6-diaza-5-oxo-octan-1.8-dioic acid (13&L
The adduct (99) (0.8g, 2.6mmol) was dissolved in ethanol (50ml), followed 
by the addition of 10% palladium on activated charcoal (0.08g). The 
suspension was hydrogenated at room temperature and atmospheric pressure 
for one hour. The catalyst was removed by filtration and the filtrate was 
evaporated to dryness under reduced pressure, to afford the crude (138). 
Recrystallization from water and ethanol gave the amino acid as a white solid. 
Yield: 0.34g, 64%.
Rf: 0.27 (solvent Bu0 H/Ac0 H/H2 0  3:1:1 v:v). 
m.p. 236-2380C.
1h  nmr (D2O): 5 3.4-3.V (m, 2H, CH O I2 ); 3.8 (s, 2H, £H 2COOH);
4.1 (m, 1H ,£H C H 2).
Mass spectrum: [M+H]"*" at m/e 206.
Anal, calcd. for C6H 1 1 N3O5 requires C 35.12; H 5.36 N 20.49.
Found: C 34.05; H 5.43; H 19.63. (The product was found to contain 0.28 
mol of water). (Calcd. for 0.28 H2O: C 34.28, H 5.50, N 19.99)
[ a ] o -20.03 (c 1.02, IM HCl).
3.4.11.2. (2Sl-2.Benzvloxvcarbonvlamino-4-aza-5-oxo-OCtan-1.8-diQk 
acid (139a).
The adduct (106) (0.7g, 2mmol) was dissolved in methanol (5ml), to which 
potassium hydroxide (0.12g, 2.1 mmol) was added. The mixture was stirred at 
room temperature for one hour and solvent was evaporated. The residue was 
taken up in water (20ml), acidified to pH3 with 2M HCl and then extracted
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into ethyl acetate (3xl5ml). The combined extracts were dried over sodium 
sulphate, filtered and the solvent was evaporated under reduced pressure to 
give the product as a colourless oil.
Yield: 0.5g, 74%.
Rf: 0.53 (solvent DCM/MeOH/AcOH 44:5:1 v:v).
1h  nmr (DMSO): 2.2-2.5 (m, 4H, CH2 CH2 ): 3.3-3.5 (m, 2H, CH£H2)’
4.0 (m, 1H,_CHCH2); 5.1 (s, 2H, CH2Ph); 6.9 (d, IH, HH); 7.3 ( s, 5H, Ph);
7.9 (IH, NH).
Mass spectrum: [M+H]"*" at m/e 339.
3.4.11.3. (2S)-2-AminQ-4-aza-5-oxo-octan>l,8-dioic acid (139).
Palladium on activated charcoal (0.04g) was suspended in a solution of the 
diacid (139a) (0.4g, l.lSmmol). in ethanol (30ml). The suspension was 
hydrogenated at room temperature and atmospheric pressure for one hour. 
The catalyst was removed by filtration and the filtrate was evaporated to 
dryness to give the crude product as a white solid. Recrystallization from 
water and ethanol afforded the amino acid as a white solid.
Yield: 0.18g, 66%. 
m.p. 223-2250C.
Rf: 0.24 (solvent BuOH/AcOH/H20 3:1:1 v:v).
1h  nmr (D2O): 5 2.2 (m, 4H, 0 1 2 ^ 2 ) ’ 33-3.5 (m, 2H, CH£H2)’
3.9 m, 1H,£HCH2).
Mass spectrum: [M+!!]■*■ at m/e 205.
Anal, calcd. for C7H 12N2O5 requires: C 41.18; H 5.88; N13.73.
Found: C 40.36; H 5.98; N 13.27. ( The compound was found to contain 
0.4mol of water).(Calcd. for 0.4 H2O; C 39.77, H 6.06, N 13.28)
[«Id . -28 5 (c 0.41,1MHC1).
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3.4.11.4. SYNTHESIS OF (SV2.7-DIAMINQ)-4-AZA-5-QXQ-HEPTANQ1C 
ACID (141).
3.4.11.4.1 (2S)-2.7-Bis(henzvloxvcarbonvlamino)-4-aza-5-QXQ-heptanQic 
acid methyl ester (141a).
Cbz protected P-alanine (0.59g, 6.62mmol) was added (under nitrogen), to a 
solution of a-N-Cbz-L-DAPA methyl ester hydrochloride (97) (1.5g, 
6.0mmol), EDC (1.21g, 6.0mmol) and triethylamine (0.64g, b.Ommol) in dry 
THF. The mixture was stirred overnight and the solvent was evaporated in 
vacuo to afford an oily residue which was taken up in dichloromethane 
(40ml), washed with three 20ml portions of saturated sodium bicarbonate, 
dried over sodium sulphate, filtered and the solvent was evaporated under 
reduced pressure to give the crude amide, which was purified by 
chromatography on silica gel (20g) eluted with DCM/MeOH 9:1 v:v). The 
amide was obtained as a white solid following crystallization from ethyl 
acetate/hexane.
Yield: 1.35g51%. 
m.p. 128-1310C
Rf: 0.3 (solvent ethyl acetate/hexane 2:1 v:v).
1h  nmr (CDCI3): 5 2.4 (t, 2H, £H2™ 2>; 3.4 (m, 2H, CH£H2)’
3,6 (t, 2H, CH2CH2 ); 3.7 (s, 3H, O O i^); ^-4 (m, IH, £HCH2);
5.1 (2s, 4H, 2x£H2Ph); 5.4 (m, IH, NH); 5.8 6.1 (d, IH, NH);
6.1 (d, IH, NH); 7.4 (2 s, 10H,Eh).
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3.4.11.4.2. (2S)-2.7-Bis(benzvloxvcarbonvlaminQ)-4-ay -^5-QXO-heDtanQic 
acid (141b).
Sodium hydroxide (0.09g, 2.2mmol) in water, (10ml), was added to a solution 
of the ester (0.98g, 2.2mmol), in methanol (10ml). The solution was stirred at 
room temperature for one hour acidified to pH3 with 2M HCl and then 
extracted with ethyl acetate (3x20ml). The combined extracts were dried over 
sodium sulphate, filtered and the solvent was evaporated under reduced 
pressure to give the product as a colourless oil.
Yield: 0.74g, 78%.
Rf: 0.13 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (DMSO): 5 2.2-2.4 (m, 2H, £H 2 ™ 2 )’ 2.5 (t, 2H, CH2O I 2);
3.2-3.5 (m, 2H, CH£H2>; 3.7-3.9 (m, IH, £HCH2);
5.0 (2 s, 4H, 2x£H2 Ph); 6.6 (d, IH, NH); 7.3 (d, IH, J9H);
7.4 (2s, lOH, 2xPli). 8.2 (d, IH, NH).
Mass spectrum: [M+H]'*' at m/e 444.
3.4.11.4.3. rSl-2.7-Diamino-4-aza-5-oxo-heDtanoicacid (141).
Palladium on activated charcoal (10%) (0.07Ig), was suspended in 25ml of 
ethanol containing the acid (141b) (0.7 Ig, 1.7mmol). The mixture was 
hydrogenated at room temperature and atmospheric pressure for one hour. 
The catalyst was removed by filtration through celite and the filtrate was 
evaporated to dryness to give the crude diamino acid. Recrystallization from 
ethanol/water gave the diamino acid as a white solid.
Yield: 0.38g, 64%.
Rf: 0.21 (solvent BuOH/H20 /AcOH 3:1:1 v:v).
m.p. 231-232^0 (decomposed, then melted with effervesence).
1h  nmr (D2O/DCI): 5 3.0 (m, 2H, £H 2™ 2)i 3.4 (m, 2H, CH2£H2);
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3.7-3.S (m, 2H, CHCH2 ); 4.3 (m, IH, £HCH2).
Mass spectrum: [M+H]"*" at m/e 176.
Anal, calcd. for C6H 13N3O3 requires: C 41.14 H7.43 N24.0. 
Found: C 41.44 H 7.39 N 23.88.
3 tSl-2.6-Bisihen7.vloxvcarhnnvlamino)-4-aza-5-QXO-hexanQk
acid methvl ester (140a).
A solution of Cbz-L-DAPA methyl ester (97) (2g, 8mmol), in dry THF was 
treated (under nitrogen) with triethylamine (0.85g, 8.4mmol), and EDC (1.6g, 
8.4mmol). The solution was stirred at room temperature for fifteen minutes, 
followed by the addition of Cbz-glycine (0.63g, 8.4mmol). The mixture was 
stirred at room temperature overnight and the solvent was evaporated in 
vacuo, the resulting light yellow residue was partitioned between 
dichloromethane and saturated aqueous sodium bicarbonate. The aqueous 
phase was extracted with dichloromethane (3x25ml), dried over sodium 
sulphate, filtered and the filtrate was evaporated under reduced pressure to 
give an oily residue, which was purified by flash chromatography on silica gel 
(25g) with DCM/MeOH 9:1 v:v as the eluent.
Yield: 2.1g 61%.
Rf: 0.69 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 3.3-3.8 (m, 7H, CH2 NH2 and CH£H2 OCH^);
4.4-4.5 (m, IH, CHCH2); 5.0 (2xs, 4H, 2x O l2 Ph); 6.3 (m, 2H, 2xMH);
7.4 (s, lOH, 2xEli); 7.5 (d, IH, m ) .
Mass spectrum: [M+H]'*' at m/e 444.
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. .^4.11.5.2. (2S)-2.6-Bis(benzvloxvcarhonvlamino)-4-aza-5-oxo-hexanQic
acid (HQliL
The ester (140a) (1.8g, 4.18mmol) was dissolved in a minimum amount of 
methanol ( 10ml) and treated with solution of sodium hydroxide ( 0.18g, 
4.6mmol) in water (10ml). The mixture was stirred at room temperature for 
one hour followed by the evaporation of methanol. The aqueous phase was 
acidified to pH3 with 2M HCl, and patitioned between ethyl acetate. The 
crude product was extracted into ethyl acetate (3x20ml), dried over sodium 
sulphate, filtered and evaporated in vacuo to give an oily residue which was 
chromatographed on silica gel (15g), eluted with DCM/MeOH 9:1 v:v. The 
product was obtained as a colourless oil on evaporation of solvent.
Yield: 0.9g,71%.
Rf: 0.77 (solvent DCM/AcOH/MeOH 44:l:5v:v).
1h  nmr (DMSO): 5 3.1-3.5 (m, 2H, CH£H2)’ ^ ^ 2H,
4.5 (s, 2H, £H 2 Ph); 5.0 (s, 6.3 (d, IH, HH);
7.4 ( 2xs, lOH, 2xElD; 7.5 (d, IH, NH).
Mass spectrum: [M+H]"^ at m/e 430.
3.4.11.5.3. (2S1.2.6-Diamino.4-a7a-5-Qxo-hexanoicacid (14flL
A suspension of 10% palladium on activated charcoal (60mg) and the acid 
(140b) (0.6g, 1.4mmol) in ethanol (50ml), was hydrogenated at room 
temperature and atmospheric pressure for one hour. The catalyst was removed 
by filtration, and the filtrate was evaporated under reduced pressure to afford 
the amino acid which was crystallized from ethanol/water.
Yield: 200mg (58%).
Rf: 0.2 (solvent BuOH/H20 /AcOH 3:1:1 v:v).
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m.p. 220-222OC.
1h  nmr (D2O); 5 3.6-3.S (m, 2H, CH£H2 ); 3.9 (s, 2H,
4.2-4.3(m, 1H ,£H C H 2).
Mass spectrum; [M+H]"^ at m/e 162.
Anal, calccl. for C5H 1 1 N3O3 requires; C 37.28 H 6.83 N 26.09.
Found; C 37.49 H 6.76 N 25.91.
[a]o -29.03 (c 0.5, IM HCl).
3.4.12. Synthesis of dipkptide analogues QF QlllSOOALIC ACID.
3.4.12.1. Attempted synthesis of Quisaiialvl-glvcine il44L
A stirred solution of benzoyl-protected quisqualic acid (62) (0.5g, 2. Immol) 
in dry THF (30ml), was treated with DCC (0.47g, 2.3mmol) and HOST 
(0.3Ig 2.3mmol). The mixture was stirred at room temperature for thirty 
minutes, followed by the addition of glycine ethyl ester hydrochloride (0.32g 
2.3mmol). Stirring was continued at room temperature overnight and the 
solvent was evaporated under reduced pressure. The resulting residue was 
partitioned between ethyl acetate and aqueous sodium bicarbonate and the 
crude product was extracted into the organic phase (3x30ml), and then 
washed with 2M HCl, then with water, followed by brine, dried over sodium 
sulphate, filtered and the solvent was evaporated in vacuo to afford an 
intractable mixture, which was not characterized. This method was 
abandoned.
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3.4.12.2. S y n t h e s is  o f  o i iisoiiALYi.-LEUCiNE (147)
3.4.12.2.1. a-N-t-Butoxvcarbonvl auisaualvl-leucine methvl ester (145L
N-t-Boc protected quisqualic acid (81) (Ig, 3.46mmol) was dissolved under 
nitrogen, in dry THF, cooled to and treated with N-methylmorpholine
(0.35g, 3.46mmol), then with isobutyl chloroformate (0.47g, 3.46mmol). The 
mixture was stirred at -25^C for two minutes, then treated with a cooled (- 
1 5 ^ 0  suspension of L-leucine methyl ester hydrochloride (0.63g, 3.46mmol) 
and NMM (0.37g, 3.6mmol ). The reaction mixture was stirred for another 
two hours at - 150C and then poured into 500ml of semi-saturated brine, 
extracted with dichloromethane (3x35ml). The combined extracts were dried 
over sodium sulphate, filtered and the solvent was evaporated under reduced 
pressure to afford the protected dipeptide as a colourless oil. Purification by 
flash chromatography on silica gel (20g), eluted with hexane/EtOAc (2:1 v:v) 
gave the product as a foamy solid on evaporation of solvent.
Yield; l.lg(76% ).
R f:0  .36 (solvent hexane/ethyl acetate 1:1 v:v).
1h  nmr (CDCI3): 5 0.9 (d, 6H, (£112)2 (s. 9H, t-Bpg);
1.6 (m, 2H, CH£H2)’ ^ (s» 3H, ^.0 (m, 2H, CH£H2)’
4.5 (m, 2H, 2xCH£H2)’ ^-4 (m, IH, NH); 5.9 (d, IH, NH); 7.4 (s, IH, iffl). 
Mass spectrum: [M+H]"^ at m/e 417.
3.4.12.2.2 (x-N-t-Butoxvcarbonvl auisQualvl leucine (146L
A solution of the adduct (145) (0.9g, 216mmol) was dissolved in a solution of 
sodium hydroxide (90mg, 2.3mmol) in water (30ml). The mixture was stirred 
at room temperature for one hour. Alcohol was evaporated in vacuOy and the 
aqueous phase was acidified at 0®C to pH3, with 0.5M HCl and then extracted
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with ethyl acetate (3x30ml). The combined extracts were dried over sodium 
sulphate, filtered and the filtrate was evaporated under reduced pressure to 
give the acid as a foamy solid.
Yield: 0.67g, 77%.
Rf: 0.57 ( solvent DCM/MeOH 9:1 v:v).
1h  nmr (DMSO): 5 1.0 (dd, 6H, 1-4 (s, 9H, t-BO£);
l .  7 (m, 2H, CH£H2) (s, 3H, 4.1 (m, 2H, CH£H2)’
4.5-4.7 (m, 2H, 2x£IiCH2); 5.4 (s, IH, HH); 6.0 (s, IH, MH);
7.4 (s, 1H,NH).
Mass spectrum: [M+H]'^ at m/e 403.
3.4.12.2.3. L-Ouisaualvl-L-Ieucine (147).
A solution of the t-Boc protected dipeptide (146) (0.5g, 1.2mmol) in IM 
HCl/AcOH solution was left standing at room temperature for one hour. The 
solvent was evaporated in vacuo and the resulting peptide hydrochloride was 
converted to the free base by ion exchange chromatography (acetate anion 
resin ) eluted primarily with water 50ml and then with 5% acetic acid 
solution. Acidic fractions were combined and concentated under reduced 
pressure, then freeze-dried to afford the peptide as an off-white crystalline 
solid.
Yield: 0.23g, 63%.
m. p. 138-140^0 (decomposition observed from 128^0).
Rf: 0.53 (solvent BuOH/H20 /AcOH 3:1:1 v:v).
1h  nmr (D2O): 5 2.8 (m, 6H, (CH^)!): 3.6-4.0 (m, 4H, C H 012 and £HCH2 
and I/2CHCH2 V. 4.3 (m, 3H, CHCH2 , and £HCH2 , and 1/2CHCH2)- 
Mass spectrum: [M+H]'*' at m/e 303.
Anal, calcd. for C iiH ig N 406 requires: C 43.71; H 5.96; N 18.54.
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Found:. C 41.43; H 6.12; N 16.86, (the product was found from 
spectroscopic and elemental analysis to contain 0.84mol of H2O and 0.2mol 
of AcOH).
[a]o  -20.4 (c 0.6, IMHCl).
alkyi atton of L-outsoualic aciil
1 .4 .13 .1 . ft-N-t-ButoxvcarbonvI-e-N-ethoxvcarbQnvImethvI QuisQualic 
acid ethoxvcarbonvimefhvi ester (148).
t-Boc Quisqualic acid (0.5g, l.Tmmol), in dry DMF, was treated under 
nitrogen with sodium hydride (0.09g, 3.7mmol). The mixture was stirred at 
room temperature for thirty minutes, followed by the addition of ethyl 
bromoacetate (1.3g, 7.5mmol). The reaction mixture was stirred overnight 
and solvent was evaporated. The residue was taken up in water and acidified 
at O^C, with IM HCl to pH3, followed by extraction with ethyl acetate 
(3x30). The extracts were combined, washed with brine, dried over sodium 
sulphate, filtered and the filtrate was evaporated under reduced pressure to 
afford the crude product as a light yellow oil. Purification by flash 
chromatography on silica gel, with 3% MeOH in DCM as the eluent gave the 
product as a light yellow oil.
Yield: 0.48g, (55%).
Rf: 0.33 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 1 2-1.6 (m, 15H, (2xCH20i2.and t-Bpc);
4.0-4.4 (m, 8H, CH£H2  + ^ 2pOOEt +
4.6-4.8 (m„ 3H, 0 £H 2C0 2 Et +, £HCH2); 5.4 (d, IH, £iH);
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3.4.13.2. a-N-t-Butoxvcarbonvl-e-N-carboxvmethvl Quisaualic add
iim
A solution of the adduct (148) (0.45g, 0.97mmol) in methanol was treated 
with 3.3 equivalents of potassium hydroxide (0.18g, 3.2mmol). The mixture 
was stirred at room temperature for one hour, and then acidified at 0®C to pH 
3 with IM HCl, followed by extraction with ethyl acetate (3x25ml). The 
combined extracts were washed with brine, dried over sodium sulphate, 
filtered and the filtrate was evaporated under reduced pressue to afford the 
acid as a foamy oil.
Yield: 0.28g, (83%).
Rf. 0.32 (solvent DCM/MeOH/AcOH 44:5:1 v:v).
iHnmr (DMSO): 5 1.4 (s, 9H, t-Boc); 3.8-3.9 (m, 2H, CH£Ii2)’
4.1 (s, 2H, CH2COOH); 4.3 (m, IH, £HCH2); 5.9 (d, IH, HH).
3.4.13.3. -F.-N-carboxvmethvI atiisaualic acid (150).
The intermediate (149) (0.25g, 0.72mmol) was dissolved in IM hydrogen 
chloride in acetic acid (15). The solution was left standing at room 
temperature for one hour. The solvent was removed in vacuo and the resultant 
amino acid hydrochloride was converted to the free base by ion exchange 
chromatography, eluted with 10% acetic acid solution. The solvent was 
concentrated in vacuo, and then freeze dried, to afford the product as a white 
solid.
Yield: 25mg,(14%).
Rf: 0.25 (solvent Bu0 H/Ac0 H/H2 0  3:1:1 v:v).
1h  nmr (D2O/DCI): 5 3.8 (s, 2H, CH2COOH); 3.9-4.2 (m, 2H, CHCH2);
4.3 (m, IH, CHCH2).
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XS. MISCELLANKODS SYNTHESES.
3.5.1. N-EthoxvcarbonvI-N-benzvIoxvurea (1511
Ethoxycarbonyl isocyanate (2.4g, 0.02m) was added, under nitrogen, to a 
solution of O-benzylhydroxylamine hydrochloride (3g, 0.019m) in 80ml of 
dry THF. The mixture was stirred at room temperature overnight. The 
solvent was evaporated under reduced pressure and the resultant white solid 
was recrystallised from ether. The amide, a white crystalline solid, was 
collected by filtration, 
yield: 4.1g, 92%. 
m.p 123-1250C.
Rf: 0.83 (solvent DCM./MeOH 9:1 v:v).
1h  nmr (CDCI3): 5 1.3 (t, 3H,CH2 £H^); 4.2 (q, 2H, 0 1 2 ^ ^ 3 ):
5.0 (s, 2H, £H 2Ph); 7.4 (s, 5H, Ph).
Mass spectrum: [M+H]'*" at m/e 239.
Anal, calcd. for C l 1H 14N2O4 requires: C 55.46 H 5.88 N 11.76.
Found: C 55.41 H 5.91 N 11.51.
3.5.2. N-EthoxvcarbonvI-N-hvdroxvurea (152).
The amide (4g, 0.017mol), in ethanol (150ml) was hydrogenated at room 
temperature and atmospheric pressure over palladium charcaol for ninety 
minutes. The catalyst was removed by filtration and the filtrate was 
evaporated in vacuo to afford the crude hydroxylamine. Purification by 
recrystallization gave the pure ester as a white crystalline solid, 
yield: 2 .3g , 93%.
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m.p. 143-145®C.
Rf: 0.34 (solvent DCM/MeOH 9:1 v:v).
1h  nmr (DMSO): 5 1.2 (t ,3H, CH2ff l^ ) ; 4.1 (q, 2 H ^ 2 ^ ^ 3 ) ’
8.9 (s, 9.1 (s, lH ,N ii); 9.3 (broad s,
Mass spectrum: [M+H]"*" at m/e 149.
Anal, calcd. for C4HgN204  requires C 32.43 H 5.40 N 18.92. 
Found: C 32.18 H 5.33 N 18.60.
3.5.3. 1.2.4-oxadia7.olidme-2.5-dione (153).
2.5ml of 2M potassium hydroxide was added to the ester (150) (0.9g, 
ó.lmmol). The solution was stirred at room temperature for ten minutes, then 
warmed to 50®C with stirring for fifteen minutes. On cooling, the resulting 
potassium salt was converted to the free base by ion exchange 
chromatography ( Dowex 50X2-100, H+ resin), eluted with 100ml of water. 
The heterocycle was collected as a white solid on evaporation of solvent. 
Yield: 0.74g 94%. 
m.p. 108-1 lOOC.
Anal, calcd. for C2H2N2O3 requires C 23.53; H 1.96 ; N 27.45.
Found: C 23.13; H 1.97; N 27.45.
Mass spectrum: [M+H]"*" at m/e 103.
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3.5.4. Attempted synthesis of N-tert-hiitnxvcarbonvl QuisQuallc acid bY 
the alkylation of the heterocvcie (153) with (3S)-(3-t- 
hiitnxvcarbnnvlamino)-oxetan-2-one (78).
The heterocycle (153) (0.55g, 5.3mmol) in 10ml of dry acetonitrile (ACN) 
was stirred under nitrogen for ten minutes, and the P-lactone (78) (0.2g, 
l.OTmmol) was added. The mixture was stirred at room temperature 
overnight. The solvent was evaporated in vacuo to give an oily residue which 
was taken up in water and acidified to pH3 with 0.5M HCl and then extracted 
with ethyl acetate (3x25ml). The combined extracts were dried over sodium 
sulphate, filtered and the solvent was evaporated under reduced pressure to 
afford the product as an oil, which was found upon characterization to be t- 
Boc serine (74).
Yield; 0.12g, 67%.
1h  nmr (CDCI3); 5 1.4 (s, 9H, t-Boc); 3.8 (m, 2H, CH O I2 )’
4.3 (m, IH, £HCH2); 6.0 (s, IH, NH).
Attempted alkylation of the heterocycle with the |3-lactone using different 
solvents such as THF, DMF, EtOAc, and temperature variation ranging from 
room temperature to 100®C either gave t-Boc serine or the the elimination 
product. At higher temperatures intractable mixtures were obtained.
Attempts were also made to alkylate the heterocycle with the mesylate (128), 
the acetate (126) and the bromide (129), in diferent solvents. At lower 
temperatures these reactions gave either protected serine (Cbz or t-Boc), or 
the elimination product. At higher temperatures intractable mixtures were 
obtained.
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3.5.5. Alkylation of the heterncvcie (153) with otsa-B-lactone (15IL
t-Boc p-lactone (78) (0.6g, 3.2mmol), was converted to the p-
toluenesulphonic acid salt according to Vederas et The protected
propiolactone was treated with trifluoroacetic acid (10ml); after fifteen 
minutes, anhydrous ptsa (0.58g, 3.36mmol) was added and the solvent was 
evaporated under reduced pressure to afford the ptsa salt of the p-lactone, 
which was triturated with dry ether, to afford the salt as a white solid.
Yield: 0.80g, 96.5%
m.p. 1750c  (decomposed) (Lit 1^4 1730c  decomposed).
1h  nmr (D2O) 6 2.52 (s. 3H, ArCH3); 4.95 (m, 2H, CH2); 5.60 (m, IH, 
CHCH2 ); 7.45 and 7.89 (ABq, 4H, ArH x 4). 11.49 (s, 3H, NH3'^)-
The heterocycle (153) (O.lg, 0.98mmol) in ACN was treated under nitrogen 
with ptsa p-lactone (0.28g, Immol). The reaction mixture was stirred at room 
temperature for four hours and solvent was evaporated. The residue was 
triturated under ether and the product was collected as a white solid after 
filtration.
Yield: O .llg, 31%.
1h  nmr (D2O) 5 2.40 (s, 3H, ArCH3), 4.33 (m, 2H, CH2),
4.39 (m, IH, CHCH2), 7.35 and 7.67 (ABq, 4H, ArHx4)
3.5.6. Synthesis of 1.2-Oxazolidine-3.5-diQne (1 5 ^
3.5.6.I. EthvI malonvl O-benzvIhvdroxamate (1601
O-Benzylhydroxylamine hydrochloride (5.1g, 0.03mol) and potassium 
carbonate (4.4g, 0.032mol) was dissolved in 100ml of toluene. Whilst being
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stirred under nitrogen at room tempterature, ethyl malonyl chloride (5g, 
0.03m) was slowly added. The mixture was heated under reflux for two hours. 
On cooling, toluene was evaporated under reduced pressure and the residue 
was partitioned between aqueous sodium bicarbonate and dichloromethane. 
The product was extracted in to the organic phase (3x30ml), dried over 
sodium sulphate, filtered and the solvent was evaporated in vacuo to afford 
the crude hydroxamate (160). Purification by flash chromatography on silica 
gel with hexane/ethyl acetate (60:40;v:v) as the eluent gave the pure 
hydroxamate as a clear oil.
Yield: 4.8g, 68%.
Mass spectrum: [M+H]"*" at m/e 238.
3.5.6.2. EthvI malónvl hvdroxamate (161).
The O-benzyl hydroxamate (160) (3g, O.Olmol) was dissolved in ethanol 
(50ml), to which was added 10% palladium on activated charcoal (0.3g). The 
suspension was hydrogenated at room temperature and atmospheric pressure 
for one hour. The catalyst was removed by filtration and the filtrate was 
evaporated to dryness to afford the hydroxyl derivative as a foamy oil.
Yield: 1.4, 95%.
Mass spectrum: [M+H]"^ at m/e 148.
3.5.6.3. l,2-Oxazolidine-3.5-dione (159).
A solution of the hydroxamate (161) (1.3g, 8.8mmol) and potassium 
hydroxide (0.54g, 9.7mmol) in water (50ml) was stirred at room temperature 
for fifteen minutes. The reaction which was followed by thin layer 
chromatography (developed by ferric chloride), was warmed to 50®C for ten 
minutes (to aid complete cyclization). On cooling the mixture was passed
193
down an ion exchange column, (Dowex 50 H+) and eluted with water. All 
acidic fractions were combined and evaporated to dryness to give the product 
as an off-white solid.
Yield; 0.8g, 89%. 
m.p.ll5-116®C.
Mass spectrum; [M+H]"*" at m/e 102.
Anal, calcd. for C3H3NO3 requires; C 35.64; H 2.97; N 13. 86.
Found; C 35.68; H 3.12; N 13.95.
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4,1 IN T R O n ilC T lQ N .
Early electrophysiological studies opened up the field into the experimental 
potential of excitatory amino acid research. These early studies, which were 
initiated by Hayashi^ and later by Curtis et a l.M  in their search for transmitter 
roles for L-glutamic acid and L-aspartic acid in mammalian brain tissue, 
provided the now accepted view that L-glutamic acid and L-aspartic acid are 
initiators of synaptic transmission in the mammalian central nervous 
system.*7»14,15 These studies, which were performed in the hope of identifying 
potential neurotransmitter substances, led to the isolation and identification of 
other excitatory amino acids, notably: N-methyl-D-aspartic acid, kainic acid, 
and quisqualic acid. The observed responses exhibited by neurones when they 
were exposed to these compounds led to the theory that specific receptors exist 
through which these responses were mediated. 7,11,14,16
4.1.2. Pharmacnloov of binding.
Pharmacologists coined the term "receptor" almost a century ago in order to 
describe the mode of action and the specificity of drugs. It is a fundamental 
assumption of any receptor theory, as stated explicitly by Ehrlich,20 that for an 
agent to act it must be bound. Thus the most important criterion for identifying 
a binding site as a neurotransmitter receptor is the detailed pharmacology of the 
binding. Thus, compounds which effectively block or mimic the effects of the 
neurotransmitter should compete for receptor sites at low concentrations. 
Conversely, ineffective drugs should compete only at very high concentrations.
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if at all. Electrophysiological and binding studies support the view that, when 
activated by an agonist,the receptor transduces its signal ultimately to provide 
the characteristic physiological response.
4.1.3. Radiolipand recent or bindiniL
The intervention of neurotransmitter or drug interaction with biological 
receptors can be studied in vitro by following the binding of suitable radioactive 
ligands. The first receptors studied by radioligand binding techniques
were nicotinic cholinergic r e c e p to r s .T h e s e  early experiments provided a 
major impetus to the design of practical procedures for radioligand binding
studies.
Using these procedures, receptor sites for almost all the known neurotransmitters 
in the peripheral and central nervous systems have been studied. The 
measurement of radioligand binding to receptors provides a means of obtaining 
valuable information on the physiological interactions between ligand and 
receptor, which would not have been obtained solely by electrophysiological 
means. Furthermore, it allows a direct measurement of ligand-receptor 
interaction from which a quantification of the numbers of receptors present in 
membrane preparations may be elucidated.
4 1.4. Radinlii?and bindino of excitatory aminO acidi
The study of excitatory amino acid receptors has been an explosive area of 
investigation in recent years. Radioligand binding to excitatory amino acid 
receptors was first introduced (simultaneously) by Roberts ^ 92 and 
Michaelis. These researchers provided the first biochemical evidence for the 
existence of specific receptor binding sites for excitatory amino acids on nerve
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membranes provided the initial methodology through which radioligand binding 
to central nervous system receptors might be investigated.
These early studies involved the binding of ^H-L-glutamic acid to nerve cell 
membranes in the presence of non-radioactive agonists and antagonists as 
displacers . At this point, interpretation of results was based on results from 
electrophysiological characterization of the ligands. Results from these early 
pharmacological studies, and the availability of other tritiated compounds, 
notably 3h -AMPA,75 3h  NMDA,194 3h  kainic acid,195 3H-D-aspartate,196 
3h -DL-AP4197 and ^H-APS^^^ provided the necessary tools for probing a 
number of questions regarding the structure, function, and regulation of 
excitatory amino acid receptors.
4.1.5. Analysis of bindino data.
4.1.5.1. Sopfifip hindine refers to the component of the radioligand binding 
which is actually bound to the receptor under investigation. Due to the low 
concentration of receptors in synaptic membranes (often in femtomoles per 
milligram of wet tissue) these can be readily saturated by the addition of an 
excess of "cold ligand", a compound that is a potent agonist or antagonist of the 
in vivo pharmacological action. For example, in an appropriate ^H-L-glutamate 
binding assay, the addition ImM of unlabelled NMD A to the ligand binding 
assay would displace the specifically-bound radioactive ligand from specific 
NMDA recptors.
4.1.5.2. Non-snecific hindino is that component of the binding that cannot be 
saturated with an excess of the appropriate displacer. This is often the result of
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non-receptor phenomena such as the partitioning of the radioligand into the lipid 
environment of the membrane preparation.
4.1.5.3. hindino is the sum of the specific and non-specific binding.
In practice, specific binding is usually derived from the difference between the 
total binding (measured when no displacer is present), and non-specific binding 
(measured in the presence of excess cold ligand ).
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5.1. Materinls and methods.
5.1.1. sources of material.
Unless stated to the contrary, the chemicals used were from the following 
sources:
Radiochemicals ; Amersham International, P.O. Box 16, Amersham, or New 
England Nuclear, DuPont, Wedge wood Way, Stevenage.
Animals Adult male Wistar rats of approximately 250g in weight were used. 
Measurement of radioactivity
Radioactivity was measured by an LKB Rack beta using a liquid scintillation 
spectrometer.
Amino acids and derivatives were from Tocris Neuramin, Bristol.
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5.2. Radiolahelled lioands.
The vast majority of receptor labelling studies involve the binding of a 
radioactive ligand (agonist or antagonist) to a suitable membrane preparation 
derived from target tissues. Since many receptor sites have an equilibrium 
dissociation constant for ligand in the nanomolar range, the most crucial step in 
radioligand binding studies is the acquisition of radiolabelled ligand of high 
radiochemical specific activity.
In view of the low concentration of receptors in the membranes, the radioactive 
ligand should ideally possess the following properties:
1 High selectivity: This ensures that the ligand binds maximally to only the 
relevant receptor population, and to a minimal extent to non-receptor 
components of the membrane.
2 High affinity: This ensures that the ligand- receptor dissociation constant is in 
the range of the receptor concentration.
2 High specific activity: This ensures that appropriate low concentrations can be 
used and the specific binding may be readily and accurately determined.
4 Reversibility: Binding should be readily reversible with a time course 
consistent with the rate of termination of the physiological action, and that 
subcellular distribution of binding sites are compatible with those for 
neurotransmitter receptors.
For the work reported here ^H-L-glutamate and ^H-AMPA were used in the 
binding experiments. These ligands were chosen in order to study receptor 
binding to:
(i) all glutamate-sensitive receptor sites.
(ii) one class of non-NMDA receptors.
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Tissue preparation.
The procedures used to prepare membranes to study the binding of ^H-L- 
glutamate and ^H-AMPA binding are shown schematically in fig. 5.3.
Brain tissue from adult male Wistar rats of approximately 250g was used for 
binding studies. The rats were killed, decapitated and their brains were rapidly 
removed and placed in ice-cold 0.32M sucrose in 5mM tris-acetate solution (pH 
7.4). The tissue (excluding the cerebellum) was homogenized in a tight fitting 
Jencons glass homogenizer with ten strokes of a teflon pestle. The homogenate 
was centrifuged at lOOOg for ten minutes. The pellet (PI) was discarded, and 
the supernatant was centrifuged at 17,000g for twenty minutes. The supernatant 
was discarded, and the pellet (P2) was suspended in 20ml of ice-cold 5mM tris- 
acetate buffer and rehomogenised.
The homogenate was lyzed by incubation at 0®C for twenty minutes, followed 
by centrifugation at 17,000g for twenty minutes. Supernatant and the bilayer (a 
soft "buffycoat") were collected, (blood cells and the mitochondrial pellet were 
discarded) and homogenized, diluted to 50ml volume with 5mM tris-acetate 
buffer, and centrifuged at 17,000g for twenty minutes. The pellet (P4) was 
washed six to eight times by resuspension in 5mM tris-acetate, (pH 7.4), 
homogenized and centrifuged at 50,000g for ten minutes. The membranes were 
then finally resuspended in 50mM tris-acetate buffer and stored at -78^0 prior
to the binding assay.
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j>.3. Tissue preparatioiL
The procedures used to prepare membranes to study the binding of ^H-L- 
glutamate and ^H-AMPA binding are shown schematically in fig. 5.3.
Brain tissue from adult male Wistar rats of approximately 250g was used for 
binding studies. The rats were killed, decapitated and their brains were rapidly 
removed and placed in ice-cold 0.32M sucrose in 5mM tris-acetate solution (pH 
7.4). The tissue (excluding the cerebellum) was homogenized in a tight fitting 
Jencons glass homogenizer with ten strokes of a teflon pestle. The homogenate 
was centrifuged at lOOOg for ten minutes. The pellet (PI) was discarded, and 
the supernatant was centrifuged at 17,000g for twenty minutes. The supernatant 
was discarded, and the pellet (P2) was suspended in 20ml of ice-cold 5mM tris- 
acetate buffer and rehomogenised.
The homogenate was lyzed by incubation at O^C for twenty minutes, followed 
by centrifugation at 17,000g for twenty minutes. Supernatant and the bilayer (a 
soft "buffycoat") were collected, (blood cells and the mitochondrial pellet were 
discarded) and homogenized, diluted to 50ml volume with 5mM tris-acetate 
buffer, and centrifuged at 17,000g for twenty minutes. The pellet (P4) was 
washed six to eight times by resuspension in 5mM tris-acetate, (pH 7.4), 
homogenized and centrifuged at 50,000g for ten minutes. The membranes were 
then finally resuspended in 50mM tris-acetate buffer and stored at -78^0 prior
to the binding assay.
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5.4. r^HI.L-Glutamate binding assay.
The frozen pellet was allowed to thaw at room temperature, resuspended in 
50ml of 50mM tris-acetate buffer (pH 7.4) and centrifuged at 50,000 rpm for 10 
minutes. The pellet was finally resuspended in 20ml of tris-acetate buffer and a 
sample was removed for protein determination. An aliquot (600 pi) of the 
membrane suspension was transferred into 1ml Eppendorf tubes containing 50 
pi (of varying concentration) of [^H] L-glutamate, and 50 pi of 50mM tris- 
acetate buffer. Non-specific binding was determined by the addition of 50 pi of 
ImM " cold" NMDA in 50mM tris-acetate buffer. The tubes were stoppered, 
shaken and then incubated for thirty minutes at room temperature.
Incubation was terminated by centrifugation using a bench microfuge centrifuge 
at 13000g for four minutes. The supernatant was rapidly removed by careful 
suction and the pellet was washed superficially with aliquots of 50mM tris- 
acetate buffer to remove adhering/trapped unbound ligand. The tip of the tube 
containing the pellet was removed and placed in a glass scintillation vial 
(F.G.B.Trident Ltd) containing 500 pi of 2% sodium dodecyl sulphate. This 
was left at room temperature to solubilise overnight. To each sample was added 
4ml of optiphase Hisafe scintillant. (Phamacia). The vials were thoroughly 
shaken to ensure that all the solubilized tissue had been dissolved in the 
scintillant and the bound radioactivity was measured by liquid scintillation 
counter using a medium quench counting efficiency of 60%. The experiments 
were carried out in quadruplicate.
Binding was then investigated using a single concentration of labelled L- 
glutamate (45Ci mmol"^) and varying concentrations (lO"^ to 10"^^M) of the
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prepared L-quisqualic acid and analogues, and 600 pi of the prepared 
membranes. Each analogue was assayed three times in quadruplicate.
¿H A m p a  hindino assay.
The experiment was carried out as outlined for L-glutamate binding assay with 
the following modifications:
1. 20nmol of tritiated AMPA (60 Ci mmol’ l) (50^ 1) was used in each assay.
2. The assays were carried out in the presence of lOOmM potassium thiocyanate 
(chaotropic agent to enhance binding)
3. Synaptic membranes in 50mM tris-acetate buffer were incubated for one 
hour in quadruplicate, with varying concentrations of radiolabelled 
ligand alone, or the presence of a range of concentrations of L-quisqualic 
acid and analogues in a fixed concentration 20nM of [^HJ-AMPA.
4. Incubation was carried out at 4®C
5. Incubation was terminated by centrifugation, and assayed as outlined for 
[3h ] L-glutamate above, for determination of their IC50 values.
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(i.RKSULTS
The pharmacological profiles of L-quisqualic acid and a range of analogues 
were investigated by ligand binding studies. The objective of the experiments 
was to determine which, if any, of the prepared compounds were capable of 
displacing [^H] L-glutamic acid and [^Hj-AMPA from cerebral tissue
preparations. ^
The percentage of inhibition was determined in a routine binding assay in the 
presence of ImM NMD A (in [^H] L-glutamate binding) and ImM "cold" 
AMPA (in AMPA binding), to give the non-specific binding.
The data were analysed by the linear regression with IC50 values determined by 
computer analysis for the single phase sites and biphasic sites.
Plots of percent displacements of specific binding vs. log concentration of the 
displacer were obtained, and their IC50 values determined from them. These are 
depicted in figures 6.1-6.4.
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Fig. 6.1. Pharmacological profile of L-i^H] AMPA binding to rat synaptic 
membrane.
Routine binding experiments were performed in the presence of increasing 
concentrations of synthesized L-quisqualic acid and cyclized analogues. Each 
analogue was assayed in quadruplicate and the data represents the mean of three 
experiments. For ease of interpretation the displacement curves and IC50 values 
for the cyclized analogues are presented in the composite figure 6.1 .
[O] L-quisqualic acid; [*] Succ. A.A [□ ] NCCX3H; [“^ ]  Dichi; [V] HY;
[A] 6 M.R.
N K
[O] L-Q uisqualic acid
[ ] Dichi
N K
O O
HgN CO2 H
[ ] 6MR
Displacement curves and IC50 values for the uncyclized analogues are shown in 
fig.6.2 overleaf.
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Fig. 6.2.
[O] Quisqualic acid; [A] ISO; [*] Succ uncyclized; [v] CH2NH2 .
C O 2 H
HgN
NH
C O 2 H
[liso
H2 N
C O 2 H
[ ] Succ uncyclized
UH,
NH
H2 N  ^ C O 2 H
[ ] CH2 NH2
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Fig 6.3
Pharmacological profile of L-[^H] glutamate binding to the rat brain synaptic 
membranes. The composite figure shows displacement curves and the IC50 
values for L-quisqualic acid and some of the prepared analogues. The 
experiment were performed in quadruplicate and the data represent the mean 
value of three independent experiments. [O] L-glutamic acid. [D] Quisqualic 
acid; [v] 6MR; [*] NCOOH;
N
H
N
^ C O 2 H
E(|] L-Q uisqualic acid
O O
C O 2 H
[-I-] 6MR
NH. HOgC
HgN COgH
[O] L-Glu
210
O) C/) 
o  13
c  m
Z n
O “H(-1
O
CD
H
>
CD
r
m
rv)
*Q
r
c
ro
li3
Q
r
m
CD
CD
a\
M M M M
n  n  n  n
ui ui (ji CD 3:
> O
en O Z CD 
> O r  
O c
0 0 0 0
U) U) en t/)
Il II II II
V V V 
k-». O
O O O • 
O  O  O  ii.
c  c  c  c
Z Z Z Z
J3
CJl O Oc c tJl z e e  
Z  Z
I  >
H
m
(D
I
CD
m
(0
rü
CJl • •
Cjl)
U0)
(O
(D
Fig. 6.4
The composite figure gives the graph and the IC50S value of the same data as 
those used in figure 6.3.
[c] L-Q uisqualic acid
COgH 
[+] 6MR
NH. HOgC
C O 2 H
[O] L-Glu
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6.1. Discussion.
The results obtained for the binding of L-quisqualic acid and its analogues 
synthesized in this work are represented graphically in figures 6.1-6.4.
The IC50 value for the displacement of [^HjAMPA by quisqualic acid (20) (in 
the presence of millimolar concentration of KSCN) was found to be 22.5 nM, this 
is in reasonable agreement with data obtained by other workers^^’^ ^. The 
variation between these results and those in the literature may be due to the type 
of buffer and detergent used in the binding experiments.
Of the synthesized quisqualate analogues, the six membered ring (85) (6.M.R. 
in figs 6.1-6.4) showed the highest activity in displacement of [^H]AMPA 
binding, with an IC50 value of 80 nM. This finding may be attributable to the 
close structural relationship of the compound (85) to quisqualic acid (20).
M
COgH
(85)
COgH
(20)
The reduction in activity of the analogue (85) in comparison to quisqualic acid 
(20) may be due to the effective decrease in acidity of the amidic ring NH of 
(85) compared with the corresponding group in quisqualic acid, which is imidic
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rather than amidic. Alternatively, the alteration in ring size may adversely affect 
the orientation of the functional groups in the side chain which, presumably, 
contribute to binding to the receptor.
As regards the activities of the other QA analogues, it is particularly surprising, at 
first glance, that the hydantoin analogue (87), in which the ring oxygen in 
quisqualic acid is replaced with a carbonyl was essentially inactive in binding to 
the AMPA receptor. An explanation for this may be found in the X-ray crystal 
structure of (86), a hydantoin analogue prepared by Bycroft,200 in which the ring 
oxygen in quisqualic acid is replaced by a methylene group. This compound, 
which was also inactive in binding to AMPA receptor, was found on X-ray 
crystallography^OO to possess a planar geometry, i.e. that the ring N bearing the 
aminopropionic acid substituent was planar, as would be expected of an amidic 
nitrogen. The corresponding N in quisqualic acid (20) was found to be pyramidal 
(with a low barrier to inversion), and therefore closer to the geometry of the sp^ 
hybridised carbon in the corresponding position in L-glutamic acid.
>— O
COgH
(86)
H2N C02H
(159)
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This finding was also in keeping with semi-empirical molecular orbital 
calculations which showed that a heteroatom a  to the ring N induces 
pyramidalization at N, possibly as a way of reducing unfavourable interactions 
between lone pairs on adjacent heteroatoms.
It is of interest to note that, in experiments carried out in the locust (Schistocerca 
gregaria) muscle, the quisqualic acid analogue (159) (homoquisqualic acid)201 
in which the side-chain was elongated by one methylene group, showed activity 
at the quisqualate-sensitive glutamate receptor site. This supports the view that 
the pyramidal geometry of the ring N may be a requisite for quisqualate binding 
activity.
The importance of the ring NH in the quisqualic acid analogues would have 
been tested by studying the receptor binding of the methylene analogue (113), in 
which the heterocyclic ring NH is replaced with a methylene group. Precursors 
to (113) were designed and synthesized in this project, but unfortunately, the 
final amino acid was not isolated.
The diamino analogue (124), which introduced another amino function (and a 
second chiral centre) into the hydantoin ring, and effectively increased the
214
electron density of the compound, showed no activity at the receptor site. This 
may be due, in part, to the replacement of an acidic centre in the heterocycle 
with a basic group.
CO 2 H
(124)
The change in ring conformation due to the presence of a planar nitrogen in 
(124) may be a contributory factor. There may also be unfavourable 
electrostatic or hydrogen bonding interactions with basic residues in the 
receptor, or simply steric congestion.
The other cyclized and the non-cyclized analogues, had IC5Q values greater than 
lOOpM, and were effectively inactive at displacing [^H]-AMPA binding from 
the post-synaptic membrane.
The pharmacological evaluation of L-quisqualic acid showed a biphasic 
displacement of [^H] L-glutamate binding from rat synaptic membranes, with 
IC50 values of 0.1 pM for the high affinity site and > 100pM for the low affinity 
binding site (figure 6.4). The observation of biphasic binding is in agreement 
with those of previous workers^!. Interestingly, the aminopyrrolidinedione
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(119) (NCOOH figs. 6.3 and 6.4), with the carboxymethyl side chain, showed 
some activity, exhibiting biphasic displacement of [^H] L-glutamate binding to 
rat synaptic membrane with IC50 values of 1.04 |iM for the high affinity site 
and >100pM for the low affinity site. It should be noted, however, that this 
compound showed no activity at the AMPA receptor. The other synthesized 
analogues were virtually inactive at displacing [^H] L-glutamate binding 
including, quite suprisingly, the 6.M.R (85).
Ideally, the best line of approach would have been to evaluate the 
pharmacological efficacies of a range of compounds as they were synthesized. 
The results obtained would therefore have provided a direction for future 
synthetic work. However, due to the inherent problems encountered during the 
course of this thesis, this approach was not possible.
7. rnNrLD.siQN.
Much of the original work described in this thesis is synthetic organic chemistry. 
In the early part of the thesis, known methodology is modified and applied to 
the first synthesis of tritiated quisqualic acid, and the details have been supplied 
to a commercial radiochemical company.
In the main part of the Thesis, a series of cyclic and peptidic analogues of 
quisqualic acid is prepared and characterized. A feature of some of these 
syntheses has been that new methodology was required to answer the synthetic 
challenges; for example, preparation of L-quisqualic acid from serine via the 
propiolactone, and the synthesis of various analogues from L-asparagine.
Finally, a selection of the new analogues was studied pharmacologically, using
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radioligand binding techniques with tritiated L-glutamic acid and tritiated 
AMPA as ligands. Two compounds, (119) and (85), showed significant binding 
to glutamate and AMPA receptors repectively. Aspects of both the synthetic 
and pharmacological studies will be published.
7.1 SiiPPestions for future work.
It may be envisaged that the work of this Thesis could be of value in future 
investigations by providing:
(a) quisqualic acid for pharmacological studies.
(b) quisqualate analogues which could be useful in future studies 
involving neuroreceptor classification.
(c) synthetic methodology of potential value if applied to other target 
structures.
The selectivity of the quinoxalinediones as antagonists of the AMPA 
receptor suggests that future synthetic ideas for quis/AMPA and/or 
metabotropic receptor agonists and antagonists should not be centered 
solely on amino acid type compounds, but also on structural analogues of 
quinoxalinediones.
Lastly, syntheses and pharmacological evaluation of synthesized 
compounds should be carried out in an iterative manner, and the 
pharmacological results would therefore provide a direction for future 
synthetic targets.
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